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Abstract 
Vascular smooth muscle cell (VSMC) accumulation is a hallmark of atherosclerosis and vascular injury. 
However, fundamental aspects of proliferation and the phenotypic changes within individual VSMCs, 
which underlie vascular disease remain unresolved. In particular, it is not known if all VSMCs 
proliferate and display plasticity, or whether individual cells can switch to multiple phenotypes. To 
assess whether proliferation and plasticity in disease is a general characteristic of VSMCs or a feature 
of a subset of cells, multi-colour lineage labelling is used to demonstrate that VSMCs in injury-induced 
neointimal lesions and in atherosclerotic plaques are oligo-clonal, derived from few expanding cells, 
within mice. Lineage tracing also revealed that the progeny of individual VSMCs contribute to both 
alpha Smooth muscle actin (aSma)-positive fibrous cap and Mac-3-expressing macrophage-like plaque 
core cells. Co-staining for phenotypic markers further identified a double-positive aSma+ Mac3+ cell 
population, which is specific to VSMC-derived plaque cells. In contrast, VSMC-derived cells generating 
the neointima after vascular injury generally retained expression of VSMC markers and upregulation 
of Mac3 was less pronounced. Monochromatic regions in atherosclerotic plaques and injury-induced 
neointima did not contain VSMC-derived cells expressing a different fluorescent reporter protein, 
suggesting that proliferation-independent VSMC migration does not make a major contribution to 
VSMC accumulation in vascular disease. Similarly, VSMC proliferation was examined in an Angiotensin 
II perfusion model of aortic aneurysm in mice, oligo-clonal proliferation was observed in remodelling 
regions of the vasculature, however phenotypic changes were observed in a large proportion of 
VSMCs, suggesting that the majority of VSMCs have some potential to modulate their phenotype. To 
understand the mechanisms behind the inherent VSMC heterogeneity and observed functionality, the 
single cell transcriptomic techniques Smart-seq2 and the Chromium 10X system were optimized for 
use on VSMCs. The work within this thesis suggests that extensive proliferation of a low proportion of 
highly plastic VSMCs results in the observed VSMC accumulation after injury, and the atherosclerotic 
and aortic aneurysm models of cardiovascular disease. 
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CHAPTER 1: Introduction  
  
In 2015, cardiovascular disease (CVD), was the primary global cause of non-communicable disease 
death (17.9 million, 95% UI) and morbidity. This figure has risen 12.5% from 2005, however when 
standardised for age, deaths from CVD fell 15.6%, primarily from the decrease in deaths due to 
cerebrovascular diseases, such as stroke (Wang et al. 2016). While CVD has, in the past, been a 
‘Western’ problem, this is no longer the case. The number of deaths CVD is responsible for per year is 
predicted to rise in the next few decades (23.6 million by 2030), with developing countries expecting 
the largest increase (Mathers and Loncar 2005). Many of the molecular mechanisms underlying CVD 
are yet to be discovered. The experiments within this thesis attempt to elucidate certain molecular 
events which take place in the progression of CVD, and improve our understanding of the disease 
which currently carries a lifetime risk of 60% (Mozaffarian et al. 2015). 
 
1.1 The Cardiovascular system  
 
The cardiovascular system comprises the heart, blood and blood vessels, and permits the delivery of 
nutrients and oxygen to cells whilst removing CO2 and other waste products.  The arterial component 
of the cardiovascular system carries blood away from the heart, oxygenated regarding the systemic 
circulation and deoxygenated regarding the pulmonary circulation. Based on the position in the 
arterial tree, arteries can be classified as either conducting, conduit or resistance arteries, each 
characterised by a slightly different compositional structure. Conducting arteries, are the largest 
within the body and are highly elastic, relative to other arteries, allowing them to deal with highly 
oscillating blood pressures. The aorta, carotid arteries and pulmonary arteries are examples of 
conducting arteries (McEniery, Wilkinson, and Avolio 2007). These larger arteries branch into conduit 
arteries, which function primarily to direct blood flow to different regions of the body, and include the 
femoral and brachial arteries (Pugsley and Tabrizchi 2000). Conduit arteries branch out to resistance 
arteries. Highly innervated by sympathetic nerves, resistance arteries form part of the 
microvasculature which allow arterioles to regulate blood flow by vaso-dilation/constriction (Rhodin 
1980).    
Arteries typically have thick walls, necessary for coping with high blood pressure, composed of three 
distinct cellular layers; the adventitia, the media and the intima (Figure 1). Each layer is dissimilar in 
its cellular composition, histology and functionality, and contributes to vascular homeostasis and 
response to injury in different ways (Stenmark et al. 2013). 
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The adventitia is the outer most layer of an artery. Composed of multiple cell types, lymphatic vessels 
and autonomic nerves, this layer is the most diverse of the three arterial layers. Adventitial fibroblasts 
and extracellular matrix (ECM) act to protect and anchor blood vessels in place while resident 
macrophage, T, B, mast and dendritic cells are involved in immune response (Galkina et al. 2006; Tieu 
et al. 2009; Swedenborg, Mayranpaa, and Kovanen 2011). Recently, the adventitia has been 
recognised as a stem/progenitor cell compartment, containing cells positive for Sca1+, c-kit, CD34 and 
Flk1, which has been proposed to maintain the intimal and medial cellular compartments, possibly in 
response to arterial injury (Zengin et al. 2006; Hu et al. 2004; Majesky et al. 2011). Furthermore, as 
the adventitia is the site where micro-vessels (e.g. vasa vasorum in the aorta) penetrate it has an 
important role in supplying nutrients to subsequent layers, trafficking immune/inflammatory cells and 
mediating communication between the three layers (Gutterman, 1999; Haurani et al., 2007). There is 
evidence that the adventitia activates early in CVDs, such as atherosclerosis, with the proliferation of 
fibroblast cells, increased NADPH oxidase production of superoxide and expansion of the vasa 
vasorum, driving the delivery of inflammatory signals/ immune cells to subsequent layers (Stenmark 
et al. 2013; Dourron et al. 2004; Ogeng’o et al. 2014). Further, confirmed and theorised, roles of the 
adventitia in CVD will be discussed in section 1.5. 
 
The intima is the innermost layer of the vessel wall. In mice the intima is composed of a single cell 
thick layer of endothelial cells (ECs) on top of a basal and elastic lamina, within humans the intima also 
contains vascular smooth muscle cells (VSMCs). Acting as the interface and barrier between the blood 
Figure 1: Schematic view of an arterial cross section 
The arterial wall has three recognisable layers; the intima, media and adventitia. Each layer has a 
unique cellular and matrix composition. The intima contains endothelial cells and a basement 
membrane, this layer acts as the interface between the blood and subsequent layers. The media 
contains vascular smooth muscle cells (VSMCs), responsible for vascular tone, and extracellular 
matrix. The adventitia is home to numerous cell types including fibroblast, stem and immune-cells 
and has roles in trafficking immune cells and signalling molecules across all layers. From: Cambridge 
Clinical School. Clinical and Biomedical Computing Unit., 1997. 
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and the vessel wall, these cells play a critical role in responding to environmental stimuli and 
maintaining tissue homeostasis. ECs can metabolise and synthesise a range of molecules responsible 
for auto and paracrine effects on the surrounding tissue (Cines et al. 1998), and serves as a semi-
permeable barrier to regulate the transfer of small and large molecules (Galley and Webster 2004). 
Importantly the endothelium maintains a protective, non-thrombogenic interface between tissue and 
blood, regulating platelet adherence, thrombosis, blood flow and vascular tone. Endothelial 
dysfunction, often characterised by a reduced production of bio-available nitric oxide (NO), is regarded 
as a key early step in the progression of many diseases, including atherosclerosis, and pulmonary and 
systemic hypertension (Kinlay and Ganz 1997; Galley and Webster 2004).   
  
The media, or middle layer of an artery, is the thickest of the three arterial layers and is characterised 
by the presence of concentric layers of VSMCs and the ECM components: elastin, collagen type I and 
III and proteoglycans. VSMCs are arranged circumferentially around the media separated by elastic 
fibres, this highly ordered matrix provides structural integrity to the vasculature and enables VSMCs 
to carry out their primary function of contraction. The number of concentric layers is variable 
throughout the vasculature, and while the mechanisms determining number of VSMC layers is still 
unknown, luminal diameter is a primary determining factor (Wolinsky and Glagov 1967; Pfaltzgraff 
and Bader 2015). Manipulating animal size or matrix composition does not change the number of 
layers in a region (Dilley and Schwartz 1989), with studies suggesting that other compensatory 
mechanisms can cope with the increases in vascular demand (Dilley and Schwartz 1989; Faury et al. 
2003). Medial thickening is, instead, regarded as a characteristic of CVD (Grobbee and Bots 1994). The 
medial layer’s involvement, and in particular, VSMC involvement in CVD will be a focus of this thesis.  
 
1.2 Vascular development and VSMC origins 
 
De novo vascular networks are laid down via the process of vasculogenesis, first occurring within the 
yolk sac of mammalian embryos and later within the actual embryo. This process is driven, firstly, by 
the recruitment of epiblast cells through the primitive streak, where they undergo epithelial to 
mesenchymal transition (EMT), and subsequently form mesoderm (Tam and Behringer 1997). 
Endothelial precursors, derived, mainly, from the splanchnic mesoderm, accumulate in networks 
which will define the earliest vasculature (Bellairs and Osmond 2009).  These early endothelial tracks 
are then refined via angiogenesis/vascular remodelling and subsequent recruitment of VSMC pre-
cursor cells (Yao et al. 2014).  
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Both platelet-derived growth factor (PDGF)-B and transforming growth factor-β (TGF-β), are important 
chemoattractants responsible for recruiting and differentiating VSMC pre-cursor cells (Yao et al 2014). 
Other signalling pathways responsible for recruiting VSMC progenitor cells can differ throughout the 
vasculature, as does the origin of these cells. Figure 2 shows which embryonic cell population VSMCs 
are derived from and their position within the vasculature (Wang et al. 2015). 
 
 
 
 
 
 
 
 
 
Using a Wnt1-Cre driven recombination of the LacZ reporter system in mice, Jiang et al. (2000) were 
able to show that the carotid arteries and aortic arch VSMCs are derived from the neural crest, a 
structure present in early embryo as a strip of cells between the neural and non-neural ectoderm 
(Jiang et al. 2000; Mayor and Theveneau 2013). As embryogenesis proceeds neural crest cells 
contribute to various mesenchymal structures, including craniofacial bone/cartilage, VSMCs and 
melanocytes, however the mechanisms underlying the contribution of neural crest-derived VSMCs to 
the aortic arch and carotid arteries is not fully understood (Wang et al. 2015). VSMCs in the descending 
thoracic aorta are derived from the somites, itself derived from the paraxial mesoderm, these 
structures are transient and contribute to the development of organs and tissues including the 
vertebrae, ribs and back muscles (Sato 2013). Based on Quail-chick chimera analysis, the sclerotome, 
part of the somite responsible for giving rise to bone/skeletal tissue, has been shown to be the exact 
cellular location which contributes the majority of VMCS to the descending thoracic aorta (Pouget, 
Pottin, and Jaffredo 2008). Interestingly each somite seems to contribute to descending aortic VSMCs 
Figure 2: Developmental fate map for VSMCs 
VSMC are derived from various embryological origins, the coloured vasculature relates to the origin 
depicted in the key. Adapted from Wang et al., 2015.  
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in a segmented way so that VSMC progenitors from each somite are restricted to specific local 
domains (Majesky 2007).  
 
Several studies suggest that the embryonic origin of VSMCs affects their underlying biology, regarding 
gene expression (Zhang et al. 2012) and predisposition to disease (Haimovici and Maier 
1971). Diseases such as atherosclerosis and aortic aneurysm typically locate to specific locations in the 
vasculature (discussed in sections 1.4 and 1.9, respectively), which could potentially be, in part, due 
to the embryonic origins of the VSMCS within these regions (Ruddy et al. 2008; DeBakey, Lawrie, and 
Glaeser 1985; Sinha, Iyer, and Granata 2014). For example, the normally atherosclerotic resistant 
thoracic aorta in a mouse model of atherosclerosis has a higher expression of Homeobox (Hox) genes 
compared to the atherosclerotic-prone aortic arch. The inverse relationship between Hox9a and 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) expression (Trigueros-Motos et 
al. 2013) provides a possible disease regulatory processes founded in embryological origin (Bennett, 
Sinha, and Owens 2016).  Congenital defects also occur at the boundaries where VSMCs from different 
embryonic origins meet, for example, coarctation and interruption of the aortic arch (Jacobs et al. 
1995; Tanous, Benson, and Horlick 2009). However, the extent to how VSMCs in different vascular 
beds differ, the underlying mechanisms for these differences and the consequences of these 
differences are still not fully understood, requiring further inquiry (Pfaltzgraff and Bader 2015).  
 
Differentiating, embryonic VSMCs are highly proliferative and migratory and secrete a large amount 
of ECM proteins vital for angiogenesis (Shang et al. 2008). Following the recruitment of VSMC pre-
cursor cells to the developing vasculature they encircle the vessel and differentiate into mature 
VSMCs, this initial patterning occurs rapidly and is later remodelled through angiogenesis once the 
heart begins to beat and perfuse the vessels with blood (Blatnik, Schmid-Schönbein, and Sung 2005; 
Chen and Tzima 2009). Indeed, as will be discussed (sections 1.4 and 1.5), hemodynamic forces serve 
as a potent force in remodelling the vasculature.  
 
1.3 VSMC function and heterogeneity 
 
The primary purpose of mature, differentiated, VSMCs is to maintain tone of blood vessels and 
regulate blood flow through vaso-constriction/dilation of resistance arterioles, thus ensuring 
intravascular pressure and tissue perfusion is maintained (Stegemann, Hong, and Nerem 2005). 
VSMCs, therefore have characteristics which make them suitable for this role. Morphologically, they 
are elongated in shape, aligned in an organised structure with surrounding VSMCs. Biochemically, they 
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can be characterised by their expression of particular calcium handling proteins, ion channels, cell 
surface receptors and contractile proteins, most notably: α-smooth muscle actin (aSMA), smooth 
muscle-myosin heavy chain 11 (MYH11/SM-MHC), Transgelin (SM22α) and Smoothelin (Rensen, 
Doevendans, and van Eys 2007). Healthy, mature VSMCs are quiescent and divide with a half-life 
ranging from 270 – 400 days (Neese et al. 2002).  
 
However, this description is an over simplification of the mature VSMC phenotype, in reality this is 
one phenotype at the extreme end of a spectrum. As discussed above, during vasculogenesis, a VSMCs 
primary act is that of proliferation and ECM synthesis, required to build the vascular wall. This 
phenotype can here be considered the other end of the spectrum on which VSMCs lie (Pfaltzgraff and 
Bader 2015). The VSMC spectrum ranges from the ‘contractile’ phenotype to the ‘synthetic’ 
phenotype. Synthetic VSMCs are epithelioid or rhomboid in shape and contain a higher number of 
organelles, necessary for protein synthesis, replacing the contractile filaments found in contractile 
VSMCs. Furthermore, synthetic VSMCs are more proliferative and migratory than their contractile 
counter parts (Hao, Gabbiani, and Bochaton-Piallat 2003). Gene expression also differs along the 
spectrum, with synthetic VSMCs expressing higher levels of certain matrix metalloproteinases (MMPs) 
and collagens, the embryonic smooth muscle myosin heavy chain (SMemb) protein and cellular retinol 
binding protein 1 (CRBP-1). Lower levels of contractile markers such as Myh11 and Smoothelin also 
typically accompany this phenotype (Rensen, Doevendans, and van Eys 2007).   
 
What is remarkable about VSMCs, and unique when compared to cardiac and skeletal muscle, is that 
they are not terminally differentiated and retain a large degree of plasticity, able to move along the 
spectrum of phenotypes and, as will be discussed later, even trans-differentiate into other cells types 
(section 1.5). The process by which VSMCs can change their phenotype is known as phenotypic 
modulation/switching, and can be induced by a variety of environmental stimuli. Typically, this process 
is studied in the direction of contractile to synthetic, and is vital in allowing a rapid response to vascular 
injury and fluctuating environments, permitting remodelling and re-vascularisation (Alexander and 
Owens 2012). 
 
Morphological differences between synthetic and contractile VSMCs were first recognised when 
cultured and in vivo VSMCs were compared (Figure 3A). Initially, studies examined visceral smooth 
muscle cells (SMCs), which when cultured lose myofilaments and gain organelles, including golgi 
apparatus, rough endoplasmic reticulum and mitochondria (Campbell et al. 1971; Rensen, 
Doevendans, and van Eys 2007).  Moreover, when primary SMCs are seeded at a high density and via 
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proliferation become confluent they begin to form an organised structure/pattern initially described 
as “hills and valleys”. After an additional few days of culture, these SMCs return to their original spindle 
shape, regain their myofilaments and begin to contract. This work concludes that SMCs not only have 
the potential to phenotypically switch, but that this ‘switch’ is reversible. Interestingly, if the cultured 
primary SMCs are seeded sparsely, by the time they reach confluency they seem unable to revert to 
their original phenotype (Campbell et al. 1971). Further work confirmed that the ability to reverse to 
a contractile state is dependent on the number of cell doubling events (<5 doublings/cells = reversible, 
>9 doublings/cells = irreversible (Chamley-Campbell and Campbell 1981)). 
 
Phenotypic heterogeneity of VSMCs is also observed in vivo in healthy tissue, immunohistochemistry 
has shown differential expression of VSMC contractile markers, as well as adhesion molecules and gap 
junctional proteins, between adjacent VSMCs (Christen et al. 2001; Frid, Moiseeva, and Stenmark 
1994; Moiseeva 2001). Distinct VSMC populations, within the same artery, have been seen in rats 
(Bochaton-Piallat et al. 1996), pigs (Christen et al. 2001; Hao et al. 2002) and in humans (Li et al. 2001), 
phenotypes of which remain distinctive in vitro. Furthermore, these VSMC populations react 
differently to similar culture conditions, and can be differentially coaxed to adopt a synthetic or 
contractile state by varying the culture conditions (Li et al. 1999; Hao et al. 2002). Based on these 
studies, Rensen et al. (2007) propose a hypothetical phenotypic spectrum occupied by multiple VSMCs 
populations, each with distinct characteristics and phenotypic switching potential (Figure 3B). 
Furthermore, Rensen et al. (2007) suggest, that there is likely an epigenetic foundation for the 
observed VSMC heterogeneity, through which the environment can act on to regulate phenotypic 
switching. 
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Figure 3: The VSMC phenotypic spectrum 
A) Structural characteristics of contractile and synthetic 
VSMCs. B) Hypothetical spectrum of VSMC phenotypes, 
populations (represented a to f) have different 
potential to phenotypically switch. Adapted from 
Rensen et al., 2007. 
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The plasticity of VSMCs has likely evolved, as the ability for VSMCs to phenotypically switch to a 
synthetic phenotype and participate in vascular repair has conferred a survival advantage. However, 
a consequence of this plasticity is that VSMCs can be exposed to environmental stimuli which 
contribute to adverse/dysregulated phenotypic switching, which, in turn, contributes to the 
progression/development of vascular disease (Owens, Kumar, and Wamhoff 2004). Indeed, hyper-
proliferation of VSMCs is integral in the formation of atherosclerotic plaques (Sherif and Zahradka 
2010).  
 
1.4 Cardiovascular disease: Atherosclerosis 
 
CVD encompasses an array of diseases affecting the heart and/or blood vessels, including, among 
others; ischaemic heart disease, stroke, cardiomyopathy and aortic aneurysm. Of the 15.6 million 
deaths relating to CVD in 2015, 85.1% were attributable to ischaemia and stroke. These diseases are 
the clinical manifestation of atherosclerosis, a chronic inflammatory condition, which locates to the 
arterial wall. Atherosclerosis is typically characterised by the accumulation of lipids, inflammatory 
molecules, immune cells and VSMCs, resulting in the formation of an atherosclerotic plaque. Plaque 
rupture, and subsequent flow limiting stenosis, results in the aforementioned diseases. (Newman et 
al., 1986; Virmani et al., 1987; PDAY research Group, 1990).  
 
Atherosclerosis often begins early in life and remains asymptomatic for several decades. The initiating 
factor for atherogenesis is typically vascular injury or dysfunction of ECs. Proposed causes are 
oscillating shear forces (from blood flow) caused by hypertension, increased low-density and 
decreased high density plasma lipoproteins, increased toxin levels in the blood (e.g. from smoking) 
and diabetes (Fuster 1994; Ross 1999; Zaman et al. 2000). The development and progression of 
atherosclerotic plaques (Figure 4) has been proposed to occur in five main steps: 1) Endothelial 
dysfunction and sub-endothelial accumulation of low-density lipoproteins. 2) Infiltration of leukocytes 
and subsequent formation of foam cells. 3) VSMC proliferation and trans-differentiation. 4) 
Production of connective tissue. 5) Plaque stabilisation or erosion/rupture leading to symptomatic 
complications (Tedgui and Mallat, 2006). However, plaque development is not necessarily orderly, 
neither does it always follow the linear classification system of plaques (type I to VI) defined by The 
American Heart Association Committee (Stary et al., 1995). 
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Atherosclerotic plaques develop in a spatially non-random and temporally non-linear process, and 
typically affects athero-prone regions of the vasculature (Tabas et al., 2015). Lesion prone areas are 
often found where the vasculature experiences oscillatory shear blood flow compared to the relatively 
uniform high-pressure flow experienced within ‘athero-protected’ regions (Chiu and Chien, 2011). 
Figure 5A shows that it is typically bifurcating and bending regions of the vasculature which develop 
atherosclerosis. Within athero-protective regions, ECs (as described in section 1.1) are exposed to 
steady laminar flow which activates signal transduction promoting EC production of NO, Kruppel-Like 
Factor 2 (KLF2) and superoxide dismutase, which actively prevents atherogenesis (Cai and Harrison, 
2000; De Caterina et al., 1995; Dekker et al., 2005; Dimmeler et al., 1999). Within athero-prone 
regions, ECs display characteristics typical of a dysfunctional, pro-inflammatory and pro-thrombotic 
phenotype. Athero-prone ECs prime the NF-kB signalling pathway which is further amplified by 
accumulating lipoproteins, causing the influx of monocytes into the neo-intima and subsequent 
activation of VSMC phenotypic switching (Figure 5B, Chiu and Chien, 2011). This activation of VSMCs 
Figure 4: A schematic view of atherosclerotic plaque development 
A) Cross section of the wall of healthy vasculature. B) The initial steps of atherosclerosis. Blood circulating 
immune cells bind ECs, leukocytes infiltrate the sub-endothelial space and monocytes mature to 
macrophages and uptake lipids to form foam cells.  C) VSMCs infiltrate the intima, a proportion of these 
cells become foam cells within the core of the plaque, and those which locate to the cap produce collagen 
and elastin, forming a mature plaque. D) Rupture of the atherosclerotic plaque and subsequent thrombus 
formation due to the coagulation of blood components. The resulting thrombus can occlude an artery, 
limiting blood flow. From Libby et al., 2011. 
 A 
 C  D 
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(Figure 4C) is perhaps the most interesting aspect in the progression of this disease, particularly in the 
context of this thesis. Concerning the migration, proliferation, trans-differentiation and synthetic 
capacity of VSMCs in atherosclerotic plaques, this stage (Figure 4 C) is often regarded as the 
transitional point whereby what was once just a site of accumulating macrophage derived foam cells 
becomes a fibrous lesion containing a lipid core, with future symptomatic prospects (Kolodgie et al., 
2007).  
 
 
 
 
 
 
 
 
 
 
 
 
1.5 VSMCs in atherosclerosis - Origin and plasticity 
 
VSMC contribution to atherosclerosis has been studied in a variety of disease models in rats and mice 
(several of which will be discussed in detail in sections 2.2 and 2.3) as well as in samples from humans. 
The models mentioned in this section fall into two categories, (1) injury-induced models of neo-intimal 
growth, in which animals undergo surgery (wire-injury, balloon-injury, carotid ligation) to cause a 
growth in the number of cells within the intima (neo-intima); and (2) diet-induced models of 
atherosclerosis, which involve feeding a high fat diet (HFD) to mice on either a low density lipoprotein 
Figure 5: Atherosclerotic plaques preferentially develop at sites of arterial branching and curvature 
A) Schematic of the major arterial vasculature illustrating the observed distribution of atherosclerotic 
plaques. 1, Aortic sinus; 2, ascending aorta; 3, inner (lesser) curvature of aortic arch; 4, outer (greater) 
curvature of aortic arch; 5, innominate artery; 6, right carotid artery; 7, left carotid artery; 8, left subclavian 
artery; 9, thoracic aorta; 10, renal arteries; 11, abdominal aorta; 12, iliac artery (adapted by Chiu and 
Chien, 2011; originally VanderLaan et al., 2004). B) Oscillatory sheer stress and pressure gradients promote 
EC dysfunction, NF-κB signalling and inflammation. Adapted from Tabas et al., 2015. 
A B 
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receptor (Ldlr) or Apolipoprotein E (ApoE) knockout background, resulting in atherosclerotic plaque 
development.    
The extent to which phenotypic modulation of fully differentiated VSMCs contribute to the 
development and overall proportion of an atherosclerotic plaque and the extent to which they can 
trans-differentiate, contributing to other cell types, has been hotly debated in recent years. Initially 
this debate was confounded by the fact that downregulation and non-specificity of VSMC contractile 
markers made it difficult to definitively identify VSMC-derived cells after phenotypic switching (Gomez 
and Owens, 2012). Several papers claimed that the majority of cells forming the plaque/neointima, 
which were positive for several VSMC markers, may be of adventitial (Hu et al., 2004) or myeloid origin 
(Sata et al., 2002). However, these claims were later refuted, Iwata et al. (2010) and Benzton et al. 
(2007) showed that while bone marrow-derived cells contribute to vascular inflammation they do not 
differentiate into VSMC lineages in models of injury induced neo-intima growth or atherosclerosis. 
Nemenoff et al. (2011) were the first to use a specific marker of VSMCs for lineage tracing purposes 
following vascular injury. Utilising mice harbouring the Myh11-CreER(T2) transgene and Rosa26-
floxStop/βGal reporter they tracked VSMCs following femoral artery wire-injury in mice. The Myh11-
CreER(T2) transgene here recombines the Rosa-26floxStop/βGal allele following tamoxifen 
administration allowing specific labelling of VSMCs. This study identified that VSMC-derived cells 
accumulate in the neo-intima, furthermore no bone marrow-derived VSMCs were detected.   
 
Contrastingly, in 2012, Tang et al. claimed that mature VSMCs were not capable of phenotypically 
switching and do not contribute to the development of neointima/atherosclerotic plaques (i.e. they 
are terminally differentiated). They suggested an alternative, a pre-cursor/stem cell population of 
multipotent VSMCs (MVSMCs) which exist in the media and are responsible for VSMC-like cells seen 
in disease/injured tissue. To substantiate this claim, Tang et al. (2012) first show that these MVSMCs 
exists within the media in rats, are negative for Sm-mhc (Myh11) and express the stem cell markers 
Sox17, Sox10 and S100β when cultured. They further suggest that neointimal VSMCs following a wire-
injury model are derived from these MVSMCs, instead of mature, Myh11 expressing, VSMCs. This 
statement, however, is not definitively backed by experimental evidence, but is based on the following 
observations: (1) no injury-induced, neointimal cells were GFP+ following lineage tracing using the 
Myh11-Cre; Rosa26-loxP-GFP mouse suggesting that Myh11-expressing cells do not contribute. And 
(2), most cells within the neointima and surrounding media express S100β, which MVSMCs also 
express. However, neither of these results definitively lineage trace MVSMCs and therefore cannot 
determine their involvement. Furthermore, the methods utilised by Tang et al., (2012) were highly 
criticised in a paper co-authored by many experts within the field (Nguyen et al., 2013), in particular 
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their use of a non-conditional lineage tracing system, and therefore the inability to rigorously label 
mature VSMCs at a given time point. It was also suggested that their model of injury was so severe 
that it killed all GFP+ VSMCs within the media. This work lead to definitive experiments to answer 
questions regarding VSMC involvement and trans-differentiation in atherosclerosis.   
Gomez et al. (2013) were the first to use the inducible Myh11-CreER(T2); Rosa26-STOP-floxedYFP; 
ApoE-/- mice to show that in a model of atherosclerosis, induced by HFD, that VSMC-derived cells 
contributed to large regions of an atherosclerotic plaque. Furthermore, they show that >95% of these 
cells are unidentifiable as VSMCs using conventional immuno-staining for VSMCs (aSma and Myh11), 
suggesting they have phenotypically modulated. Herring et al. (2014) confirmed the study of 
Nemenoff et al. (2011), using Myh11-CreER(T2)/R26R-mTmG mice, in the carotid ligation injury model 
as opposed to the femoral wire injury model. The mTmG reporter gene marks all cells with mTomato 
prior to tamoxifen administration and specifically marks Myh11-expressing cells irreversibly with 
mEGFP post tamoxifen-induced Cre-mediated recombination. Tamoxifen injected mice then 
underwent carotid ligation surgery. Most cells (79 ± 17%) within the neo-intima were mEGFP positive, 
and were therefore the progeny of Myh11-expressing, differentiated VSMCs prior to injury. Inter-
mouse variability in the proportion of VSMC derived neo-intimal cells in the carotid ligation (5-70%) 
and femoral injury wire injury (0-85%) models has since been reported (Yang et al., 2015).     
 
To investigate the extent to which VSMCs phenotypically switch/trans-differentiate, Shankman et al. 
(2015) also utilised the Myh11-CreER(T2); Rosa26-STOP-floxedYFP; ApoE−/− mice on HFD to lineage 
trace VSMCs in a model of atherosclerosis. And combined with immunohistochemistry showed that a 
large proportion of cells and cell types within mature atherosclerotic lesions were VSMC derived. 
Shankman et al. (2015) quantify that 30% of VSMC-derived cells had trans-differentiated into 
macrophage-like (express LGALS3), 12% into myofibroblast-like (express aSMA and PDGF-B), 7% into 
mesenchymal stem cell (MSC)-like (express SCA1) and 32-51% into an indeterminate like – cell type. 
Furthermore, 36% of the total macrophage marker LGALS3+ cells within the lesion were of VSMC 
origin, a proportion of which were lipid laden, suggesting that VSMC-derived macrophage-like cells do 
indeed take on some phagocytic properties. However, in vitro experiments showed that VSMC-
derived MSC-like cells could not differentiate into osteoblasts and adipocytes and therefore do not 
take on the multipotent properties of true MSCs. VSMCs that locate to the outer most region or cap 
of the plaque express contractile markers (aSMA), resembling a typical VSMC seen in healthy 
vasculature (Shankman et al., 2015). 
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The studies discussed here clearly demonstrate that a large proportion of an atherosclerotic plaque is 
VSMC-derived and that VSMCs can trans-differentiate into multiple like-cell types. A major limitation 
of these lineage tracing systems is that they require the use of genetically modified organisms and 
cannot be performed in the same way in humans. To address this, Shankman et al. (2015) used an in 
situ hybridization proximity ligation assay (developed by Gomez et al., 2013), to trace cells positive for 
Histone H3 lysine 4 dimethylation (H3K4me2) within the MYH11 locus. Only VSMCs express this 
epigenetic mark at this locus, and it is retained in trans-differentiated VSMCs. This work showed that 
VSMCs can transition to macrophage-like cells within lesions from human samples. Combined these 
works shows that VSMCs can trans-differentiate into multiple cell types, some of which preferentially 
locate to distinct regions of an atherosclerotic plaque (Figure 6). What in unknown, however, is 
whether individual VSMCs can generate phenotypically distinct VSMC-derived cells (i.e. multipotent) 
or if these cells originate from different unipotent VSMCs1.   
 
                                                          
1 Thesis aim 1: Determine if phenotypically distinct VSMC-derived plaque cells are generated from single 
(multi-potent) VSMCs or if distinct VSMCs produce a single or subset of these (uni/oligo-potent) 
Figure 6: Schematic of an atherosclerotic plaque and origin of plaque cells 
VSMCs retain a large degree of plasticity and undergo phenotypic switching to multiple distinct phenotypes 
within atherosclerotic lesions. VSMCs within the core of the plaque take on properties of macrophage and 
stem cells while those which locate to the cap resemble a contractile VSMC. From Bennett, Sinha, and 
Owens, 2016. 
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However, the origin of all cells (positive or negative for VSMC markers) within a plaque/arterial disease 
is still currently under intense investigation. Kramann et al. (2016), show that in a wire-injury model 
of the femoral artery, that a large proportion of aSma+ cells within the neo-intima are derived from 
Gli1+ MSC-like adventitial cells. Furthermore, they show that Gli1+ adventitial cells can migrate into 
an atherosclerotic plaque, within the kidney vasculature of animals with chronic kidney disease, and 
contribute to osteoblast-like cells which in-turn contribute to vascular/plaque calcification (Kramann 
et al. 2015). They further suggest, but do not definitively show that these cells go through an 
intermediate VSMC stage before trans-differentiation into the osteoblast-like cells. Nurnberg et al., 
(2015) identified that medial and adventitial cells expressing Transcription factor 21 (Tcf21) prior to 
injury, migrate and give rise to VSMC marker-positive cells within the cap and subcapsular regions of 
late stage plaques. Typically, few cells within the media express Tcf21 and there is minimal overlap 
with VSMC markers (aSma). Other studies have re-visited the idea of myeloid derived-VSMCs, using a 
LysM-Cre, Albarrán-Juárez et al. (2016) suggests that up to 30% of all aSma+ cells within 
atherosclerotic plaque have a myeloid origin. This Cre is however constitutively active, therefore 
VSMC-derived cells which induce LysM expression will be labelled in this model. The same study, using 
the Myh11-CreER(T2) transgene did indeed find that a large proportion of plaque cells are VSMC 
derived, including 16% of CD68+ cells (Albarrán-Juárez et al. 2016).  
 
Other groups have focused on Sca1+ adventitial cells, showing that they are capable of 
dedifferentiating into VSMCs in response to PDGF-B in vitro (Hu et al. 2004). Furthermore, when 
adventitial Sca1+ cells are transferred to the adventitial side of a vein graft they can be lineage traced 
to the neointima of an atherosclerotic plaque in ApoE-/- mice (Hu et al. 2004) and neointima of wire-
injured mice arteries (Yu et al. 2016). Yu et al. (2016) further suggest that it is the release of 
chemokines CCL2 and CXCL1 from pre-existing VSMCs which drives this migration of Sca1 adventitial 
cells, where they then dedifferentiate into VSMCs. Others have even suggested that there exists a 
VSMCs progenitor population of Sca1+ cells within the media (based on flow cytometry analysis), 
which can differentiate into VSMCs in vitro (Sainz et al., 2006).  
 
Finally, the Song group, that previously identified Sox10+ MVSMCS as VSMC progenitors (Tang et al., 
2012) performed experiments which suggests the existence of two types of neointima following 
carotid ligation or wire-injury methods (Yuan et al., 2017). Type I is VSMC-derived, based on lineage 
tracing using a Myh11-Cre; Rosa-loxP-RFP mouse. Type II is not VSMC-derived and is possibly derived 
from Sox10+ vascular stem cells. However, this is not definitively shown as specific lineage tracing is 
not used. Indeed, much of the work investigating potential progenitor cells rely on immuno-
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staining/use markers which do no clearly define the origins of the cell type nor exclude VSMCs as a 
pre-cursor. Unfortunately, many of the proposed adventitial stem cell-precursor-cells lack cell specific 
markers to use for lineage tracing (Bennett, Sinha, and Owens 2016). 
 
Considering the work discussed here it seems there is still a degree of debate surrounding the origin 
of VSMC-like cells within the plaque. While mature VSMCs seem capable of trans-differentiation and 
migration in to neointima/atherosclerotic plaques in some studies, they may not be the only source 
from which plaque VSMC-like cells are derived. Furthermore, given the known heterogeneity of 
VSMCs (section 1.3) it is not known whether all VSMCs have the potential to contribute to plaque 
growth or if only a proportion of VSMCs are capable2. 
 
1.6 VSMCs in atherosclerosis - The clonality hypothesis  
 
In 1973, Benditt and Benditt proposed that VSMCs within atherosclerotic plaques may be mono-
clonally derived, this was based on a study of X-inactivation patterns of the X-linked glucose-6-
phosphate dehydrogenase protein in female humans (Benditt and Benditt, 1973). Their study revealed 
that the majority of atherosclerotic plaques, including plaques exceeding a diameter of >0.5 cm, 
predominately contained one of the protein isotypes, while relatively small patches of healthy media 
(<0.1 mm3) contained both isotypes (Benditt and Benditt, 1973). However, this notion came under 
scrutiny when more sensitive methods to measure X-inactivated genes found large medial patches 
expressing the same X-inactivation pattern (Schwartz and Murry, 1998), suggesting that plaques 
would, inevitably, have the same inactivated X-chromosome. Furthermore, as has been discussed 
(section 1.2) VSMCs within distinct regions of the vasculature have different embryological origins, 
the ascending aorta, arch and carotid arteries derive from the neural crest, the descending aorta from 
the somites, the aortic root from the lateral plate mesoderm and the coronary arteries from the 
proepicardium (Majesky, 2007; Wasteson et al., 2008; Jiang et al., 2000). As X-inactivation occurs prior 
to gastrulation (Rastan, 1982) all cells within each region would therefore be expected to share the 
same inactivated X-chromosome (i.e. local proliferation of VSMC progenitors sharing the same 
inactivation pattern build the vessel wall), which also explains why this would be the case for a plaque.   
 
Feil et al. (2014), have more recently, suggested that VSMC-derived macrophages and indeed the 
entire plaque is clonally derived. The mice in this study contained the multi-colour R26R-Confetti 
                                                          
2 Thesis aim 2: Determine the proportion of VSMCs which respond in vascular disease/ injury  
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reporter (discussed in section 2.1) and the inducible Sm22α Cre recombinase. While this study does 
not definitively confirm clonality, due to various limitation discussed later (section 5.2), if shown to be 
true would imply that a single VSMC can differentiate into multiple distinct cell types known to occupy 
the plaque3. It would also raise questions concerning the proliferative potential of all VSMCs and 
whether the underlying heterogeneity of this population has functional consequences.    
 
1.7 VSMCs in atherosclerosis - Proliferation and migration  
   
The ability of VSMCs to cross the elastic lamina and enter the intima and contribute to plaque 
development relies on the upregulation of ECM degrading MMPs released by multiple cell types 
including VSMCs (Newby, 2006). It is not fully understood whether phenotypically switched cells 
preferentially activate proliferative or migratory responses in turn or simultaneously (Sherif and 
Zahradka, 2010). Zahradka et al. (2004) suggest that migration of VSMCs into the neo-intima can take 
place independently of VSMC proliferation, as inhibiting DNA synthesis did not inhibit migration in cell 
culture or neointimal formation in a porcine organ culture system. However, blocking migration, 
through inhibition of MMPs, did inhibit neo-intimal formation in this system. De Donatis et al. (2008), 
identified a PDGF gradient-dependant, differential response, in fibroblast cells, with low PDGF 
concentration activating migration and high PDGF concentrations activating proliferation without 
migration. Although this has not yet been confirmed within VSMCs, PDGF is key in inducing both 
proliferation and migration in VSMCs (De Donatis et al., 2008). Sherif and Zahradka (2010) suggest 
that the known release of cyclin-dependant kinase inhibitors post vascular injury which prevents G1/S 
transition may initially cause a preferentially state of migration. Several studies have attempted to 
label all proliferating cells following vascular injury models using either 3H-thymidine loaded mini-
pumps (inserted into rats, Clowes and Schwartz 1985)) or 5-bromo-2'-deoxyuridine (BrdU) loaded 
drinking water (given to mice, Yu et al. 2011)). Results from these studies indicate that a large 
proportion (>40%) of neointimal cells have migrated independent of proliferation, as they have not 
incorporated either molecule, both studies claim this specifically refers to VSMCs, although neither 
use definitive lineage tracing strategies to confirm this  (Clowes and Schwartz 1985; Yu et al. 2011). 
Furthermore, these strategies for labelling proliferating cells may not be 100% efficient. The notion 
that migration may occur prior to or independent from proliferation is, perhaps, not expected if 
plaques are mono-clonal.  
                                                          
3 Thesis aim 3: Determine if VSMC remodelling occurs by the clonal expansion of single VSMCs or proliferation 
of numerous VSMCs 
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1.8 VSMCs in atherosclerosis - Function and consequences  
 
The contribution of VSMCs to the development of an atherosclerotic plaque is without doubt, at least 
when considering certain research, however the implications are still questioned. Typically, the 
accumulation of lipids within the sub-endothelial space precedes the development of advanced 
atherosclerotic plaques, however this early phenotype does not always proceed on to the advanced 
stage. Accumulation of fibrous tissues in the cap region, the bulk of which is synthesised by VSMCs, in 
plaques is the hallmark of an advanced stage (Libby., 2005). It is unclear whether the overall 
contribution of VSMCs to plaque development is beneficial or detrimental in the progression of 
atherosclerosis.  
 
Trans-differentiation of VSMCs into macrophage like-cells and their subsequent formation of foam 
cells increases the lipid content of the plaque core (Shankman et al. 2015). Foam cell necrosis as well 
as VSMC-mediated cytokine release have both been shown to induce a negative, inflammatory, plaque 
phenotype (Jaulmes et al., 2006; Hofnagel et al., 2004; Okura et al., 2000). Furthermore, VSMCs which 
become senescent within atherosclerotic plaques actively contribute to the chronic inflammatory 
plaque phenotype through the release of interleukin-1α which primes adjacent cells to a pro-
atherosclerotic state (Gardner et al. 2015). However, EMC-producing VSMCs which locate to the cap 
of the plaque, encapsulating the necrotic core, stabilise the plaque and protect against rupture and 
thrombosis (Schwartz, Virmani and Rosenfeld 2000). The normal adult artery has very low rates of 
proliferation and apoptosis, however within the plaque, multiple factors including inflammatory 
cytokines, inflammatory cells and oxidised lipoproteins alter the balance between proliferation and 
apoptosis (Bennett, 2002). Furthermore, VSMCs are intrinsically more sensitive to apoptosis within a 
plaque than healthy tissue (Bennett et al., 1995), expressing death receptors (e.g. interleukin-1 
converting enzyme, Geng and Libby, 1995). Loss of plaque VSMCs often, therefore, occurs by 
apoptosis (Figure 7, Bennet, 1999) and subsequent thinning of the VSMC containing fibrous cap is 
associated with rupture (Newby et al., 1999). Indeed, plaques which rupture and directly lead to heart 
attack show a scarcity of cap VSMCs compared to stable lesions (Davies et al., 1993). Replicative 
senescence is also thought to contribute to VSMCs inability to replace apoptosed cells in late stage 
plaques due to observed shortened telomeres (Matthews et al., 2006). 
 
It therefore appears VSMCs have both a positive and negative impact on atherosclerotic plaque 
progression, their involvement is thought necessary for plaque growth and the development of the 
necrotic core (Shankman et al. 2015). However, while their contribution is vital for stabilising a plaque 
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their subsequent apoptosis/senescence results in plaque rupture (Figure 7, Bennett, Sinha, and 
Owens, 2016; Schwartz, Virmani and Rosenfeld, 2000). VSMC accumulation is also known to 
contribute to in-stent restenosis (Marx, Totary-Jain, and Marks, 2011), but the role of VSMCs in other 
CVDs has not been as intensively studied. 
 
 
 
 
 
 
 
 
 
 
 
 
1.9 Cardiovascular disease: Aortic aneurysm 
 
Abdominal aortic aneurysm (AAA) is defined as the permanent dilatation of the abdominal aorta (the 
region extending from the diaphragm to the bifurcating iliac arteries, Figure 8) of >30 mm or >50% the 
size of normal diameter (Johnston et al. 1991). AAA is prevalent in 8.2% of men and 1.7% of women, 
however, this prevalence is not uniformly distributed across all age ranges and dramatically increases 
with age (Singh et al. 2001). Inflammatory biomarkers are present systemically in patients with AAA 
(Tambyraja et al. 2007), however, local irregular aortic enlargement is the primary identifier (Singh et 
al. 2001). As vessel diameter increases, so does the risk of AAA rupture (Filardo et al. 2012), which 
carries with it a high risk of mortality (60-80% which reduces to 30-65% if reaching a hospital alive) 
(Basnyat et al. 1999; Samy, Whyte, and Macbain 1994) accounting for 1% of deaths in the Western 
Figure 7: Schematic of an advance atherosclerotic plaque and a number of processes VSMCs undergo 
Within a late stage plaque, the balance between VSMC proliferation and apoptosis/senescence begins to 
change leading to a thinning of the fibrous cap. Additionally, senescent and apoptosed VSMCs release 
molecules which contribute to the development of the necrotic core, subsequently leading to plaque 
rupture. From Bennett, Sinha, and Owens, 2016. 
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world (Collin et al. 1988). Treatment of AAA relies on pre-rupture diagnosis followed by elective 
surgery to repair the aneurysm. This is however problematic as the majority of AAA remain 
asymptomatic prior to rupture (Scott et al. 1995). 
 
AAA and atherosclerosis share many risk factors (age, smoking, hypercholesterolemia, and 
hypertension) and features such as inflammation. Historically, they were thought to be causally 
related, with AAA the result of atherosclerotic degeneration of the vascular wall. However current 
research suggests that while there is a significant correlation between the occurrence of both diseases 
within an individual, these diseases are distinct entities (Johnsen et al. 2010; Tromp et al. 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
AAA pathogenesis is a complex process involving the destructive remodelling of the affected 
vasculature, the main stages are typically characterised by: (1) chronic inflammation, pro-
inflammatory cytokine release and neo-vascularisation within the outer wall of the aorta; (2) 
dysregulated production of MMPs; (3) degradation of the structural matrix proteins collagen and 
elastin, resulting in arterial weakening and dilatation, and; (4) VSMC death and impaired replacement 
of connective tissue (Thompson, 1996). The risk of rupture relies on several variables, including the 
biochemical, hemodynamic and proteolytic conditions of individual regions of the diseased 
vasculature (Choke et al., 2005). Traditionally biomechanical factors were thought to be the best 
predictor for aneurysm rupture, with areas of the diseased tissue under the highest tensile strength 
thought to be the most at risk (Stringfellow et al., 1987). However, factors relating to enzyme activity 
are now thought to contribute substantially, for example, Vallabhaneni et al. (2004), identified local 
Figure 8: Aneurysm susceptible sites across 
the aorta 
Aneurysms typically locate to the abdominal 
and descending thoracic aorta, and the 
aortic arch. Adapted from Tromp et al., 
2010. 
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‘hot spots’ of MMP hyperactivity, which could lead to weakening, and hence rupture, of the aortic 
wall in areas under relatively low intraluminal pressure. MMP activity fluctuates during normal 
remodelling of the aortic wall, however during AAA the activated MMPs aggressively degrade collagen 
and elastin. Annabi et al. (2002), for example, show that MMP-1, MMP-9 and MMP-12 are all 
upregulated in AAA tissue compared to healthy tissue. Furthermore, the balance between MMPs and 
proteins which regulate MMPs, tissue inhibitors of MMPs (TIMPs), favours the degradation of elastin 
and collagen (Elmore et al., 1998). TIMP-1 and TIMP-2, lack upregulation in AAA contributing to an 
imbalanced proteolytic state (Howard et al., 1991; Tamarina et al., 1997).  
 
1.10 VSMCs in abdominal aortic aneurysm 
  
As described above (sections 1.1 and 1.3) VSMCs are important structural components of the vascular 
wall, as such their role in aortic aneurysm where degeneration of the vascular wall is observed, is likely 
important. Rowe et al. (2000), confirming the results of Lopez-Candales et al. (1997), found that VSMC 
apoptosis was increased in AAA samples from humans, in conjunction with a decrease in VSMC density 
when compared with healthy aortas and aortas with aortoiliac occlusive disease. Furthermore, 
Parastatidis et al. (2013) showed that by specifically augmenting expression of catalase, a H2O2 
scavenging enzyme, in VSMCs within a model of AAA they could reduce apoptotic cell death and 
protect from AAA. Liao et al. (2000) further suggest that replicative senescence of VSMCs within AAA 
contribute to an exhaustive repair potential of these cells, which could in turn be the reason large AAA 
had a reduced capacity for connective tissue repair (Thompson, 2002; Choke et al., 2005).  
 
While it is known that VSMC loss relates to the reduction of the vascular wall’s synthetic capacity and 
structural weakening (Airhart et al., 2015), there is also growing evidence that dysregulated VSMCs 
contribute directly to the degeneration of the vascular wall. Multiple studies have shown that MMPs 
released directly from VSMCs into the ECM are involved in AAA formation (Ailawadi, Eliason, and 
Upchurch 2003; Airhart et al. 2014). VSMCs cultured from AAA and healthy vasculature exhibit 
differential gene expression, further still they differ from those extracted from atherosclerotic 
plaques, supporting the notion that these two diseases are distinct and the AAA phenotype unique 
(Airhart et al., 2014). Compared to healthy tissue, AAA VSMCs upregulate expression of MMP-2 and 
MMP-9 and cysteine proteases with properties ideal for elastolysis. Mutations within VSMC genes 
have also been shown to contribute to aneurysm, mutations in aSMA and MYH11 result in abnormal 
VSMC contraction and aortic aneurysms (Guo et al., 2007; Pannu et al., 2007). Ailawadi et al. (2009), 
suggest that VSMCs undergo phenotypic switching early on in AAA. Using an elastase-perfusion model 
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for AAA within mice they show that by day 7 post-surgery VSMC marker genes (aSma and Sm22a) 
were downregulated, consistent with VSMC phenotypic modulation, prior to aneurysm formation. 
Furthermore, human aortic aneurysms extracted at time of resection had significantly less aSMA 
compared to aortic tissue extracted during coronary artery bypass grafting, and significantly higher 
MMP-2 and apoptosis marker Caspase-3 expression. While this study implies that VSMCs are changing 
in AAA, the extent of these phenotypic changes and associated VSMC proliferation cannot be 
definitively determined.    
 
VSMCs within AAA clearly have an important role, the extent of which remains unknown, similar to 
the early atherosclerosis experiments describe above (section 1.5), phenotypic switching makes these 
cells difficult to track without using mice carrying the Myh11-Cre transgene, which has yet to be 
performed in AAA.  
 
1.11 Molecular mechanisms of VSMC phenotypic switching  
 
The stimuli inducing VSMC phenotypic switching are numerous and wide ranging, factors such as 
vascular injury, mechanical force, growth factors/inhibitors, inflammatory/oxidative stress and cell – 
cell/matrix interactions are all known to induce such an event (Owens 1995).  
 
The VSMC cytoskeleton and surrounding medial ECM play a key role in phenotypic modulation and 
migration/proliferation of VSMCs. For example, type I collagen present in the ECM, induces VSMC 
production of cyclin-dependant kinase 2 inhibitors, preventing VSMC proliferation (Koyama et al. 
1996). The cytoskeleton of VSMCs, a 3D structure composed of protein microfilament/tubules, 
remains intact in contractile VSMCs. However, actin cytoskeletal degradation, induced by loss of 
tensile stress in an organ culture system, inhibits VSMC marker gene expression (e.g. Myocardin) 
thereby enhancing phenotypic switching (Zheng et al. 2010).  
 
A significant step forward in understanding the regulatory processes behind phenotypic switching was 
the identification of promoter/enhancer regions within a selection of VSMC marker genes, conferring 
specific expression in VSMCs in mice (Mericskay et al., 2000; Li et al., 1996; Mack and Owens, 1999; 
Kim et al., 1997; Masen et al., 1998). The transcriptional regulation of these regions within VSMC 
marker genes rely on a multitude of factors which are expressed ubiquitously or selectively by VSMCs 
(Figure 9). The best characterised model of transcriptional regulation is the ‘CArG-SRF dependant 
regulation model’. Studies have identified that expression of many VSMC specific/marker genes rely 
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on CArG elements (CC(AT)6GG) within enhancer/promotor sites. These elements bind serum response 
factor (SRF, a MADS-box transcription factor) which coordinate gene expression. Myocardin, a potent 
SRF activator which is exclusively expressed within SMCs and cardiomyocytes, plays an important role 
in promoting interactions between CArG boxes and SRF, and subsequent recruitment of RNA 
polymerase II (Pol II) specifically within VSMCs (McDonald et al., 2006; Yoshida et al., 2003). In fact, 
within the majority of CArG-dependant VSMC marker genes tested, including aSMA, MYH11, SM22α 
and Calponin, Myocardin induces selective expression (Du et al., 2003; Yoshida et al., 2003; Alexander 
and Owens, 2011). Disruption of Myocardin-induced SRF-CArG binding is thought to play a role in 
phenotypic switching, Wang et al., (2004) showed that PDGF-BB – induced decreases in VSMC marker 
genes was, in part, due to phosphorylation of Elk-1, which subsequently competed with Myocardin 
for CArG-SRF binding. Tang et al. (2008) further showed that NFκB also binds Myocardin to reduce its 
interaction with SRF and CArG. Conversely Angiotensin II (Ang II) increases the expression of VSMC 
marker genes, mediated through the upregulation of paired-related homeobox gene 1 (Prx1) which 
promotes CArG-SRF-Myocardin interactions (Figure 9, Yoshida, Hoofnagle, and Owens 2004).   
 
 
Figure 9: Transcriptional regulation of VSMC marker genes 
VSMC-selective gene expression is mediated through a complex process of combinatory cis-regulatory 
elements and transcription factors. Myocardin acts as a potent co-activator of SRF binding to CArG elements 
within promoters of VSMC marker genes, which promotes the recruitment of Pol II to initiate transcription. 
Other factors such as paired-related homeobox gene 1 (Prx1) and protein inhibitor of activated stat 1 (PIAS1) 
complexed with basic helix-loop-helix (bHLH) factors at E-box cis regulatory elements promote Myocardin-
SRF-CArG interactions. Transcription factors KLF4, Elk-1 and HES-related repressor protein (Herp2) act to 
repress VSMC marker gene expression, at least in part by inhibiting Myocardin-SRF-CArG interactions. 
Transcription factor Forkhead Box O4 (FoxO4) and the p65 subunit of NFκB compete with SRF to bind 
Myocardin, inhibiting VSMC marker gene expression. From Alexander and Owens, 2011. 
34 
 
Epigenetic factors also play a crucial role in the ability of SFR to bind CArG containing regions of VSMC 
genes (Figure 10). Studies have identified that the histone modifications Histone H4 acetylation 
(H4ac), H3K4me2, Histone H3 acetylation (H3ac) and Histone H3 lysine 79 dimethylation (H3K79me2) 
are involved in the ability of Myocardin-SRF to bind to CArG sites, activating VSMC gene expression 
programmes and the differentiation of VSMC precursor-cells (Qui and Li, 2002; Cao et al., 2005; 
Manabe and Owens, 2001; Macdonald et al., 2006). Furthermore, PDGF-B treatment of cultured 
VSMCs and an in vivo balloon-injury model induced VSMC phenotypic switching in conjunction with a 
reduction in histone H4 acetylation at CArG elements and SRF binding (McDonald et al., 2006).  
McDonald et al. (2006) further suggest that H4 deacetylation is due to the recruitment of histone 
deacetylase 4 (HDAC4) by KLF4. Indeed, KLF4 had previously been shown to be a potent repressor of 
VSMC marker genes, both by down regulating Myocardin expression and inhibiting Myocardin-SRF 
binding to CArG elements (Figure 9, Liu et al., 2005). H3K4me2, however, was unaffected in 
phenotypically switched VSMCs induced by either PDGF-B or the balloon injury models. Thought to 
represent a lineage memory mark, H3K4me2 may allow VSMCs to reverse the process of phenotypic 
switching and, as discussed previously (section 1.5), acts as a useful marker to examine phenotypically 
switched VSMCs in humans (McDonald et al. 2006; Gomez et al. 2013). Furthermore, global DNA 
hypomethylation and expression of DNA methyltransferases are increased in VSMCs within 
atherosclerotic plaques compared to those in healthy media (Hiltunen et al., 2002).  
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MicroRNAs (miRNAs), a group of single stranded 20-25 nucleotide, non-coding RNAs active in many 
post-transcriptional regulatory processes within a cell act to indirectly regulate transcription and 
within VSMCs.  Several studies have now implicated miR-145 and miR-143 in regulation VSMC 
phenotype, in part by degrading KLF4 (a zinc finger transcription factor) transcripts, promoting the 
contractile phenotype. Furthermore, miR-145 and miR-143 are both downregulated in injured and 
atherosclerotic vasculature (Cordes et al., 2009; Xin et al., 2009; Cheng et al., 2009). Multiple other 
miRNAs are involved in maintaining the contractile phenotype/causing the switch to a synthetic 
phenotype (reviewed  in Zhang et al., 2016). 
 
Studies on the epigenetic and molecular regulation of VSMC differentiation and phenotypic 
modulation are plagued by the use of cells from culture systems which do not faithfully recapitulate 
the in vivo environment. Furthermore, ex vivo bulk tissue processing, necessary for techniques such 
Figure 10: Epigenetic regulation of VSMC phenotype 
During VSMC differentiation histone proteins within promotors of VSMC marker genes (e.g. aSMA and 
MYH11) are modified. Acetylation of H3 and H4 and dimethylation of lysine’s 4 and 79 on H3 open allow 
binding of SRF-Myocardin to CArG elements. VSMCs induced to phenotypically switch/modulate undergo 
loss of histone modifications H3/H4 acetylation and H3K79 dimethylation, inhibiting CArG accessibility. 
From Alexander and Owens,   
2011. 
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as chromatin immunoprecipitation (ChIP)/ChIP-seq, are inevitably contaminated by other cells types 
(Gomez, Swiatlowska, and Owens 2015). To further understand the mechanistic processes underlying 
VSMC behaviour it is becoming increasingly necessary to employ new techniques capable of 
performing analyses at the single cell level either in vivo or on tissue taken directly from living animals. 
Techniques available include those capable of single-cell epigenetic analysis (Bheda and Schneider, 
2014), single cell RNA sequencing4 (scRNA-seq, Tang et al., 2009) and single cell genome wide DNA 
methylation analysis (Smallwood et al., 2014).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
4 Thesis aim 4: Optimise scRNA-seq methods for VSMCs 
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1.12 Aims and hypothesis  
 
VSMCs, which are typically contractile and quiescent, have remarkable plasticity, able to 
phenotypically switch and trans-differentiate in response to multiple environmental stimuli and 
vascular diseases. The non-random positional occurrence of atherosclerotic lesions and aortic 
aneurysms within the vasculature suggests that very particular environmental stimuli are required to 
activate the dysregulated response of VSMCs in either disease. Furthermore, as mentioned above 
there is a large degree of heterogeneity in the VSMC population. This raises the question of the relative 
contribution of cell intrinsic and external factors, in particular, whether all VSMCs have the same 
potential to phenotypically switch. For example, cells which proliferate in response to injury/disease 
could belong to specific sub-population of VSMCs or all VSMCs may be equipotent, capable of 
activating in response to disease. The experiments conducted within this thesis attempt to understand 
these questions, first by assessing clonal VSMC proliferation within multiple disease models and 
secondly by understanding heterogeneity at the level of the single cell.  
 
Hypothesis: The reported heterogeneity within the VSMC population results in differences in VSMC 
functionality in models of CVD 
 
Aims: 
1. Determine if phenotypically distinct VSMC-derived plaque cells are generated from single 
(multi-potent) VSMCs or if distinct VSMCs produce a single or subset of these (uni/oligo-
potent) 
2. Determine the proportion of VSMCs which respond in vascular disease/ injury  
3. Determine if VSMC remodelling occurs by the clonal expansion of single VSMCs or the 
proliferation of numerous VSMCs 
4. Optimise scRNA-seq methods for analysis of VSMCs heterogeneity 
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CHAPTER 2: Methodology 
 
To investigate the described aims, a system of methods will be employed, the principles of several of 
these methods are described here for later reference and to aid the understanding of the results. 
 
2.1 VSMC specific, multi-colour lineage tracing – the Confetti system   
 
Lineage tracing within this study utilises an inducible Cre-lox system to drive the stochastic 
recombination of the multi-colour confetti reporter, specifically within VSMCs (Figure 11). This multi-
colour labelling is advantages over single or dual colour systems as clonal proliferation can be detected 
while using a much higher labelling frequency, due to the unlikely event that only cells of the same 
colour proliferate by chance.  
 
The Cre recombinase used here is fused to a triple mutant form of the human oestrogen receptor, 
which binds the synthetic oestrogen 4-hydroxytamoxifen (and not its natural ligand, 17β-estradiol). 
Confined to the cytoplasm of a cell, CreER(T2) can only access the nucleus following tamoxifen 
administration. Thus, allowing recombination to be induced when desired. To ensure that CreER(T2) 
activity was specific to VSMCs upon tamoxifen administration the CreER(T2) sequence was inserted 
into the ATG site of a bacterial artificial chromosome (BAC) carrying the Myh11 gene, the most specific 
marker of VSMCs (Nguyen et al., 2013). The 180 kb BAC was then injected into the pro-nuclei of mice 
oocytes. Myh11-CreER(T2) transgenic mice where the transgene had integrated into the Y 
chromosome were chosen for breeding on to the C57BL/6 background (Wirth et al., 2008). This Cre is 
therefore only present in male animals, hence the reason only male animals are used in these studies. 
It should be noted that sex bias in biomedical research, i.e. the neglect of females, is common place. 
This, however, should be avoided where possible and should have been considered by those who 
performed the mouse transgenics, as tangible differences can often be seen between sexes (Beery 
and Zucker 2011). While the activation of this transgene seems to faithfully recapitulate endogenous 
expression of the true Myh11 gene (Wirth et al. 2008; Nemenoff et al. 2011), it should always be 
considered that differences in chromosome location/local genomic environment, may affect a 
transgene’s promotor activity relative to the endogenous protein’s promotor (Liu 2013).  
  
The confetti reporter (Figure 11), located in the Roas26 locus, contains (1) a CAG promoter, which 
permits high levels of gene expression, (2) a loxP flanked stop cassette, such that protein translation 
in this system is Cre-recombinase dependant and (3) the Brainbow 2.1 sequence, containing the floxed 
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cDNA for red (RFP), yellow (YFP), cyan (CFP) and green (GFP) fluorescent proteins. Cre driven 
recombination of this construct causes the stochastic expression of one of the four fluorescent 
proteins. RFP and YFP localise to the cytoplasm, whereas tagging results in recruitment of CFP to the 
membrane and GFP to the nucleus (Snippert et al., 2010; Livet et al., 2007). Without further Cre 
activity, the progeny of a labelled cell express the same fluorescent protein at equal intensity to the 
pre-cursor cell.  
 
 
 
 
 
 
 
2.2 The ApoE-/-, high fat diet model of atherosclerosis  
 
The C57BL/6 mice strain was found to be one of the most susceptible inbred strains to atherosclerosis, 
primarily when subjected to HFD, and has since been commonly used as a diet induced atherosclerosis 
model (Paigen et al., 1987; Nakashima et al., 1994). However, the lesions which develop in these mice 
when given HFD typically resemble large fatty streaks with little involvement from VSMCs (Paigen et 
al., 1987). To develop more efficient models of atherosclerosis, mice have been genetically modified 
to disrupt gene products involved in cholesterol metabolism. Homozygous mice for the ApoEtm1Unc 
(ApoE-/-) mutation have increased total plasma cholesterol due to their inability to properly catabolise 
triglyceride-rich lipoproteins (Nakashima et al., 1994). Following six weeks of HFD, in ApoE-/- animals, 
there is evidence of cell adhesion to the endothelium and foam cell formation within the sub-
endothelial space, after ten weeks mice develop ‘intermediate lesions’ consisting of multiple cell types 
including VSMCs and foam cells and by fifteen weeks large fibrous plaques have formed in the 
branching regions of the aorta and major vessels. The plaques within ApoE-/- mice follow similar 
Figure 11: Schematic of the ‘Confetti’ multi-colour lineage tracing system 
A, Schematic of the Myh11-CreERt2 transgene (top) and the Rosa26-Confetti reporter allele (below). B, 
Schematic illustrating tamoxifen-induced recombination at the Rosa26-Confetti locus resulting in 
expression of one of four fluorescent proteins, which are stably propagated independent of Myh11 
expression within progeny. From Chappell et al. (2016) 
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developmental steps seen within humans (Nakashima et al., 1994). The major difference between the 
ApoE-/- mouse model and humans is that plaques within these mice typically do not rupture and 
therefore fail to show the final and deadliest stage of atherosclerosis. Additionally, an important 
distinction between mice and humans is that within human vasculature, VSMCs exist within the intima 
at certain positions of the vascular tree, primarily at branch sites, prior to disease (Doran et al., 2008). 
However, despite differences in cardiovascular physiology, lipid profile and cholesterol metabolism, 
and the differences noted in plaque pathology, this system remains one of the most useful tools in 
studying atherosclerosis (Meir and Leitersdorf, 2004).   
 
2.3 The carotid ligation injury model of vascular remodelling   
 
Vascular remodelling within carotid arteries, characterised by medial and intimal thickening, is 
regarded as a phenotypic predictor for CVD in humans, and is seen in the early stages of 
atherosclerosis (Davis et al., 2001). This can be modelled by performing carotid ligation surgery within 
mice (Figure 12), where blood flow through the vessel is reduced/abolished (Korshunov and Berk, 
2003). As mentioned previously (section 1.4), haemodynamic forces experienced by a vessel are 
important in the maintenance and susceptibility of athero-protective and athero-prone phenotypes, 
respectively. Flow disruption within this model therefore leads to rapid endothelial dysfunction and 
an acute proliferative response from VSMCs (Nam et al., 2009). Four weeks post ligation, lumen area 
is reduced by approximately 80%, primarily due to VSMC-rich neointima formation. Typically, 
monocytes and macrophages are not detectible, however some leukocytes (CD45 positive cells) 
infiltrate the media and neointima (Kumar and Lindner, 1997). This model, therefore, allows the study 
of vascular remodeling at the molecular level by causing an acute proliferative VSMC response, which 
is typically more reproducible and quicker than HFD protocols which generate plaques. 
 
 
 
 
 
Figure 12: Illustration of carotid ligation surgery of the left carotid artery 
Illustration of the aortic arch and protruding vessels and the site of carotid ligation. Within the carotid 
ligation model of CVD, the left carotid artery is ligated directly below the bifurcation indicated by red line. 
Adapted from Nam et al., 2009.    
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2.4 The Angiotensin II perfusion model of aortic aneurysm  
 
There are multiple methods to induce AAA within mice, however, the Ang II perfusion model is the 
most widely used technique as, it is believed, to faithfully recapitulate AAA and the surgery required 
is relatively non-invasive compared to other methods (Cao et al., 2010).  To perform this method, Ang 
II containing osmotic mini-pumps are inserted subcutaneously into mice, on one side of the posterior 
flanks (Daugherty and Cassis, 1999). Typically, ApoE-/- or Ldlr-/- mice fed either normal chow or HFD 
are used in these studies (Daugherty and Cassis, 1999; Daugherty et al., 2000; Manning et al., 2002). 
Ang II perfusion will lead to AAA in normocholesterolemic mice (i.e. wild type for ApoE), but at a lower 
incidence rate (3-4 fold) compared to hyperlipidaemic mice (Deng et al., 2003; King et al., 2006). The 
mechanisms by which Ang II induces aneurysm are not fully understood, although it has been 
demonstrated that AAA develops in this model independently of Ang II induced hypertension, but may 
result from mechanisms related to inflammation (Cassis et al., 2009). Features of the Ang II model 
include: (1) an early accumulation of macrophages to the adventitia and media of the suprarenal aortic 
region; (2) medial dissection and an increase in lumen diameter, along with the appearance of thrombi 
located to the media, contained by the adventitia; (3) abnormal matrix deposition and thrombus 
resolution 28 days post mini-pump insertion, which continue to remodel and have features associated 
with immune response and neovascularisation (Saraff et al., 2003; Barisione et al., 2006; Rateri et al., 
2011). Wang et al. (2010) combined Ang II perfusion with injections of anti-TGF-β to study the role of 
TGF-β in the Ang II model of AAA.  Results demonstrated that TGF-β neutralisation increased the AAA 
in the normally resistant, normocholesterolemic, ApoE wild type mice on the C57BL/6 background. 
However, anti- TGF-β administration in ApoE-/- mice show no difference compared to ApoE-/- receiving 
Ang II alone (King et al., 2009). Wang et al. (2010) further show that TGF-β is important in controlling 
excessive monocyte/macrophage activation, thus protecting from AAA. The Ang II + anti-TGF-β model 
has the advantage that it is not confounded by hypercholesterolemia from the ApoE-/-  mice, and is 
also more reproducible (Wang et al., 2010). 
 
It is difficult to evaluate exactly how similar Ang II induced models of AAA are to human AAA as human 
samples are typically only collected at the end stage of the disease (Daugherty and Cassis., 2004). 
However, two main differences/problems noted are: 1) within Ang II perfused mice aneurysms 
typically locate to the suprarenal, compared to the infrarenal aorta in humans (Saraff et al., 2003); and 
2) a large degree of heterogeneity between mice under the same protocol exists, which has led to the 
development of a classification system from Grade I – IV (Daugherty at al., 2001). The reasons for the 
difference in position of AAA are considered to be due to potential haemodynamic/mechanical 
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differences, and/or differences in elastin/collagen matrix composition, between mice and human 
arteries (Halloran et al., 1995; Saraff et al., 2003). However, no definitive mechanisms responsible for 
preferential location were known (Daugherty et al., 2011).  
 
These ideas, however, have recently been challenged, and indeed the Ang II model itself as a method 
of recapitulating AAA. Trachet et al. (2017), published recent work investigating the variability in the 
shape of the ‘dissecting aneurysms’ observed in the AAA method, using in vivo ultrasound and ex vivo 
phase-contrast X-ray tomography microscopy. Trachet et al. (2017) suggest a temporal sequence of 
events leading to the observed phenotypes in the AAA model. The steps include: 1) micro ruptures 
around the celiac and mesenteric arteries propagate to a medial tear; 2) the medial tear causes the 
adventitia to dissect; 3) intramural blood makes small side branches rupture; 4) the dissection is 
stopped by large side branches; and 5) an intramural haematoma forms with or without a false 
channel (a second, false, lumen supporting blood flow parallel to the lumen proper). Trachet et al. 
(2017), first point out that it is the location of the micro tears at the ostium of the celiac and mesenteric 
arteries within the Ang II model which is the reason why aneurysms locate to the suprarenal region of 
the aorta. Secondly, they suggest that the variability in the Ang II model can be explained by presence 
or absence of: 1) medial tears; 2) intramural haematoma (IMH); and 3) a false channel. Trachet et al., 
(2017) note significant differences between the Ang II model and human AAA, namely, that within the 
Ang II model, focal tears within the media at specific branch regions initiate aneurysm compared to 
circumferential medial degradation in human; IMH is caused by adventitial dissection rather than an 
intraluminal thrombus; and that there is a false channel increase in size in a subset of animals rather 
than gradual luminal dilatation in all.  Based on this information, Trachet et al., (2017) suggest that 
Ang II infusion in mice is better suited to studying aortic dissection and does not recapitulate human 
AAA accurately.   
 
Whether the Ang II model will be reclassified regarding the disease it models will be subject to some 
debate and further work. This does however raise one important conclusion, that all animal models 
regardless of how well they seem to recapitulate a disease within humans, will differ in many ways 
and should only be used with this in mind. 
 
2.5 Single cell transcriptomics  
 
In the last decade technologies have been developed/adapted to perform RNA-sequencing on single 
cells, enabling intra-population heterogeneity and cell-cell transition states to be examined at the 
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transcript level. Thus, revealing cell subtypes and dynamics in cellular transcription/gene expression, 
which can be masked by bulk population sequencing (Wills et al., 2013; Trapnell et al., 2014; Liu and 
Trapnell, 2016).  Two methods to perform scRNA-seq are used within this study, the first is Smart-seq2 
(Picelli et al., 2013), this method relies on isolating single cells, which can be performed by 
fluorescence-activated cell sorting (FACS) or laser dissection microscopy (Nichterwitz et al., 2016). 
Once isolated, cells undergo a protocol in which the RNA from single cells are reversed transcribed to 
generate full-length cDNA, which are then indexed and pooled to create a sequencing library (Figure 
13). This method uses ‘off the shelf’ reagents, a step by step protocol is outlined in section 3.18.  
 
 
 
 
 
 
Figure 13: Flow chart for Smart-seq2 
protocol 
To preform Smart-seq2, single cells are 
first isolated. Oligo(dT) primer then binds 
the Poly(A)+ tail of RNA transcripts and 
reverse transcription is performed. Upon 
reaching the 5’ end of the RNA template 
the polymerase adds several additional 
nucleotides (mostly deoxycytidine) to 
the 3’ end of the synthesised cDNA. 
These bases act as a site for the template 
switching oligo (TSO) to bind, at which 
point the polymerase switches templates 
and continues replication to the end of 
the 5’ end of the TSO. Universal primers 
(ISPCR) are then added and cDNA 
amplification performed. To prepare 
sequencing libraries, a hyperactive 
derivative of the Tn5 transposon is used 
to fragment and incorporate 
predetermined oligonucleotides into the 
cDNA, which are then PCR enriched. To 
allow pooling of up to 96 samples, a duel 
indexing system (index 1 (i7) and index 2 
(i5)) is used. Following sequencing, data 
from individual cells can be extracted 
based on the unique cell index. From 
Picelli et al., 2014. 
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Smart-seq2 is typically performed in 96 well plates (i.e. 96 single cells at a time), and is labour intensive 
compared to most other methods of scRNA-seq, however it is recognised as one of the most sensitive 
methods to use when performing scRNA-seq on relatively few cells (Ziegenhain et al., 2017). 
Compared to scRNA-seq techniques such as MATQ-seq (Sheng et al. 2017), smart-seq2 only captures 
polyadenylated RNA as it uses oligo(dT) to isolate and purify mRNA, furthermore strand specificity is 
lost in this method (Picelli et al., 2013). 
 
The second method of scRNA-seq used here utilises the 10X Genomics, Chromium system. This system 
is a droplet based system in which dissociated cells are loaded into a Chromium machine and are then 
processed so that individual droplets contain a single cell and a bead, containing the necessary 
reagents to perform reverse transcription (referred to as single cell gel beads in emulsion, GEMS, 
Zheng et al. 2017). Reverse transcription then takes place within each GEM, importantly, during first 
strand cDNA synthesis each transcript is tagged with a cell barcode and a unique molecular identifier 
(UMI). Following cDNA amplification and library preparation the cDNA is then sequenced. The cell 
barcode can then be used to aggregate sequencing reads for individual cells similar to the indexing 
method used in Smart-seq2. One significant advantage of this method compared to methods such as 
Smart-seq2 is that the UMIs can be used to assign sequencing reads to individual transcript molecules, 
this helps to remove biases and amplification noise generated from scRNA-seq, furthermore it allows 
the determination of the relative abundance of different transcripts (Kivioja et al. 2011; Zheng et al. 
2017).  
 
Relative to Smartseq-2, the 10x system for scRNA-seq is extremely high throughput, allowing up to 
10,000 cells to be captured and processed in one experiment, this is partly due to the early attachment 
of cell barcodes, during first stand synthesis of cDNA, which allows for multiplexing of the cDNA during 
amplification (Hashimshony et al. 2012; Jaitin et al. 2014). Furthermore, all steps following tissue 
dissociation to single cells are automated, meaning the labour costs are low. One disadvantage of this 
method compared to Smart-seq2 is that only the 3’ ends of each transcript is read during sequencing, 
this is necessary due to the use of UMIs which only attach to one end of the transcript and must be 
read. Smart-seq2 however, captures full length transcript data, which increases its sensitivity as lowly 
expressed transcripts are preferentially detected using full-length transcript methods, this is thought 
to be due to particular 3’-proximal sequences which are difficult to align to the genome (Ziegenhain 
et al. 2017).  
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CHAPTER 3: Methods 
 
This study was conducted within the Cardiovascular Medicine Division, Department of Medicine, 
University of Cambridge. All animal experiments have been approved by the UK Home Office 
(PPL70/7565), were performed according to Home Office guidelines and were approved by the local 
ethics committee. 
 
3.1 Animal experiments   
The ‘Confetti mice’ used here were made by crossing two different genetically modified lines: The 
Gt(ROSA)26Sortm1(CAG-Brainbow2.1)Cle/J, (R26R-Confetti) mice (Snippert et al., 2010) from The 
Jackson Laboratory were crossed with the B6.FVB-Tg(Myh11-cre/ERT2)1Soff/J, (Myh11-CreER(T2)) 
mice (Wirth et al., 2008), also from The Jackson Laboratory. The Myh11-CreER(T2) mice were on an 
inbred C57Bl/6 background (for at least 10 generations), whereas the R26R-Confetti allele was on a 
mixed C57Bl/6 / BALB/c background prior to cross breeding.  
The ApoE-/- Confetti mice were made by crossing a third genetically modified line, the B6.129P2-
Apoetm1Unc/J (Piedrahita et al., 1992) purchased from Charles River Laboratories, to the Confetti mice. 
The Apoe-/- were on an inbred C57Bl/6 background (for at least 10 generations) prior to cross breeding.  
The Myh11-CreER(T2) transgene is Y-linked, therefore all experimental animals in this study are males. 
Experimental animals used were backcrossed to the C57Bl/6 for 1-6 generations (Appendix A and C), 
no difference in described phenotype between mice from different generations was observed.  
 
3.2 Tamoxifen administration and dose optimisation  
Tamoxifen (Sigma-Aldrich) solution was made in batches of 9 ml of 10 mg/ml in corn oil (Sigma-
Aldrich). To make, tamoxifen is diluted in pre-warmed (55 oC) ethanol (EtOH, 200 proof) to a 
concentration of 10 mg/0.1 ml, and shaken to dissolve. This solution was then diluted into sterile 
filtered (0.22 µm filter) corn oil warmed to 55 oC to a concentration of 10 mg tamoxifen/ml, vortexed 
and aliquoted into 1.5 ml Eppendorf tubes. Three rounds of sonication (Sonics Vibra.Cell), 20 seconds 
on 60% output, with cooling on ice in-between ensured tamoxifen was fully dissolved. Tamoxifen 
aliquots were then stored in the dark at -20oC.       
When necessary, tamoxifen was further diluted in corn oil to desired concentrations, 100 µl of the 
tamoxifen solution was injected intraperitoneally into each mouse per injection. Dose optimisation 
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was completed by injecting various concentrations of tamoxifen (displayed in results) and analysed 
via confocal microscopy of tissue and flow cytometry of dissociated cells, described below.  
 
3.3 Tissue removal and fixation 
Mice were culled via CO2 asphyxiation prior to perfusion with 10 ml cold phosphate buffered saline 
(PBS). The left (LCA) and right (RCA) carotid arteries and aorta were removed and cleaned of fat by 
microdissection under a light microscope. Fixing was performed in fresh 4% paraformaldehyde (Sigma-
Aldrich) for 20 mins at room temperature (RT).  
 
3.4 Medial dissociation to single VSMCs  
To isolate VSMCs to a single cell suspension, microdissection was used to remove the external fat and 
to open the aorta into a sheet. The ECs were lightly scraped off the inside of the sheet. A partial 
digestion step in a mixture of 1 mg/ml Collagenase type IV (Gibco) and 1 U/ml Elastase (Worthington 
Biochemical) dissolved in Dulbecco’s Modified Eagles Medium (DMEM, Sigma-Aldrich) for 8 mins at 
37 oC allowed the separation of the adventitia from the media using forceps. A final digestion in fresh 
enzyme mixture (1 ml for 1 aorta) at 37 oC with frequent pipetting using a P1000 was used until a 
single cell suspension has been achieved, typically 2 hours. Isolated cells were centrifuged at 1000 rpm 
for 3 mins and re-suspended in 3% bovine serum albumin (BSA) in PBS (this process was repeated 3x) 
and filtered through a 70 µm cell strainer. 
 
3.5 Flow cytometry 
A BD LSR Fortessa was used for flow cytometry. A 405 nm violet laser, 488 nm blue laser and a 561 nm 
yellow laser combined with 450/50, 530/30 and 610/30 BP filters, detects CFP, GFP/YFP and RFP, 
respectively. Where possible 10,000 cells were analysed as a minimum. Flowing software (Terho, 
version 2.5.1) was used to analyse the raw data to determine proportions of labelled cells. 
 
3.6 Blood plasma and bone marrow isolation  
Blood was removed from CO2 asphyxiated mice via cardiac puncture with a 27G needle and collected 
into heparinized tubes (Microvette® 55LH, SARSTEDT). Red blood cells were lysed by incubation in lysis 
buffer, composed of 55mM NH4Cl, 10mM KHCO3 and 0.1mM EDTA (pH 7.3) for 10 minutes. White 
blood cells were pelleted via centrifugation at 300 x g for 5 mins and the supernatant discarded. 
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Isolated cells were centrifuged at 1000 rpm for 3 mins and re-suspended in 3% bovine serum albumin 
(BSA) in PBS (this process was repeated 3x) and filtered through a 70 µm cell strainer. 
For bone marrow, femurs were removed from mice, the ends of the bone were cut off and the bone 
marrow flushed out with PBS using a 27G needle. The bone marrow cells were passed through a cell 
strainer (70 µm) prior to flow cytometry. 
 
3.7 Vibratome sectioning  
Following the tissue removal/fixing steps in section 3.3 the tissue was submerged in liquid 4% low 
melt agarose (Thermo Scientific) and left at RT until solidified. Sections, 50-100 µm thick, were then 
cut on a vibratome (LEICA • VT 1200S), on to polysine slides (Thermo Scientific). Sections were then 
mounted in RapiClear 1.52 (Sunjin lab) with a coverslip.  
 
3.8 Cryo-sectioning 
Following the tissue removal/fixing steps in section 3.3 the tissue was submerged in a 30% sucrose 
(Sigma Aldrich) solution in PBS overnight at 4oC. Tissue was then transferred to a 50:50 solution of 
30% sucrose solution:OCT compound (VWR) for 1 hour at RT before a final incubation of 1 hour in 
100% OCT at RT. Samples were then placed into OCT within plastic moulds and snap frozen using dry 
ice prior to storage at -80 oC. A cryostat was used to cut 20, 14 or 12 µm thick sections on to 
Superfrost™ Ultra Plus Adhesion Slides (Thermo scientific), slides were stored at -80 oC. 
 
3.9 Immuno-staining 
All immunostaining was performed on cryo-sections. Sections were briefly rinsed in PBS, 
permeabilised in 0.5% TritonX-100 in PBS (20 min at RT) and incubated for 1 hour at RT in blocking 
buffer (1% BSA, 10% normal goat serum (Dako) in PBS). Staining with the following primary or isotype 
control antibodies diluted in blocking buffer was done overnight at 4˚C: aSMA - biotin, (Abcam, 2.5 
µg/ml, ab125057); aSMA-Alexa Fluor 488, (Abcam, 2.5 µg/ml, ab184675); Mac3-Alexa Fluor 647, 
(Biolegend, 2.5 µg/ml, 08511); Myh11, (Abcam, 2.5 µg/ml, ab53219); Mouse IgG2a, k-biotin, 
(Biolegend, 2.5 µg/ml, 400203); Rat IgG1, k-Alexa Fluor 647, (Biolegend, 2.5 µg/ml, 400418); Rat IgG2a, 
k-Alexa Fluor 647, (Biolegend, 2.5 µg/ml, 400526); Rabbit IgG, (Abcam, 2.5 µg/ml, ab27478); Cd41 
(eBioscience, 2.5 ug/ml, 14-0411-82). Sections were then washed 3x 5 mins in PBS and incubated with 
a secondary antibody diluted in blocking buffer where necessary; Streptavidin-Alexa Fluor 647, 
(Biolegend, 0.5 µg/ml, 405237); Goat Anti-Rabbit IgG-Alexa Fluor 647, (0.5 µg/ml, ab150079). Sections 
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were then washed 3 times: first in PBS for 5 mins, secondly in in DAPI, (1 µg/ml in PBS, 10 min at RT) 
and finally in PBS again for 5 mins. Sections were then mounted in RapiClear 1.52 with a coverslip.  
 
3.10 5-ethynyl-2'-deoxyuridine administration and detection  
5-ethynyl-2'-deoxyuridine (EdU) is a thymidine analogue able to incorporate into the DNA of 
proliferating cells. 300 µl EdU diluted in PBS (5 mg/ml) was injected intraperitoneally into mice post 
carotid ligation surgery (section 3.11) or during the high fat diet (section 3.12) and AAA (section 3.13) 
protocols at various time points (indicated in figure legends). At the point of choosing, carotid arteries 
and the aorta were removed and fixed as disused previously (section 3.3) and sectioned in the case of 
the atherosclerosis and AAA studies. The Click-iT® Plus EdU Alexa Fluor® 647 Imaging Kit (Life Tech, 
C10640) was then used to fluorescently label the incorporated thymidine analogue with the Alexa 
Fluor 647 dye. The protocol provided with the kit was followed closely for cryo-sections with a few 
adaptions listed below for the whole mount samples obtained from the ligation experiments. 
Permeabilisation time was increased from 30 mins to 1 hour in 0.5% Triton X-100 in PBS and incubation 
time within the Click-iT® Plus reaction mix was increased from 20 mins to 1 hour.   
 
3.11 Carotid ligation protocol 
Myh11-CreER(T2); R26R-Confetti mice of at least six weeks old were injected with either 1x 0.1mg, 1x 
1 mg or 10x 1 mg of tamoxifen (over 2 weeks) to induce the desired level of recombination of the 
confetti allele (Figure 11). Animals were then rested for at least one week to allow tamoxifen depletion 
in order to avoid further recombination events.  
To perform the ligation surgery, animals were anaesthetised (by inhalation) using a mixture of oxygen 
(1.5 L/min) with 2.5-3% isoflurane and given a pre-operative analgesic (~0.1 mg/kg body weight, 
Buprenorphine, Temgesic®) subcutaneously. The neck was shaved and cleaned with antiseptic soap 
prior to making a 1.5 cm long incision slightly to the left of the midline of the neck. Blunt forceps and 
retractors were then used to move the salivary gland and muscle out of the way to expose the LCA. 
Angled forceps were then used to separate the LCA from the surrounding vessels and vagus nerve. A 
piece of 0.7 braided suture (LOOK™) was then passed under the LCA and tied with two single throws 
to tighten just below the bifurcation. Several interrupted sutures, 0.7 polyglactin 910 absorbable 
suture (VICRYL™), were then used to close the incision prior to the mouse being placed in an incubator 
at 30 oC to recover. A proportion of mice were injected with EdU every week day following ligation up 
until and just prior (2 hours) before mice were culled (section 3.10). Mice were culled between 1-28 
days post ligation surgery, tissue was processed as described (section 3.3). Post fixing, nuclei were 
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stained with 4', 6-diamidino-2-phenylindole (DAPI, 1ug/ml in PBS) for 1 hour at RT. Rapiclear 1.52 was 
used to clear (approx. 300 µl per aorta) and mount tissues between two coverslips containing a 0.5 
mm iSpacer (Sunjin Lab) and imaged via confocal microscopy (section 3.14). 
 
3.12 Atherosclerosis, high fat diet protocol  
Myh11-CreER(t2); R26R-Confetti; ApoE-/- mice of at least six weeks old were injected with either 1x 
0.1 mg, 1x 1 mg or 10x 1 mg of tamoxifen (over 2 weeks) to induce the desired level of recombination 
of the confetti allele (Figure 11). Animals were then rested for at least one week to allow tamoxifen 
depletion in order to avoid further recombination events.  
Mice were then switched from chow to a HFD (Western Rd (p) Product code:829100 SDS, containing 
21% fat and 0.2% cholesterol). EdU was injected for 7 days (including 2 hours) prior to culling between 
16-19 weeks post switch to HFD (except where animals had to be culled prematurely, see Appendix 
A), tissue was then removed and fixed as described above (section 3.3). Samples were either 
embedded for cryo or vibratome-sectioning (sections 3.7 and 3.8), stained for Mac-3, aSma or Edu 
(section 3.9 and 3.10) and imaged by confocal microscopy (section 3.14). 
 
3.13 Abdominal aortic aneurysm (AAA) protocol 
All surgery, injections and live mouse work in this section was performed by Dr. Marc Clement, 
everything else was performed by Joel Chappell.  
Myh11-CreER(T2); R26R-Confetti mice either on the ApoE-/- or wild type background and at least six 
weeks old were injected with 10x 1 mg of tamoxifen (over 2 weeks) to induce the desired level of 
recombination of the confetti allele (Figure 11). Animals were then rested for at least one week to 
allow tamoxifen depletion in order to avoid further recombination events. 
Ang II (10 mg/ml in PBS, Sigma, A9525) was loaded in to Azlet model 2004 osmotic mini-pumps (Durect 
Corporation, Cupertino, CA) following the manufactures protocol, which will release Ang II at an 
approximate rate of 1000 ng/kg/min (as described in Daugherty and Cassis, 1999). For mini pump 
surgery, mice were anaesthetised by inhalation, using a mixture of oxygen (1.5 L/min) with 2.5-3% 
isoflurane and given a pre-operative analgesic (Temgesic, Buprenorphine) subcutaneously. A 1 cm cut 
was made across the back of the neck, blunt scissors were then inserted into the opening and used to 
separate the subcutaneous tissue by opening and closing the scissors to create a pocket. The mini-
pump was then inserted into the pocket with the delivery portal going in first. The incision point was 
then closed and glued to seal.  
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Mice belonging to the Ang II-aTGFb protocol were injected with 250 µg mouse anti-human/mouse 
TGFb (Bioxcell, clone 1D11, BE0057) 3x per week intraperitoneally for four weeks if they were on a 
wildtype background and for only the second two weeks if they were on the ApoE-/- background, of 
the Ang II protocol. EdU was injected in all mice on days 15-21 before being culled day 28 post mini-
pump surgery. Tissue was then processed as described (section 3.3) and cryo-sectioned in serial, prior 
to staining.  
 
3.14 Confocal microscopy and image processing 
Imaging was performed using confocal laser scanning microscopy (Leica SP5 or SP8), sequential scans 
with laser lines and detectors set for maximal sensitivity without spectral overlap, typically; DAPI (405 
laser, 417-508 nm), CFP (458 laser, 454-502 nm), GFP (488 laser, 498-506 nm), YFP (514 laser, 525-560 
nm), RFP (561 laser, 565-650 nm) and Alexa Fluor 647 (633 laser, 650-700 nm). A 20x oil objective 
(Plan Apochromat, numerical aperture 0.75, Multi-Immersion Correction Collar) was used to scan 
whole mount aortas, tile scans of Z-stacks totalling ~400 µm (~6-8 µm between each Z-section) were 
acquired, Z-compensation (laser power and gain) was used to allow for differences in fluorescent 
protein excitation/detection throughout the tissue. Vibratome sections were imaged using a 20x oil 
objective with a Z-stack typically totalling 100 µm (~5 µm between each Z-section). Cryo-sections were 
imaged using a 40x oil objective (Plan Apochromat, numerical aperture 1.30, Oil Immersion) with a Z-
stack typically totalling 14 µm (~3 µm between each Z-section). Data was acquired at an optical section 
resolution of 1024 x 1024 and tiles were stitched using LAS software (Leica). 
Imaris 8 software was used for image processing and analysis of whole-mount, vibratome and cryo-
section samples. Processing includes brightness and contrast adjustments, generation of maximal 
projections, virtual cross sectioning and surface rendering. For calculation of patch size within whole-
mount samples, surface modelling of individual patches using the surface rendering function within 
Imaris was used. A ‘patch’ was defined as a large contiguous mass of cells which share the same colour 
and occupy both neointimal and medial compartments of the vessel. To estimate cell number per 
patch, the surface volume was divided by the volume of an average of 8 individual VSMCs of the same 
colour.   
Images shown in the results sections are maximal Z-projections (generated in Imaris) where indicated 
in figure legends or individual scans from a confocal Z-stack generated in FIJI (Schindelin et al., 2012). 
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3.15 Plaque and neointima scoring 
Plaques were analysed from three regions within the vasculature; the carotid arteries (CA) comprising 
the region from where the right and left CA bifurcate to where they meet the aorta; the aortic arch 
(Arch) comprising the ascending aorta proximal to the aortic root and the arch region; and the 
descending aorta (DA) comprising the region distal to the Arch region to the diaphragm. For 
quantification of imaged cryo-sections, plaques were separated into three distinct regions; the cap 
region, which was defined as the organized layer of elongated cells on the inner most surface of the 
plaque adjacent to the lumen; the core region, which was defined as a disorganized mass of cells 
towards the centre of a plaque; and the shoulder region, which was defined as the mass of cells within 
the plaque which are immediately adjacent to the arterial wall on either side of the plaque. The 
neointima, within carotid ligation samples, was defined as the area between the inner elastic lamina 
(IEL) of the artery wall and the lumen. The few plaque samples observed which did not contain 
Confetti+ cells were not image and therefore not included in any analysis.  
Quantification of labelled (Confetti+) and marker positive (Stain+) cells was performed on immuno-
stained cryo-sections (20 µm for plaque and 14 µm for ligated arteries). Cells within an area of 1 mm2 
were counted for each plaque region and neointima. For almost all plaque regions/neointima (>60%, 
except where they were too small) two areas were scored for each and the average frequency used. 
Cell scoring was performed on confocal Z-stacks in Imaris in 3D to evaluate staining within Z-sections 
below and above the cell of interest. This ensures that counts are made on a cell by cell basis in the 
high-resolution Z-stacks. t-test and two-way ANOVA tests were performed within R (R Core Team, 
2016) on selected variables to determine significant differences (p<0.05) as indicated in figures. 
 
3.16 Calculating theoretical distribution of plaque colours 
To compare the observed distribution of colours per plaque to what would be expected if plaques 
were generated from proliferation of 1, 2, 3 or 4 cells, a theoretical distribution was calculated as 
follows. All possible combinations of coloured cells were considered (e.g. if 3 cells proliferate there 
are 64 possible combinations: red-red-red, red-red-green, red-green-red, red-yellow-blue…). To 
calculate the probability of each colour combination, the known recombination frequency of each 
colour was applied (for example: red-red-red = 0.34 x 0.34 x 0.34, red-red-green = 0.34 x 0.34 x 0.07, 
red-green-red = 0.34 x 0.07 x 0.34, red-yellow-blue = 0.34 x 0.25x 0.33…). The frequencies for colour 
combinations of 1, 2, 3 and 4 colours were summed; for example, out of the 64 possible combinations 
of 3 cells there are 4 yielding one colour (red-red-red etc.) with a summed frequency of 0.063, 36x 
two colour combination (summed frequency=0.563), 24x three colour combinations (summed 
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frequency=0.375) and 0 x four colour combinations. The expected distribution is shown in Figure 23 C 
for comparison to the observed distribution shown in Figure 23 B.  
 
3.17 Statistical analysis of bipotency  
A Chi2 test was used to assess whether monochromatic regions occupying both cap and core were 
observed more frequently than what would be expected by chance. This analysis was performed by 
Prof. Ben Simons (from Chappell et al., 2016). 
To address the question of bipotency for each Confetti colour the observed data was compared 
against the null hypothesis that “the VSMC cap and core progenitors are unipotent”. The fact that 
some plaques were observed with lineage labelled cells in either the cap or the core but not both 
suggests that, following activation, at least some of the cells are unipotent.  To assess whether this 
could be the case, first it is assumed that contiguously labelled patches in the cap or the core region 
derive from clonal events. Then, according to the null hypothesis, the probability that a patch in the 
core will be labelled in colour c is given by 
𝑃core,𝑐 = 𝑓𝑞𝑐 
where f denotes the fraction of fluorescently labelled cells, estimated at around 0.8 in the densely 
labelled sample, and q denotes the relative labelling efficiency of colour c. Similarly, the probability 
that a patch in the cap is labelled in colour c is given by 𝑃cap,𝑐 =  𝑃core,𝑐. Then the chance that a clone 
of colour c in the core but not the cap is given by  
𝑃core,𝑐(1 − 𝑃cap,𝑐) 
(similarly cap but no core), while the probability that both core and cap acquire colour c is given by 
𝑃core,𝑐𝑃cap,𝑐 
If focus is shifted on to the ensemble of clones that contain colour c in the cap, the core or both, the 
relative probabilities must be normalized by the factor 
𝑃 = 𝑃core,𝑐(1 − 𝑃cap,𝑐) + 𝑃cap,𝑐(1 − 𝑃core,𝑐) + 𝑃core,𝑐𝑃cap,𝑐 
So that the relative chance of finding a plaque with core labelling of colour c 
𝑟core,𝑐 =  
𝑃core,𝑐(1 − 𝑃cap,𝑐)
𝑃
 
Which is equal to 𝑟cap,𝑐, while the relative chance of finding both labelled in colour c is given by  
𝑟both,𝑐 =  𝑃core,𝑐𝑃cap,𝑐/𝑃 
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Finally, for an ensemble of clonal events, it is expected that the statistical error on the measured 
fractions should become defined by the standard error of the mean, given by 
𝑟core,𝑐(1 −  𝑟core,𝑐)/𝑁)
1/2 
where N denotes the total number of plaques sampled that contain colour c. 
Thus, the observed Cap+Core frequencies are significantly higher for all four Confetti colours: 
 
YFP Cap Core Cap+Core N 
Observed 3 4 20  
27 Calculated (r*N) 12 12 3 
error (SEM)  1.1 1.1 0.2 
 
nGFP Cap Core Cap+Core N 
Observed 1 1 8  
10 Calculated (r*N) 5 5 0.4 
error (SEM)  0.8 0.8 0.02 
 
mCFP Cap Core Cap+Core N 
Observed 4 3 20  
27 Calculated (r*N) 12 12 4 
error (SEM)  1.1 1.1 0.2 
“Observed” is the measured number of cap only, core only and cap+core clones, “Calculated” is the 
expected number against the null hypothesis, and “Error” denotes the expected error (SEM) given the 
total number of clones that are measured (N). 
 
 
 
 
 
 
 
 
 
 
RFP Cap Core Cap+Core N 
Observed 6 9 48  
63 Calculated (r*N) 26 26 11 
error (SEM)  1.6 1.6 0.5 
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3.18 Smart-seq2 protocol 
The protocol used for Smart-seq2 is adapted from Picelli et al., 2014. Steps and reagents which 
encountered cells post FACS but prior to cDNA amplification were performed/prepared in a 
designated (pre-PCR, scRNA-seq) isolation hood. Where possible, all steps, unless otherwise 
stipulated, were performed on ice, cold block or at 4oC. 
Sample preparation and FACS/index sorting  
Aortas and carotid arteries were dissected and dissociated to single cells as described above (sections 
3.3 and 3.4). The single cells suspension was initially washed in PBS and pelleted (1000 rpm for 5 mins) 
and re-suspended in a solution consisting of Zombie near infrared viability dye (Zombie NIR, Biolegend, 
423105) diluted 1:100 in PBS (total volume ~150 µl), for 20 mins at RT. Cells were then washed in 0.5% 
BSA in PBS, to block non-specific binding of immunoglobulin to the Fc receptors, cells were then re-
suspended in TruStain fcX (BioLegend, 101320, diluted 1:100 in 0.5% BSA in PBS) for 10 mins at 4oC. 
To this solution Anti-Sca1-APC (Miltenyi Biotec, 130-102-343) or Rat-IgG2a-APC (Miltenyi Biotec, 130-
102-655) was added so to be diluted 1:10 and incubated for 15 mins at 4oC. Cells were then washed 
in 0.5% BSA in PBS twice before being re-suspended in a final volume of 300 µl 0.5% BSA in PBS and 
filtered through a 70 µm cell strainer.      
Single Confetti+, Zombie NIR-negative VSMCs were isolated/sorted by FACS, into individual wells of a 
96 well plate (Thermo Scientific) containing 2.3 µl recombinant ribonuclease inhibitor (RRI, 40 U/µl, 
Clontech) diluted to 1:20 in 0.2% TritonX (in RNase-free dH2O, Sigma-Aldrich), per well. Following FACS 
sorting the plate was sealed (Microseal ‘B’, BIO-RAD), spun down (1 min at 1000 rpm, 4oC) and placed 
in a -80oC freezer for ~30 mins.    
Reverse transcription PCR (RTPCR)  
After allowing the cells to thaw, 2 µl of annealing mixture, containing: 0.1 µl ERCC (stock product was 
previously diluted 1:400,000 in dH2O, Invitrogen, 4456740), 0.1 µl Oligo-dT (100 µM, Biomers.net, 5'–
AAGCAGTGGTATCAACGCAGAGTAC(T30)VN-3'), 1 µl dNTP (10 mM, Life Technologies, R0192) and 0.8 
µl dH2O was pipetted into each well of the 96 well plate. The plate was spun down (1 min at 1000 rpm, 
4 oC) and incubated at 72oC for 3 mins before being immediately placed on ice. 5.7 µl of reverse 
transcription mixture, containing 0.5 µl PrimeScript Reverse Transcriptase (200 U/µl, Clontech), 0.125 
µl RRI, 2 µl 5X PrimeScript Buffer (Clontech), 0.5 µl 1,4-Dithiothreitol (DTT, 100 µM, Sigma), 2 µl 
Betaine (5 M, Sigma, B0300), 0.06 µl MgCl2 (1 M, Invitrogen), 0.1 µl Template switching oligo (TSO, 100 
µM, Exiqon, 5'–AAGCAGTGGTATCAACGCAGAGTACATrGrG+G-3') and 0.415 µl dH2O was then pipetted 
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into each well of the plate. The plate was spun down and placed in a SimpliAmp Thermal Cycler (Life 
Technologies) with the following conditions:  
 
 
 
 
 
cDNA amplification 
Following RTPCR, 15 µl of PCR mixture, containing: 12.5 µl KAPA HiFi Hotstart (Kapa Biosystems), 0.25 
µl ISPCR oligo (10 µM, Biomers.net, 5'-AAGCAGTGGTATCAACGCAGAGT-3') and 2.25 µl dH2O, was 
added to each well.  The plate was then spun down and placed in a thermal cycler under the following 
conditions:     
Cycles no. Temperature (oC) Time 
1 98 3 min 
 
24 
98 20 secs 
67 15 secs 
72 6 mins 
1 72 5 mins 
- 4 hold 
 
PCR clean up 
A bead clean-up method was then used to clean the sample of left over reagents/unwanted material, 
Ampure XP beads (Agencourt) were equilibrated at RT for 15 mins and vortexed. 25 µl of beads were 
then added to each well and mixed (by slow vortexing) and incubated at RT for 8 mins. The plate was 
placed on a magnetic stand (Thermo Fisher) for 5 mins to collect the beads to one edge of each well. 
The supernatant was then discarded and each well washed twice with 200 µl 80% EtOH (vol/vol) for 
30 secs while the plate remains on the magnet. The plate was then spun and any remaining EtOH 
removed before being left to air dry for 5 mins. 20 µl elution buffer (Qiagen) was then added to each 
well and mixed (very slowly by vortexing). Finally, the plate is placed on the magnet for a further 2 
mins and the cDNA containing supernatant transferred to a new plate.  
 
 
Cycle no. Temperature (oC) Time 
1 42 90 mins 
10 50 2 mins 
42 2 mins 
1 70 15 mins 
- 4 hold 
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Quality control  
Following bead clean up samples went through a quality control step. In total, 9 samples across the 
plate were run on an Agilent Bioanalyzer using the Agilent High Sensitivity DNA Chips (Agilent 
Technologies), to the manufacturers protocol. If samples contain uncontaminated cDNA (i.e. only 
cDNA is detected within the sample, as in Figure 49) the whole plate passes this quality control step.  
cDNA from all samples was then quantified using the Quant-iT™ PicoGreen™ assay kit (Thermo Fisher), 
following the manufacturers protocol. In short each well in a U-bottom plate (PerkinElmer) is filled 
with 49 µl 1x TE buffer, 50 µl pico-green (diluted 1:200 in TE) and 1 µl of sample (control wells, 
necessary for calculating standard curve, received 1 µl of Lambda DNA, so that 25 ng, 10 ng, 2 ng, 0.4 
ng, 0.08 ng and 0.016 ng samples were represented). The plate was then left to incubate for 5 mins in 
the dark and read on a plate reader (BioTek, Synergy HT). Finally, samples were diluted so they are 
roughly the same concentration (typically to ~5 ng/µl).  
Library preparation 
cDNA library preparation was performed using the Nextera XT kit, the manufacturers protocol 
followed. In brief, the NT and tagmentation buffers were brought to RT and gently vortexed to mix. 
Tagmentation DNA buffer and the amplicon tagment mix were mixed to a ratio of 2:1, and 3.75 µl of 
this mix was added to each well of a new plate. Also added to each well is 1.25 µl of sample cDNA 
(~6.25 ng). The plate is then sealed and spun at 2000 rpm for 1 min before being placed in a thermal 
cycler at 55 oC for 10 mins. Following this incubation, to each well the following was added: 1.25 µl of 
NT buffer, 3.75 µl Nextera PCR mix, 1.25 µl of index primer 1 and 1.25 µl of index primer 2. Every single 
well contained a different combination of the index primer 1 and 2 which allows cell identification 
following sequencing. The plate was then sealed, spun down at 2000 rpm for 1 min and placed on a 
thermal cycler, under the following conditions:     
 
Cycles no. Temperature (oC) Time 
1 72 30 secs 
 
12 
95 10 secs 
55 30 secs 
72 30 secs 
1 72 5 mins 
- 10 hold 
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Library pooling/clean up 
Ampure XP beads were again used for post PCR clean-up purposes. Beads were equilibrated at RT for 
15 mins and vortexed, 1 µl of cDNA from each well was pooled together and mixed with 87 µl of beads. 
The pooled sample was mixed by pipetting and incubated at RT for 5 min before being placed on a 
magnet for 2 mins. Supernatant was then discarded and the beads were washed twice with 180 µl 
70% EtOH (vol/vol). The sample was then spun down and any remaining EtOH removed before being 
left to airdry for 5 mins. 43 µl of elution buffer was then added and the sample vortexed and left to 
incubate at RT for 2 mins. The sample was then placed on the magnet for a further 2 mins and the 
supernatant collected into a new tube.  
Quality control and library quantification  
The pooled sample was checked for quality and contamination on an Agilient Bioanalyzer (described 
above) and quantified using the KAPA Library Quantification kit (Kapa Biosystems) following the 
manufacturers protocol. 
Sequencing  
For sequencing the NextSeq 500 Mid Output 75 bp Paried End system was used in the Babraham 
Institute’s sequencing facility, Cambridge. 
 
3.19 Chromium 10x protocol 
To perform scRNA-seq using the 10x Chromium system (10x Genomics), the carotid arteries and aorta 
were dissected from Confetti mice (section 3.3), digested to a single cell suspension (section 3.4) and 
stained with Zombie NIR (section 3.18).  Single cells were sorted on an Aria-Fusion FACS machine in 
0.1% BSA in PBS, using a strict gating strategy in order to collect cells positive for only one of each 
fluorescent proteins. Following FACS, the cells were spun down at 3000 rpm for 3 mins at 4OC and the 
supernatant discarded. The collected cells were then re-suspended to a concentration of 6000 
cells/33.8 µl in 0.1% BSA in PBS. Cells, on ice, were then delivered to the Genomics core facility in 
Cancer Research UK, Cambridge Institute and loaded in to the Chromium machine (10x Genomics) 
where automated RTPCR, cell barcoding and cDNA amplification took place. NextSeq 500 Mid Output 
75 bp Paried End sequencing was then performed in the Babraham Institute’s sequencing facility, 
Cambridge. 
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Chapter 4: Characterisation and specificity of the Confetti reporter 
 
The Confetti reporter (Figure 11, section 2.1) is a valuable tool for multi-colour lineage tracing and 
can, if used correctly, determine clonality. To use the Confetti system effectively and ensure it is 
functioning as required for subsequent experiments (Chapters 5-8) it was important to test its tissue 
specificity when recombined by the Myh11-CreER(T2), and determine its labelling efficiency given 
different amounts of tamoxifen. To achieve this, whole-mount imaging and flow cytometry of 
tissue/cells from tamoxifen injected Myh11-CreER(T2); Rosa26-Confetti mice was analysed.  
 
Aims: 
1. Determine optimal tamoxifen dose/concentration for low density (clonal) and high density 
(mosaic) labelling of VSMCs 
2. Determine specificity of the Myh11-CreER(T2) transgene when recombining the Rosa26-
Confetti construct  
3. Determine the relative activation of each fluorescent protein within the Confetti construct  
 
4.1 Tamoxifen dose and recombination of the confetti reporter  
 
To determine the relationship between tamoxifen dose and recombination frequency of the Confetti 
allele, different concentrations of tamoxifen were injected intraperitoneally into Myh11-CreER(T2); 
Rosa26-Confetti mice. Knowing the frequency at which the confetti construct is recombined given an 
amount of tamoxifen allows the construction of experiments tailored to answering different 
questions, for example, whether proliferative events can be considered mono or poly-clonal or 
determining the proportion of cells which proliferate post injury. Low doses of tamoxifen (0.2-0.08 
mg) were injected to obtain the optimal dose for ‘clonal labelling’ of VSMCs. Meaning a recombination 
frequency sufficiently low that a single labelled cell will be substantially separated from the nearest 
labelled cell of the same colour. To achieve a high or ‘mosaic’ labelling frequency, 10 mg of tamoxifen 
was administered over 2 weeks, this was based on previous studies using the same Cre-transgene, to 
achieved >95% recombination frequency of a Rosa26-STOP-floxedYFP allele in mice (Gomez et  al., 
2013). 
  
Initially, whole-mount imaging (Figure 14) was used to test the tamoxifen dose-recombination 
relationship. Despite some variability between mice injected with the same dose of tamoxifen, 0.12 
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and 0.08 mg doses (Figure 14, D/G/H) appeared suitable for the clonal analysis planned for later 
experiments. Dense, mosaic, labelling was achieved by injecting 10 mg of tamoxifen (Figure 14, A) as 
expected based on a previous study using the same Myh11-CreER(T2) transgene (Gomez et  al., 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
To quantify the level of recombination at each tamoxifen dose, flow cytometry was used to analyse 
dissociated cells from the aorta of Myh11-CreER(T2); R26R-Confetti mice injected with different 
concentrations of tamoxifen. This analysis (Table 1), identified that 10 mg of tamoxifen administered 
over a two-week period resulted in labelling up to 93% of VSMCs, however there was a great deal of 
variability at this dose (79% ±14%). The doses 0.12 and 0.08 mg, identified by microscopy as a good 
dose for ‘clonal’ labelling, labelled approximately 1% of VSMCs.   
 
 
 
 
 
 
Figure 14: Clonal and mosaic labelling of VSMCs is achievable by varying tamoxifen concentration in 
Myh11-CreER(T2); R26R-Confetti mice 
Images are max projection confocal images of flattened sheets of aortic tissue from Myh11-CreER(T2); R26R-
Confetti mice injected with different concentrations of tamoxifen 1 week prior to death. Tamoxifen dose is 
displayed on each panel.  
A: 10 mg tamoxifen  B: 0.2 mg tamoxifen  C: 0.2 mg tamoxifen  
 
 
D: 0.08 mg tamoxifen  
  
E: 0.2 mg tamoxifen F: 0.16 mg tamoxifen  G: 0.12 mg tamoxifen  H: 0.08 mg tamoxifen  
  RFP   YFP   GFP   CFP   
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*NA: Not applicable 
 
When flow cytometry and whole-mount data were considered together, 0.1 mg of tamoxifen was 
chosen to induce a labelling frequency appropriate for delineating clonal expansion in later 
experiments. For mosaic labelling of up to 90% of cells, 10 mg was selected, higher doses of tamoxifen 
were not considered desirable to inject mice with.   
It should be noted that there were some issues in optimising flow cytometry analysis of Confetti 
samples, this was due to the significant number of cells which were detected positive for two 
fluorescent markers, particularly between the violet and yellow lasers, detecting CFP and RFP, 
respectively.  Confetti+ embryonic stem cells cloned from cells containing each individual fluorescent 
protein did not give double positive cells (data not shown). It is possible that the VSMC isolation 
protocol (section 3.4) results in the fragmentation of some cells and that these fragments stick to 
other single cells, this may be particularly prevalent with membrane bound CFP. However, regardless 
of the reason for the double positive VSMCs this demonstrates the need for strict gating strategies to 
ensure that single cells can be identified and isolated in future experiments, as will be discussed in 
Chapter 8.  
To confirm labelling frequencies and calculate the proportion of cells expressing each colour, 
aortas/carotid arteries from tamoxifen injected mice were cryo-sectioned and stained with DAPI prior 
to confocal microscopy. Figure 15 shows examples of sections from densely (A) and clonally (B) 
labelled animals, it is clear from these data that the majority of DAPI positive cells within the media of 
the high labelled tissue are confetti positive with the reverse true for the clonally labelled tissue. True 
Cell type, Genotype, Tamoxifen 
dose (n no.) 
Fluorescently labelled (%) Non-labelled (%) 
Average Max Min Average Max Min 
VSMCs wild type, 10 mg (n=1) 0 N/A N/A 100 N/A N/A 
VSMCs confetti+, 0 mg (n=2) 0.4 0.4 0.3 99.7 99.7 99.6 
VSMCs confetti+, 10 mg (n=6) 78.5 92.9 69.6 21.5 30.4 7.1 
VSMCs confetti+, 0.2 mg (n=2) 2.9 3.7 2.2 97.1 97.8 96.3 
VSMCs confetti+, 0.16 mg (n = 1) 1.7 N/A N/A 98.3 N/A N/A 
VSMCs confetti+, 0.12 mg (n = 1) 1 N/A N/A 99 N/A N/A 
VSMCs confetti+, 0.1 mg (n=3) 0.8 1 0.5 99.2 99.5 99 
VSMCs confetti+, 0.08 mg (n=2) 0.6 0.7 0.5 99.4 99.5 99.3 
VSMCs confetti+, 0.004 mg (n=1) 0.1 N/A N/A 99.9 N/A N/A 
Table 1: The tamoxifen dose-recombination relationship within Myh11-CreER(T2); R26R-Confetti mice  
Flow cytometry data for isolated VSMCs from Myh11-CreER(T2); R26R-Confetti mice and wild type mice 
given different doses of tamoxifen. Adapted from Chappell et al., 2016. 
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for both is that DAPI positive cells within the adventitia and intima are always confetti negative (as 
indicated by the arrow heads in A, ii). 
   
 
    
 
 
 
 
 
 
 
 
 
Quantifying the proportion of cells expressing each colour (Table 2) shows that the Confetti construct, 
following recombination by the Myh11-CreER(T2) transgene, results in a bias against the expression 
of nuclear GFP relative to the other three proteins, this phenomenon has also been observed in others 
work under the control of different Cre transgenes (Snippert et al., 2010).  The reason for this is not 
entirely clear, however, one reason could be that GFP may be more toxic compared to the other 
fluorescent proteins. Resulting in the death of GFP+ cells. A second reason, suggested by Snippert et 
al., (2010) and The Jackson Laboratory (2015), is that low Cre activity favours the inversion of the loxP-
STOP-loxP-GFP-PFY-Pxol sequence (Neo-GFP-YFP region, Figure 11) over the excision of the loxP-
STOP-loxP sequence, leading to fewer GFP expressing cells.  
 
 
 
A B 
Figure 15: Clonal and dense labelling of VSMCs within arteries from Myh11-CreER(T2); R26R-Confetti 
mice 
Carotid artery cross sections from high density-labelled (A, 10x 1 mg tamoxifen) or low density-labelled 
(B, 1x 0.1 mg tamoxifen) animals, region outlined in (i) is magnified in (ii). Signals for fluorescent proteins 
are shown with (left) and without (right) nuclear DAPI staining (white). VSMCs, indicated by arrows in (A 
and B ii), are labelled with RFP (red), YFP (yellow), nuclear (n)GFP (green) or membrane associated 
(m)CFP (blue), whereas cells within the adventitia and endothelium, indicated by arrow heads, are 
unlabelled. In (B ii) arrows point to the few labelled VSMCs, open arrows point to unlabelled VSMCs 
within the media. Scale bars are 100 µm in (i) and 50 µm in (ii). Adapted from Chappell et al., 2016. 
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As the proportion of colours are not equal it is important to factor this knowledge into any statistical 
calculations that may be used in future experiments which assume that clonality can be determined 
based on how often groups of cells expressing the same colour are seen. Later sections will explain 
how this is done in order to identify clonality.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Mosaic/dense 
labelling  
Clonal labelling  
Fluorescent 
protein  
Percent of medial cells 
labelled  
CFP 31 1 
RFP 32 2 
GFP 7 0 
YFP 23 1 
No colour 7 96 
Table 2: Proportion of cells within the medial layer of the aorta and carotid arteries which 
express each of the four fluorescent colours within Myh11-CreERt2; R26R-Confetti mice. Adapted 
from Chappell et al., 2016. 
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4.2 The tamoxifen activated Myh11-CreER(T2) transgene specifically recombines the R26R-Confetti 
reporter in VSMCs   
 
As the Myh11-CreER(T2); R26R-Confetti mice will be used to analyse VSMC proliferation within 
multiple models of CVD, it is vital that the Confetti reporter is specifically expressed in VSMCs. 
Particularly as the origin of cells within the neointima of injured vessels has been disputed in the past, 
with evidence supporting that these cells are derived from bone marrow, adventitial and medial stem 
cells (Albarrán-Juárez et al., 2016; Kramann et al., 2015; Tang et al., 2012, section 1.5). Other groups 
have observed selective expression of other reporter constructs when recombined by the Myh11-
CreER(T2) transgene (Gomez et al., 2013; Nemenoff et al., 2011), indicating that the Confetti reporter 
should also be selectively expressed. Indeed, longitudinal cross sections of the arterial wall (Figure 16) 
identify that only medial cells express the Confetti construct, within the vascular wall following the 
administration of tamoxifen (10x 1 mg), and that no adventitial or endothelial cells express any of the 
fluorescent proteins.  
 
 
 
 
 
 
 
 
Figure 16: Confetti+ cells are localised to 
the media of the arterial wall in Myh11-
CreER(T2): R26R-Confetti mice 
Longitudinal cross section of a whole- 
mount carotid artery from a Confetti 
animal labelled at high density (10x 1 mg 
tamoxifen). Signals for fluorescent 
proteins are shown with (i) and without (ii) 
nuclear DAPI (white). Arrows point to 
labelled VSMCs within the medial layer, 
arrow heads point to unlabelled cells 
within the endothelium and adventitia. 
The luminal side is denoted as "L" and the 
adventitial side marked "A". Scale bar is 50 
μm. Adapted from Chappell et al., 2016. 
 
 
 
 
64 
 
To assess the tissue specificity of recombination in other (non-vascular) tissues, fluorescence was 
analysed from a number of other cell types and tissues. As bone marrow and circulating blood born 
cells have been implicated in vascular disease, these cells were extracted from mice and analysed via 
flow cytometry alongside cells dissociated form the aorta of Myh11-CreER(T2); R26R-Confetti mice 
which had received tamoxifen to induce dense labelling. Out of the three Confetti+ mice analysed 
(Table 3) there were very few events in either the peripheral blood or bone marrow, the few positive 
events detected occurred at a comparable rate to that seen in Wild type animals, so is therefore likely 
the result of auto-fluorescence or contamination (e.g. red blood cells or dead cells).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Mouse 
no. 
ID Sample Proportion of positive 
events 
Number of singlet events 
1 Wild type  
 
Peripheral 
blood 
0.0006 >25000 
2 Wild type 0.0003 >65000 
3 Wild type 0.00007 >65000 
4 Confetti+ 0.0001 >65000 
5 Confetti+ 0.00009 >65000 
6 Confetti+ 0.0001 >65000 
1 Wild type  
 
Bone 
marrow 
0.00002 >400000 
2 Wild type 0.00001 >400000 
3 Wild type 0.00007 >200000 
4 Confetti+ 0.00001 >400000 
5 Confetti+ 0 >400000 
6 Confetti+ 0.00002 >400000 
1 Wild type  
 
Aorta 
0.0002 >9000 
2 Wild type 0.0001 >30000 
3 Wild type 0.0005 >30000 
4 Confetti+ 0.62 >30000 
5 Confetti+ 0.63 >30000 
6 Confetti+ 0.67 >30000 
Table 3: Specific labelling of VSMCs in Myh11-CreER(T2); Rosa26-Confetti mice  
 Flow cytometry analysis demonstrating background levels of fluorescence in bone marrow and 
peripheral blood from non-tamoxifen treated wild type animals and experimental Myh11-
CreER(T2); Rosa26-Confetti animals labelled at high density (10x 1mg tamoxifen). Samples were 
gated for live cells (FSC-A, SSC-A) and singlets (FSC-A, FSC-H). Positive cells were identified based on 
gates set on VSMCs from Wild type and Confetti+ animals. Adapted from Chappell et al., 2016 
. 
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To assess specificity in solid tissues, vibratome sections of liver, skeletal muscle and lung from Myh11-
CreER(T2); Rosa26-Confetti mice, injected with 10 mg tamoxifen, were analysed by confocal 
microscopy. The only detectable florescence from these sections were within the vasculature within 
each tissue (Figure 17) confirming recombination is specific to VSMCs in all tissues/cell types analysed. 
 
 
4.3 Conclusion from the Confetti characterisation and specificity experiments 
 
Results within this chapter show that the Myh11-CreER(T2) transgene specifically recombines the 
Confetti construct within VSMCs and that there is a relationship between the quantity of tamoxifen 
injected and the proportion of cells labelled. Dosing strategies were established for high density (10x 
1mg tamoxifen) and low density (1 x 0.1 mg tamoxifen) labelling of VSMCs, which will be used in 
subsequent experiments (Chapters 5-8). It was also noted that there is a slight bias against the 
expression of nuclear GFP, in favour of the other three fluorescent proteins which are expressed at 
near equal levels.  
 
Figure 17: Specific labelling of VSMCs in Myh11-CreER(T2); Rosa26-Confetti mice 
Confocal microscopy images showing absence of recombination in liver (i, iv), skeletal muscle (ii, v) and 
lung (iii, vi) in Confetti animals after tamoxifen treatment (10x 1 mg). Note that labelled cells in (vi) 
correspond to VSMCs lining a blood vessel. Signals for fluorescent proteins are shown with (i, ii, iii) and 
without (white, iv, v, vi) nuclear DAPI staining. Scale bars are 100 µm.  
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Chapter 5: VSMC proliferation and plasticity in a model of atherosclerosis  
 
As discussed in (sections 1.5 and 1.6) there has been, in recent years and indeed as far back as the 
1970’s, some discussion concerning the origins of atherosclerotic plaque cells, for example; VSMC-
derived, bone marrow-derived or adventitial-derived, and if they are indeed VSMC-derived whether 
this is a clonal process arising from the proliferation of few cells (Gomez et al., 2013; Albarrán-Juárez 
et al. 2016; Kramann et al. 2015; Benditt and Benditt, 1973; Feil et al., 2014). Furthermore, it is known 
that VSMCs have the potential to trans-differentiate into multiple cell types within a plaque, including: 
macrophage-like, MSC-like and myofibroblast-like cells (Shankman et al., 2015). It is not, however, 
clear whether single VSMCs are multi-potent, capable of trans-differentiating into all observed VSMC-
derived cell phenotypes or if distinct VSMCs are, for example, uni-potent and produce a single subset 
of these cells. 
If plaques are monoclonal and derived from the proliferation of a single VSMC, then this would suggest 
that a single VSMC has the potential to trans-differentiate into all known VSMC-derived plaque cells. 
Furthermore, it would suggest that individual VSMCs which respond to disease may be inherently 
different to medial VSMCs which do not respond to disease. Plaque mono-clonality was originally 
hypothesised by  Benditt and Benditt (1973), based on their study investigating X-inactivation patterns 
of the X-linked glucose-6-phosphate dehydrogenase protein. Their work demonstrated that plaques 
would typically contain only one of the protein isotypes, whereas the media would contain both 
(Benditt and Benditt 1973). This hypothesis was, however, challenged when more sensitive methods 
using PCR amplification of an X-inactivated gene showed that large portions of the non-atherosclerotic 
media also contained only one protein isotype (Schwartz and Murry, 1998). More recently, Feil et al., 
(2014) used the confetti system (described in section 2.1 and Chapter 4) to lineage trace VSMCs in a 
mouse model of atherosclerosis. Based on this study Feil et al., (2014) suggest that plaques are mono-
clonally derived as they appeared to be single coloured, their work was however limited in several 
ways: (1) plaques were imaged in whole mount, which does not allow investigation of cells within the 
plaque as the lipid content prevents light penetration; (2) a labelling frequency of 11% was used, 
meaning there is significant potential for unlabelled VSMCs to contribute to plaques; and (3) the 
Sm22α-CreER(T2) transgene was used, while Sm22α is a classical marker used to define VSMCs it is 
not exclusively expressed in VSMCs. Indeed Cre expression in mice containing the Sm22α-Cre has 
previously been detected in myeloid and lymphoid cells, with the authors suggesting that caution 
should be taken when analysing data using the Sm22α-Cre given known contributions of myeloid cells 
to vascular development and CVD (Shen et al. 2012). Espagnolle et al. (2014), have since shown an 
association between CD146 expression and bone marrow mesenchymal stem cell (BM-MSC) 
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commitment to a VSMC lineage, with CD146(High) BM-MSCs expressing detectable levels of Sm22α. 
Others have also detected Sm22α-Cre expression in epithelium (Proweller et al. 2006) and 
cardiomyocytes  (Zhang et al. 2006). Based on these limitations, the experiments by Feil et al. (2014) 
cannot definitively show that plaques are mono-clonally derived.  
To answer the questions regarding plaque clonality and the ability of single VSMCs to trans-
differentiate into multiple VSMC-derived cell types, the Myh11-CreER(T2) is used to recombine the 
Confetti reporter (described in section 2.1) in ApoE-/- mice fed a HFD for 16-19 weeks. The ApoE-/- 
background in combination with HFD is used here as it recapitulates a chronic inflammatory model of 
atherosclerosis, resulting in the formation of large atherosclerotic plaques by week 16 of HFD feeding 
(described in section 2.2). To investigate clonality, thick vibratome-sections and thin cryo-sections are 
analysed to visualise every cell within a plaque. Furthermore, cryo-sections are stained for aSma 
(contractile maker) and Mac3 (macrophage marker) to identify if a single VSMC can give rise to 
different VSMC-derived cell types. Finally, VSMC contribution to/between: (1) plaques in different 
regions of the vasculature (aortic arch, descending aorta (DA) and carotid arteries (CA), Figure 18A); 
(2) different regions of a plaque (cap, core and shoulder, Figure 18 B); and (3) plaques in individual 
mice, are investigated.      
Aims: 
1. Assess the extent of clonal proliferation of VSMCs within atherosclerosis  
2. Assess relative contribution of VSMC migration as opposed to proliferation within 
atherosclerotic plaques 
3. Determine if the progeny of a single VSMC can trans-differentiate into multiple cell types 
 
 
 
 
 
 
 
 
 
 
Carotid 
arteries  
Aortic 
arch  
Descending 
thoracic 
aorta   
Lumen   
Core   
Cap   
Shoulder   
Shoulder   
Media   
Figure 18: Vascular and plaque regions scored 
A, Diagram of the aorta with indication of vascular regions analysed. 
Red lines show typical sites analysed by cross sectioning. B, Diagram of 
arterial cross section of an atherosclerotic plaque indicating the 
lumen, media and different regions of the plaque which have distinct 
cell composition and morphology, which were therefore analysed 
separately. 
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5.1 The Confetti reporter is selectively expressed in VSMCs in Myh11-CreER(T2); R26R-Confetti;  ApoE-/- 
mice in the HFD model of atherosclerosis  
 
To test that the ApoE-/- background and/or the 16-week HFD protocol does not cause non-tamoxifen 
induced recombination of the Confetti reporter or that tamoxifen administration alone does not cause 
plaque growth, vibratome sections from control animals on HFD were analysed (Figure 19).  Results 
demonstrate that: (1) no fluorescence is detectable in Wild type; ApoE-/- mice which received 
tamoxifen and HFD (Figure 19, A/B), (2) tamoxifen and HFD does not cause atherosclerosis in Myh11-
CreER(T2); R26R-Confetti; ApoE+/- mice (Figure 19, C/D) and (3) HFD does not induce recombination 
of the confetti allele in Myh11-CreER(T2); R26R-Confetti; ApoE-/-  mice (Figure 19, E/F). These controls 
confirm that the Confetti mice are suitable for future studies and that there are no off target effects 
of either tamoxifen or the Confetti reporter in combination with HFD/the ApoE-/- background.  
A) Wild type; ApoE-/- 
10 mg tamoxifen         
C) Confetti+; ApoE+/- 
10 mg tamoxifen 
 
E) Confetti+; ApoE-/-  
0 mg tamoxifen 
 
B) Wild type; ApoE-/- 
10 mg tamoxifen         
 
D) Confetti+; ApoE+/- 
10 mg tamoxifen 
 
F) Confetti+; ApoE-/- 
0 mg tamoxifen 
 
Figure 19: Specificity control data in the HFD model of atherosclerosis 
Max projection of confocal scans of 100 µm thick vibratome sections from mouse aortas and carotid 
arteries of experimental/control animals after 16-weeks of HFD, showing signals from fluorescent proteins 
with (A, C, E) or without (B, D, F) DAPI. ApoE and Confetti genotype and dose of tamoxifen is displayed on 
each image. Sections containing plaque are visible in (A) and (E). Scale bars are 200 µm. 
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5.2 VSMCs clonally expand to contribute to plaque development   
 
To definitively determine whether VSMC-derived cells within atherosclerotic plaques are clonally 
derived, 6-8-week-old Myh11-CreER(T2); Rosa26-Confetti; ApoE-/- mice were injected with 10 mg of 
tamoxifen to induce dense labelling of VSMCs. Mice were then rested for 1 week to allow tamoxifen 
depletion and avoid further recombination events prior to feeding them an atherosclerosis-inducing 
HFD for 16-19 weeks (Figure 20 A, Appendix A). 
 
 
  
 
 
 
 
 
 
 
Accumulation of VSMC-derived cells was assessed by confocal microscopy of arterial cross sections. 
Cells expressing the Confetti reporter (Confetti+), and therefore derived from mature Myh11- 
expressing VSMCs, were observed within atherosclerotic plaques and constituted a significant 
proportion of the total plaque cell number (Figure 20 B, C). In order to assess and compare VSMC 
contribution to plaques within different regions of the vasculature (Arch, DA and CA) and within 
different regions of the plaque (cap, core and shoulder) these regions were quantified separately 
(Figure 18). It is important to consider these different vascular and plaque regions as: (1) VSMCs within 
Figure 20: VSMC-derived cells generate oligo-clonal atherosclerotic plaques 
A, Experimental protocol for the atherosclerosis studies. B, C, Arterial cryo-sections from high density-
labelled animals (10x 1 mg tamoxifen) presenting plaques containing VSMC-derived cells of a single colour 
(CFP/blue, B) and more than one colour (RFP/red, mCFP/blue, YFP/yellow. C). The region outlined in (i) is 
magnified in (ii). Scale bars are 150 µm (i) and 50 µm (ii). Signals for fluorescent proteins and nuclear DAPI 
in (ii, white) are shown. Arrows in (ii) point to non-labelled cells interspersed throughout the plaque. 
Adapted from Chappell et al., 2016. 
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different vascular regions are derived from different pre-cursor populations (i.e. Arch and CA from the 
neural crest and the DA from the somites, Wang et al. 2015, section 1.2, Figure 2) which may change 
the characteristics of these cell types (Bennett, Sinha, and Owens 2016); and (2) different plaque 
regions contain vastly different environments, with a necrotic, lipid dense core and a fibrous cap (Libby 
et al., 2011), which may affect the ability of VSMC-derived cells to survive and contribute to these 
different compartments. On average 65.5% of cells within plaques containing at least one Confetti+ 
cell, were Confetti+ (Figure 21). The proportion of VSMC-derived cells ranged from 41-94% between 
plaques, this variation however was not explained by plaque region, as a similar VSMC cell 
contribution to the cap, shoulder and core regions was observed (Figure 21 A). Further stratification 
also showed there was no significant difference between plaques taken from different vascular 
regions or animals (Figure 21 B, C), suggesting inter-plaque variation is not linked to differences 
between animals, differences in regional hemodynamics and/or VSMC developmental origin which 
are different across vascular regions (Wang et al., 2015). The proportion of VSMC-derived plaque cells 
observed here (65.5%) is higher compared to Shankman et al. (2015) who detected 37.6%, using the 
Myh11-CreER(T2); R26R-floxed-STOP-eYFP mouse. This may be due to differences in the strain of mice 
used (they do not list their strain) or differences in the way plaques cells were counted.  
 
In contrast to the mosaic, stochastic labelling observed in the vascular wall, VSMC-derived cells within 
plaques were found in large monochromatic regions with little intermixing between colours as shown 
in 20 µm cryo-sections (Figure 20 B, C) and 50-100 µm vibratome sections (Figure 22). Where plaques 
Figure 21: Proportion of atherosclerotic plaque cells derived from VSMCs 
A) Box plot showing the proportion of the total number of cells (DAPI) which express the Confetti reporter 
(Confetti+) within each plaque region (in 23 plaques from 6 animals). B) Box plot quantifying the proportion of 
all cells (DAPI) within plaques from each of the indicated regions of the vasculature (Arch, carotid arteries (CA) 
and descending aorta (DA)) which express the Confetti reporter (Confetti+), each point represents a plaque 
region not a whole plaque. C) Bar chart showing the proportion of the total number of cells (DAPI), which 
express the Confetti reporter (Confetti+) within 23 plaques (plaque regions combined) from 6 individual 
animals. Mean across all animals is indicated by the orange bar (0.65 ±0.16). Adapted from Chappell et al., 
2016. 
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contained more than a single colour they typically (>90%) localised to very defined regions. For 
example, in Figure 20 C three colours are observed within the plaque, however, these different 
coloured regions overlap and only mix at their borders. Very few plaques (<10%) showed intermingling 
of colours (for example GFP+ and YFP+ cells in Figure 22 B), and this is likely the result of two proximate 
cells of different colours expanding at the same time. Monochromatic VSMC-derived patches did 
contain some interspersed non-labelled cells (arrows in Figure 20 B ii and C ii), consistent with known 
infiltration of monocytes that contribute to lesion development (Tacke et al., 2007). Because VSMC 
labelling was not 100% (Table 1 and 2), it cannot be ruled out that these are unlabelled VSMCs. 
However, this is unlikely, as no plaques were observed which contained singlet VSMC-derived cells 
expressing another confetti colour within a monochromatic region. The coloured patterns observed 
in Figure 20 and 22 are highly indicative of clonal expansion of VSMCs in atherosclerotic plaques as it 
is unlikely that such large regions would be observed if multiple VSMCs were to proliferate. To 
demonstrate this result statistically, the likelihood that the observed result could have occurred by 
the chance expansion of multiple VSMCs of the same colour can be assessed.  
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Figure 22: Clonal VSMC expansion in atherosclerotic plaques 
Examples of monochromatic plaques (A) and plaques containing VSMC-derived cells in more than one colour 
(B-D). B, example of a plaque containing two intermingled clones (YFP/yellow and GFP/green). The section 
shown in panel (D) is cut through the top of the aortic arch and includes a portion of the right carotid artery. 
Signals from fluorescent proteins in 50- 100 µm vibratome sections are shown with (i) and without nuclear 
DAPI staining (white, ii). All plaques are from animals labelled at high density (10x 1 mg tamoxifen). Scale bars 
are 100 µm (A-C) and 200 µm (D). From Chappell et al., 2016. 
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Plaques showed substantial variation in colour pattern (Figure 22), but the frequency of individual 
colours was not significantly different compared to the initial labelling frequency, demonstrating that 
there was no bias towards expansion of VSMC-derived cells expressing a particular fluorescent protein 
(Figure 23 A). Quantification of coloured regions revealed that most plaques contained one (52%) or 
two (40%) colours, with a small proportion containing three (6%) or four (2%) colours (Figure 23 B). 
To compare the observed distribution of colours per plaque with the expected distribution if plaques 
were not clonally derived, the number of colours expected per plaque if 1, 2, 3 or 4 coloured cells 
proliferated can be calculated (Figure 23 C) based on the observed recombination frequency in healthy 
tissue (Figure 23 A). The difference between the observed and expected results suggests that very few 
Myh11-expressing VSMCs undergo massive expansion to contribute to plaque formation. If, for 
example, more than two cells frequently proliferated, the number of single coloured plaques would 
be close to zero (Figure 23 C). This data, however, also indicates that plaques are not exclusively mono-
clonal (48% without taking into account single coloured plaques derived from more than one cell of 
the same colour, Figure 23 B) suggesting that a large proportion of plaques are oligo-clonal, derived 
from a few proliferating VSMC-derived cells. 
 
When stratified into vascular region the proportion of colours per region remained similar throughout 
(Figure 24). The biggest difference was in the number of colours detected per plaque between the 
aortic arch and the descending aorta (Figure 24 B and D). This may result from the fact that the lumen 
of the aortic arch is large and the plaques observed here were typically larger than the descending 
aorta.   Stratification by plaque region (Figure 24) suggests that the number of VSMCs contributing to 
Figure 23: Colour distribution and number of observed and expected colours per plaque 
A) Bar chart showing the proportions of each of the Confetti colours in VSMCs directly after recombination 
(light grey) and in monochromatic regions within atherosclerotic plaques (dark grey). B) Bar chart showing the 
number of colours observed per plaque (82 plaques from 16 animals). C) Bar chart showing the theoretical, 
number of colours per plaque resulting from proliferation of 1, 2, 3 or 4 VSMCs labelled at the recombination 
frequency observed in high density-labelled animals. All data is from animals labelled at high density (10x 1 mg 
tamoxifen). Adapted from Chappell et al., 2016. 
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each region is consistent and there is no preference for more cells to contribute to the cap or core of 
a plaque. 
 
 
 
 
 
 
Given the initial observations that plaque VSMC-derived cells appear to be oligo-clonally derived, 
predictions can be made as follows: if tamoxifen dose is lowered, and therefore the proportion of 
labelled medial VSMCs is decreased, then plaques should still be observed containing VSMC-derived 
cells of one or two colours. To test this, Myh11-CreER(T2); R26R-Confetti; ApoE-/- mice were injected 
with 1 mg of tamoxifen (a 10-fold reduction in dose) which induced at a labelling frequency of ~40%. 
Following the HFD protocol described above (Figure 20 A), many unlabelled plaques and plaques 
where a single coloured region occupied a large part of the plaque area were observed (Figure 25, 
Appendix B). Within the section displayed in Figure 25 a large proportion of the lumen is occupied by 
a plaque which is, likely the result of multiple plaques merging. The right and left portions are 
unlabelled, the top portion contains RFP+/red cells occupying the cap and the core while the bottom 
portion is split in two with RFP+/red and YFP+/yellow cells. The size of the monochromatic regions 
Figure 24: Number and distribution of Confetti colours within atherosclerotic plaques 
A-D, Bar charts showing the proportion of plaques in high density (10x 1 mg tamoxifen) labelled animals with 
one, two, three or four colours. Bars represent the entire plaque (grey, also shown in Figure 23 B), the cap 
(light grey) or the core of the plaque (dark grey). A, Data is shown for all plaques (82 plaques from 16 animals). 
B, C, D, Data is shown for plaques in different vascular regions (B, Aortic Arch; C, Carotid artery; D, Descending 
aorta;). Arch: aortic arch, DA: descending aorta, CA: carotid artery. Adapted from Chappell et al., 2016. 
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observed in animals with reduced labelling frequency was comparable to what was found in high-
density labelled animals, suggesting that large regions are not the result of multiple cells of the same 
colour expanding but that a single cell is capable of massive expansion through multiple rounds of 
proliferation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The experiments here strongly suggest that monochromatic regions within lesions are generally the 
progeny of a single cell, signifying that VSMC-derived cells in atherosclerotic lesions are typically 
formed by the oligo-clonal expansion of very few VSMCs. This observation is similar to that of Feil et 
al. (2014) who demonstrated using the Confetti tracing system, recombined by the Sm22a-Cre(T2) 
that, macroscopically, plaques appeared a single colour. Importantly, however, they used a relatively 
low labelling frequency (11%) and did not section or clear the plaque to image throughout so could 
not definitively confirm this. Furthermore, Feil et al. (2014) used a Sm22α-CreER(T2) transgene which 
is not specifically recombined within VSMCs (Shen et al. 2012; Espagnolle et al. 2014; Proweller et al. 
Figure 25: Animals labelled at medium density develop plaques with several large monochromatic 
regions, which span both the cap and core 
A, An atherosclerotic plaque from a medium density-labelled (1x 1 mg tamoxifen) Confetti ApoE-/- animal 
following 16 weeks of high fat diet. Signals from fluorescent proteins are shown with (i) and without (ii) 
nuclear DAPI (white). Scale bars are 100 µm. From Chappell et al., 2016. 
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2006; Zhang et al. 2006). The clonality hypothesis was first proposed by Benditt and Benditt in 1973 
and the experiments here confirm their hypothesis with one adjustment, that the VSMC-derived 
component of a plaque is not necessarily mono-clonal but can consist of the progeny of several VSMCs 
(i.e. oligo-clonal). Furthermore, it does not appear that migration of VSMCs independent of 
proliferation contributes to late-stage plaque cellularity as singlet cells of a different colour were not 
observed within monochromatic regions; however, this may be a factor during earlier stages. 
 
5.3 Progeny of single VSMCs can take on different phenotypes 
 
Given that plaques are typically mono/oligo-clonal regarding their VSMC-derived component it seems 
logical to suggest that the progeny a single VSMC can trans-differentiate into the multiple VSMC-
derived cells which can occupy a plaque (section 1.5). To test the plasticity of single VSMCs, sequential 
cryo-sections were stained for either the VSMC marker aSma or Mac3, a marker upregulated in VSMCs 
which adopt a macrophage-like state (Figure 26 and 28). aSma+ cells were frequently located within 
the cap and shoulder regions of an atherosclerotic plaque and less so within core of the plaque (Figure 
26), similar to other studies (Shankman et al. 2015).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26:  VSMC-derived aSma+ cells locate to the cap of an atherosclerotic plaque 
Immunostaining for aSma of a plaque cryo-section from a high density-labelled animal (10x 1 mg 
tamoxifen), containing RFP-expressing VSMC-derived cells. Signals for fluorescent proteins, nuclear DAPI 
(white) and aSma (magenta) are shown as indicated on each image. The region outlined in A are magnified 
in B, C, D. Arrows in B, C, D point to RFP+ aSma+ cells, arrow heads point to RFP- aSma- cells. Scale bars are 
150 µm. Adapted from Chappell et al.,2016  
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Quantification of all stained plaque sections (Appendix B) showed that 72% (±26) and 64% (±25) of 
Confetti+ cells within the shoulder and cap regions were aSma+. In contrast only 15% (±21) of 
Confetti+ cells within the core were aSma+ (Figure 27). Others who have lineage traced VSMCs in 
atherosclerosis using a single coloured reporter suggest that 18% (Shankman et al. 2015) and 30% 
(Albarrán-Juárez et al. 2016) of VSMC-derived cells are aSma+, these studies do not sub-categorise the 
plaque into multiple regions. Within this study, without plaque region sub-categorisation, on average 
50% (±15) of all VSMC-derived cells were aSma+, which is 32% and 20% higher than the studies by 
Shankman et al. (2015) and Albarrán-Juárez et al. (2016). This varitation might be due to differences 
between mice in different facilities, the details with which positive cells were defined/scored and/or 
the fact that two regions (cap and core) which are highly aSma+ were scored here, compared to one 
region (core) which contains less aSma+ cells. No significant difference between vascular region and 
individual mice regarding the porpotion of Confetti+ cells or all cells (DAPI) which were aSma+ was 
observed (Figure 27 C-F), suggesting that variation is between individual plaques. The majority of 
aSma+ cells (97% ±7) were Confetti+ and therefore VSMC-derived, this result is consistent with studies 
which have shown that bone marrow-derived cells can, but rarely, upregulate aSma (Yu et al. 2011). 
Others have, however, suggested that up to 31% of aSma+ cells are not VSMC-derived and that 17% 
of aSma+ cells are derived from macrophage cells (Albarrán-Juárez et al. 2016). The former result is 
hard to reconcile, but again may be due to differences in how positive cells were scored or perhaps 
differences in labelling frequencies. One possible reason for the latter claim is that Albarrán-Juárez et 
al. (2016) use a constitutively active Cre recombinase (rather than a tamoxifen inducible Cre), driven 
by the myeloid marker gene LysM, which might be induced in VSMC-derived cells which have entered 
the plaque. 
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Mac3-staining of cryo-sections sequential to those stained for aSma identify that Mac3+ cells are 
predominately located within the core of the plaque (Figure 28), which is similar to what was shown 
in other studies using macrophage markers such as Lgals3 (Shankman et al. 2015). 
Figure 27: Quantification of Confetti+ aSma+ cells in plaques 
Box plots and bar charts showing the proportion of cells that express the Confetti reporter and stain positive 
for aSma (Confetti+ Stain+), relative to all cells expressing the Confetti reporter (A, C, E) and all cells which 
stain positive for DAPI (B, D, F). A and B are stratified by plaque region. C and D are stratified by vascular 
region, Arch = aortic arch, CA = carotid arteries, DA = descending aorta. E and F are stratified by individual 
mouse. A red star indicates a significant difference (p<0.05) determined by a two-way ANOVA. Data are from 
23 plaques from 6 animals. All data is from animals labelled at high density (10x 1 mg tamoxifen).  Adapted 
from Chappell et al., 2016.    
  
A 
B 
C 
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On average 48% (±28) of Confetti+ and 29% (±19) of all (DAPI) core cells were Mac3+, whereas only a 
small proportion of Confetti+ cap (15% ±19) and shoulder (26% ±20) cells were Mac3+ (Figure 29 A, 
B). These results suggest that VSMC-derived cells within the plaque core are more likely to trans-
differentiate into macrophage-like cells compared to cap and shoulder cells. Similarly, Shankman et 
al. (2015) found that 30% of all VSMC-derived cells were positive for the macrophage marker Lgals3. 
Of all the Mac3+ cells counted 72% (±20) were Confetti+, and therefore VSMC derived. Previous 
studies have shown that only 16% of plaques cells expressing CD68 were VSMC-derived (Albarrán-
Juárez et al. 2016), this difference may be due to the fact that CD68 is a stricter method of staining for 
macrophage-like cells. The proportion of Confetti+ Mac3+ cells relative to Confetti+ or all cells (DAPI) 
did not differ over vascular region or mice, except in one case between mice 1 and 3 regarding the 
proportion of Confetti+ cells which are also Mac3+ (Figure 29 C-F). Which, again, shows the trend that 
inter-plaque differences accounts for most of the variation observed.   
Figure 28: VSMC-derived Mac3+ cells locate to the core of an atherosclerotic plaque 
Immunostaining for Mac3 of a plaque cryo-section from a high density-labelled animal (10x 1 mg 
tamoxifen), containing RFP-expressing VSMC-derived cells. Signals for fluorescent proteins, nuclear DAPI 
(white) and Mac3 (magenta) are shown as indicated on each image. The region outlined in A are magnified 
in B, C, D. Arrows in B, C, D point to RFP+ Mac3+ cells, arrow heads point to RFP- Mac3+ cells. Scale bars 
are 150 µm. Adapted from Chappell et al., 2016. 
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As Confetti+, Mac3+ cells and aSma+ cells were detected in all regions of the plaque (Figures 27 and 
29), questions regarding the plasticity of a single VSMC-derived cell were raised. For example, can one 
cell express both proteins at once or can, for example, Mac3 only be expressed following the 
downregulation of aSma. To test this, plaques were co-stained for both proteins, however, as the 
entirety of the useable light spectrum is already being used to image all Confetti colours, DAPI and a 
single immuno-stain stain, this proved problematic. To overcome this, only red or blue-
monochromatic plaques were selected and the aSma stain was visualised in the channel normally 
reserved for GFP (488 laser). Co-staining revealed that a proportion of Confetti+ cells express both 
Figure 29: Quantification of Confetti+ Mac3+ cells in plaques 
Box plots and bar charts showing the proportion of cells that express the Confetti reporter and stain positive 
for Mac3 (Confetti+ Stain+), relative to all cells expressing the Confetti reporter (A, C, E) and all cells which 
satin positive for DAPI (B, D, F). A and B are stratified by plaque region. C and D are stratified by vascular 
region, Arch = aortic arch, CA = carotid arteries, DA = descending aorta. E and F are stratified by individual 
mouse. A red star indicates a significant difference (p<0.05) determined by a two-way ANOVA. Data are from 
23 plaques from 6 animals. All data is form animal labelled at high density (10x 1 mg tamoxifen). Adapted 
from Chappell et al., 2016.     
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aSma and Mac3 (26% ±20, Figure 30). The majority of these VSMC-derived cells located to the plaque 
core, however, were generally within the region bordering the core and cap (Figure 30). This is in 
agreement with recent single cell RNA data suggesting that co-expression of inflammatory and VSMC-
markers is present in VSMC-derived plaque cells (Albarrán-Juárez et al. 2016). Of the 1100 Confetti-
negative cells counted less than 0.03% were double positive for both Mac3 and aSma, suggesting that 
co-expression of VSMC and macrophage markers are typically restricted to VSMC-derived plaque cells. 
 
 
 
 
  
 
Figure 30: VSMC-derived plaque cells can express both aSma and Mac3 
A, Arterial cryo-section containing RFP-expressing VSMC-derived cells, co-stained for aSma and Mac3. The 
region outlined in (i) is magnified in (ii-iv). Arrows point to RFP+ Mac3+ aSma+ cells. Scale bars are 150 µm 
(i) and 50 µm (ii-vi). Signals for fluorescent proteins, nuclear DAPI (white), aSma (green) and Mac3 
(magenta) are shown as indicated on each image. B, Box plot showing the proportion of cells expressing 
the Confetti reporter (Confetti+) which co-stain for aSma and Mac3 (Confetti+Sma+Mac3+) within different 
plaque regions (7 plaques from 6 mice). Only red and blue plaques were used for this analysis as the 488 
channel was required for aSma imaging. All data is from animals labelled at high density (10x 1 mg 
tamoxifen). Adapted from Chappell et al., 2016. 
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In total, 27/37 monochromatic regions in 23 plaques contained single cells expressing aSma or Mac3. 
Given that monochromatic plaque regions will generally arise from clonal proliferation of a single 
VSMC this suggest that, at least a proportion of, individual VSMCs have the propensity to generate 
plaques cells of different phenotypes. Several plaques, however, contained monochromatic regions 
which occupied only the core or the cap (for example Figure 22 C, D) raising the question whether 
particular VSMCs will preferentially occupy a particular plaque region and therefore either regional 
phenotype (aSma+ cap and Mac3+ core). To test whether VSMCs are preferentially biased towards 
either the aSma+ cap or Mac3+ core, the positions of 126 monochromatic regions in 82 plaques form 
16 high density-labelled animals were scored with respect to the plaques cap and core (Figure 31). 
 
 
 
 
 
The majority of monochromatic regions (96/126) spanned both plaque domains with a few restricted 
to either the cap (11%) or core (13%) (Figure 31). The frequency at which single monochromatic 
regions occupied both plaque regions was significantly larger than expected by independent chance 
labelling of two proximate uni-potent clones of the same colour (2=228, p<0.01, 3 degrees of 
freedom, n=96; statistical analysis for each colour is detailed in the Methods Chapter, section 3.17). 
Furthermore, 14/17 plaques from the animals labelled at a ~40% labelling efficiency (example shown 
in Figure 25) contained monochromatic regions which spanned both the cap and core plaque regions. 
This data therefore suggests that VSMC-derived cells originating from the clonal expansion of a single 
VSMC do not preferentially locate to either plaque region nor associated phenotype. One hypothesis 
explaining the observed occurrence of monochromatic regions locating to either the cap or the core, 
Figure 31: Monochromatic regions occupy both the cap and core 
regions of the plaque more frequently than just the cap or core 
Bar chart showing the proportion of monochromatic regions 
which occupy both the cap and core or only a single region within 
an atherosclerotic plaque (126 regions in 82 plaques from 16 high 
density-labelled animals). A red star indicates a significant 
difference (p<0.05) determined by a t-test. Adapted from Chappell 
et al., 2016. 
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but not both, may be due to the way in which a plaque grows. For example, a process whereby one 
cell grows underneath or over the top of a pre-existing plaque, creating a layered effect.   
 
5.4 Medial VSMCs that do not form monochromatic regions in the plaque still phenotypically switch   
 
Given that the evidence in sections 5.2 and 5.3 suggests that the VSMC-derived component of an 
atherosclerotic plaque is oligo-clonally-derived, formed through the expansion of a few VSMCs, 
questions are raised regarding what the response of the remaining medial-VSMCs is to atherosclerosis 
causing stimuli. To test the extent of phenotypic modulation in medial cells in response to disease, 
VSMCs adjacent to and directly underneath plaques were analysed in aSma and Mac3 stained plaque 
cryo-sections. To enable this analysis to be unbiased by proliferating VSMCs which are connected to 
the plaque, only medial-VSMCs expressing a different colour to those within the atherosclerotic 
plaque were analysed. Results show that the medial VSMCs directly under plaques lose their 
characteristic, elongated morphology, a proportion of these VSMCs downregulate aSma expression 
and upregulate Mac3 expression (Figure 32). This therefore suggests that medial VSMCs underneath 
an atherosclerotic plaque undergo phenotypic switching. 
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Quantification of plaque sections showed that there was a 30% reduction in Confetti+ aSma+ cells in 
the media lying directly under the plaque compared to the comparatively healthy media adjacent to 
the plaque (Figure 33). A similar reduction (54%) has previously been observed by (Shankman et al. 
2015). VSMCs underlying the plaque were also frequently more often Mac3+ (33%) compared to those 
adjacent to the plaque (5%) (Figure 33). VSMCs therefore seem capable of phenotypic change 
independent of proliferating. If indeed these medial VSMCs had proliferated, then small coloured 
medial patches would be observed. Whether the phenotypic change is in response to or a cause of 
neointimal/plaque growth is un-resolved in this study, but is possibly more reasonable to suggest that 
it is in response to the plaque environment, as VSMCs underneath the plaque will be exposed to a 
highly pro-inflammatory environment.  
Figure 32: VSMCs within the media 
directly underlying atherosclerotic 
plaques undergo phenotypic 
switching without contributing to 
the cell mass of the lesion 
A, B, Serial cryo-sections from artery 
of high density-labelled (10x 1 mg 
tamoxifen) animal containing a 
plaque with RFP+ VSMC-derived cells, 
stained for aSma (A) and Mac3 (B). 
The region outlined in (i) is magnified 
in (ii-iv), white dotted lines outline 
the media. Signals for fluorescent 
proteins, nuclear DAPI (white), aSma 
(magenta, A) and Mac3 (magenta, B) 
are shown as indicated on each 
image. Arrows in (A) point to aSma-
negative cells within the media, 
which express the Confetti reporter 
(excluding RFP expressing cells). 
Arrows in (B) point to Mac3-positive 
cells within the media, which express 
the Confetti reporter (excluding RFP 
expressing cells). Scale bars are 150 
µm in (i) and 50 µm in (ii-vi). Adapted 
from Chappell et al., 2016. 
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5.5 Conclusions from the atherosclerosis experiments 
The experiments here were performed to test the hypothesis that the VSMC-derived component of 
atherosclerotic plaques are clonally derived (as hypothesised by Benditt and Benditt 1973 and Feil et 
al. 2014) and whether the progeny of single VSMCs are capable of taking on both the aSma+ cap 
phenotype and the Mac3+ core phenotype. To test for clonality, the multi-colour lineage tracing 
Confetti system combined with the Myh11-CreER(T2) was used in combination with the ApoE-/- mice 
fed a HFD for 16-19 weeks. These mice developed large atherosclerotic plaques, imaging cross-
sections of these plaques using confocal microscopy show that a large proportion of cells (65.5%) 
within a plaque are Confetti+ (Figures 20, 21 and 22), and are therefore VSMC-derived, which has 
been demonstrated previously (Shankman et al. 2015; Gomez et al. 2013). However, in contrast to the 
mosaic, stochastic labelling observed in the vascular wall, VSMC-derived cells within plaques were 
found in large monochromatic regions (Figures 20 and 22). The number of monochromatic regions 
per plaque was typically one or two (53% and 40%) with a few plaques containing three or four (6% 
and 2%, Figure 23), however these regions rarely intermingled, suggesting that plaques are oligo-
clonal.   
To test if the progeny of single VSMCs can take on the aSma+ cap and Mac3+ core cell phenotypes 
within a plaque, cryo-sections were stained for these markers (Figures 26- 29). Results showed that 
monochromatic VSMC-derived regions contained aSma+ cap cells and Mac3+ core cells, also observed 
Figure 33: Quantification of aSma+ and Mac3+ medial VSMCs directly underneath and adjacent to an 
atherosclerotic plaque 
A) Box plot quantifying the proportion of cells expressing the Confetti reporter, which stain positive for aSma 
or Mac3 (Confetti+ Stain+), relative to all Confetti+ cells. Only cells containing confetti fluorescent proteins not 
found in the plaque (-plaque colour) within the media underlying or adjacent to a plaque were counted (based 
on 17 plaques, selected from the 23 analysed in Figures 26-29, from 6 animals). Red stars indicate a significant 
difference based on a two-way ANOVA, p<0.05. All data is from animals labelled at high density (10x 1 mg 
tamoxifen). Adapted from Chappell et al., 2016. 
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was a small proportion of cells which stained positive for both these markers (Figure 30). These results 
therefore confirm that VSMCs are capable of trans-differentiating into cells with different plaque 
phenotypes. Given that some plaques were observed to be mono-clonal it is likely that a single VSMC 
has the potential to trans-differentiate into all other known VSMC-derived cell types which were not 
tested here (e.g. MSC-like and myofibroblast-like cells, Shankman et al. 2015). 
Finally, to test whether medial VSMCs, which do not contribute to cells within the plaque, 
phenotypically switch, VSMCs adjacent to and directly underneath plaques were analysed in aSma and 
Mac3 stained plaque cryo-sections. Results from this experiment demonstrated that VSMCs 
positioned within the media underneath the plaque phenotypically switch (down regulating aSma and 
upregulating Mac3) more often than medial VSMC adjacent to the plaque (Figures 32 and 33). 
Furthermore, these phenotypically switched VSMCs do not proliferate, and if they are able to enter 
the plaque they do not survive long enough to be detected in these experiments.    
The most interesting question raised form experiments within this Chapter relates to the fact that the 
VSMC-derived cells within a plaque are derived from oligo-clonal expansion of a few single VSMCs and 
why, for example, other VSMCs in close proximity do not also respond in this proliferative way. 
Possible explanations for this finding are that only a few VSMCs contain the potential to proliferate 
and trans-differentiate, contributing to plaque development. In contrast, perhaps, all VSMCs are equi-
potent and rely on some specific environmental or stochastic cues in order to react in this way. Other 
possible mechanisms will be discussed in detail in sections 9.2 and 9.3. 
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Chapter 6: VSMC proliferation and plasticity in an injury model of neointimal formation  
 
The observation made in Chapter 5 that plaques are oligo-clonally derived suggests that very few 
VSCMs proliferate in response to disease and that this low frequency response may be an inherent 
feature of VSMCs in response to atherosclerosis causing-stimuli. As discussed previously (section 2.2), 
the ApoE-/- HFD model induces the formation of complex atherosclerotic plaques which contain 
multiple inflammatory molecules, lipids and immune cells, all of which might affect the way in which 
VSMCs behave. To test whether the low frequency response seen in the HFD model is an inherent 
feature of VSMCs, it is possible to use other methods to induce VSMC proliferation. 
Common methods to induce VSMC proliferation in vivo often rely on surgical techniques to injure an 
artery without causing its rupture. There are multiple methods which can be employed to achieve this, 
including wire-injury, carotid ligation and balloon injury (Xu, 2004). Injury models are typically 
described as modelling restenosis, a disease which occurs in humans following angioplasty to treat 
coronary artery disease, in which neointimal lesions containing VSMCs and ECM develop (Levine, 
Chodos, and Loscalzo 1995; Schwartz, deBlois, and O’Brien 1995). The two most commonly used 
models are wire injury, in which a thin wire is inserted into an artery and used to scrape the endothelial 
cells off a portion of the intima (Lindner, Fingerle, and Reidy 1993), and carotid ligation, in which the 
blood flow through a carotid artery is prevented by ligating the artery with a piece of suture (section 
2.3, Kumar and Lindner 1997). Both models result in an acute proliferation of VSMCs within 2-4 weeks. 
Wire Injury is a technically challenging technique and the degree to which complete denudation of 
endothelial cells is achieved can be variable, furthermore the resulting neointima is relatively small 
compared to other techniques (Lindner, Fingerle, and Reidy 1993; Kumar and Lindner 1997). Carotid 
ligation, however, leads to the development of large neointima with intact endothelium, which by 4 
weeks post-surgery can reduce lumen size by ~80% (Kumar and Lindner 1997). Carotid ligation 
effectively stops all forward blood flow from where the carotid artery bifurcates, this disruption in 
blood flow leads to a rapid proliferation of VSMCs. Indeed, Kumar and Lindner (1997) report that by 
day 5 post-ligation, the VMSC replication index is approximately 23.4% within the media and 27.6% 
within the developing intima, in the following 2 weeks medial proliferation falls sharply while intimal 
proliferation remained high up until the end of week 4. Herring et al. (2014), have previously shown, 
using the Myh11-CreER(T2) transgene, that mature VSMCs contribute to the formation of the 
neointima. VSMCs within the ligated artery also undergo classical features of phenotypic switching, 
including a downregulation of contractile markers (e.g. Myh11, Tagln, Acta2) and activation of the NF-
κB pathway (Yoshida et al. 2013; B. Paul Herring et al. 2017). One major difference between the carotid 
ligation model and the ApoE-/- HFD model is the lack of immune cell involvement, as 
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monocytes/macrophages are not detectable within the carotid ligation-induced neointima (Kumar 
and Lindner, 1997). As carotid ligation is technically less challenging than wire-injury and a more 
effective method to induce proliferation of VSMCs/neointimal development (Lindner, Fingerle, and 
Reidy 1993; Kumar and Lindner 1997), this method was chosen to test whether the low frequency 
response is a common feature of VSMCs in response to disease/injury.  
To test if a small number of VSMCs clonally proliferate to form injury-induced neointima, as seen 
within the ApoE-/- HFD model (Chapter 5), carotid ligation was performed on Myh11-CreER(T2); 
Rosa26-Confetti mice. Due to the rapid proliferation of VSMCs caused by carotid ligation, this model 
is used here to try to ‘switch’ more VSMCs to a proliferative phenotype than seen in the chronic, but 
less severe protocol used to induce atherosclerosis. Indeed, as previously suggested, the replicative 
index of VSMCs following carotid ligation is around 25% as early as 5 days post-surgery (Kumar and 
Lindner, 1997), which suggests that more VSMCs are capable of proliferating and remodelling arteries 
in response to injury.   
 
Aims 
1. Determine if a low proportion of cells proliferate following carotid ligation, as observed in the 
HFD atherosclerosis model 
2. Test the extent of phenotypic switching of VSMCs in the carotid ligation model of neointimal 
growth    
 
 
6.1 Carotid ligation surgery induces clonal expansion of few VSMCs to create large coherent VSMC- derived 
monochromatic patches 
 
To test if, similar to the ApoE-/- HFD model, few cells clonally expand in a more severe, carotid ligation, 
model of VSMC proliferation, Myh11-CreER(T2); Rosa26-Confetti mice were labelled at high frequency 
(10 x 1 mg tamoxifen) prior to ligation of the left carotid artery (Figure 34 A). Non-ligated right carotid 
arteries showed stochastic labelling of VSMCs, as expected, and no neointimal growth, indicating 
there was no proliferation in this artery post-surgery of the left carotid artery (Figure 34 B). In contrast, 
the neointima formed in the left carotid artery 28 days after ligation surgery was composed of large 
contiguous monochromatic VSMC-derived patches, which occupied defined volumes (Figure 34 C). 
This result is similar to that seen in the HFD model and suggests that the neointima is formed by the 
clonal proliferation of a small proportion of VSMCs. Confetti+ VSMCs only intermingled where two or 
more coloured patches met/overlapped (Figure 34 C iii). The majority of high density labelled animals 
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analysed (11/12) displayed 2-8 coloured patches per artery, with one artery displaying 20 patches 
(Appendix C). This variation is likely explained by the fact that the carotid ligation model of neointimal 
growth is variable in the degree to which it affects the entire artery, with some arteries being 
remodelled throughout and others in just defined regions. Indeed, the number of patches correlated 
with the size of the remodelled area (R2=0.7).  
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Figure 34: A subset of VSMCs proliferate to form the injury-induced neointima 
A, Experimental protocol for carotid artery ligation studies. B, C, Whole-mount control right carotid artery (B) 
or ligated left carotid artery (C) from a high density-labelled animal (10x 1 mg tamoxifen), 28 days post-surgery 
(the point of ligation is 20-100 µm superior to the top of the ligated artery (Ci) as shown). Maximal projection 
of confocal Z-stack covering the entire artery is shown in (B) and (C i), whereas (C ii, iii) show magnified 
longitudinal cross section of the regions outlined in (C i). All scale bars are 150 µm. From Chappell et al., 2016.  
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Similar to the atherosclerosis model, patches of all colours were observed following ligation at 
frequencies comparable to labelling frequencies (Figure 35), again confirming that recombination 
does not confer a selective advantage to cells expressing a particular fluorescent protein. 
 
 
 
 
 
 
 
 
To determine the size of patches (cells per patch), confocal images of whole-mount, ligated, carotid 
arteries were processed (using Imaris) to surface render individual patches or cells in 3D. The volume 
was then calculated for each rendered surface, using the volume function within Imaris. By dividing 
the patch volume with the average volume for a single cell (with the same colour as the patch) it is 
possible to approximate the number of cells per patch. This figure ranged from 48 to > 7000 cells/patch 
with a mean of 962 and median of 436 cells/patch (Figure 36, Appendix C). Intra-animal patch size 
variation was similar to inter-animal variation, suggesting that this size range is not associated with 
slight differences in the ligation surgery between animals. The large patch sizes observed suggest that 
a single cell has vast expansionary capabilities (i.e. between 6-9 rounds of uniform doubling to create 
patches with 128-1024 cells) in order to remodel such large sections of the artery.  
 
Figure 35: Colour distribution observed in carotid ligation patches 
Bar chart showing the proportions of each of the Confetti colours in VSMCs directly after recombination (light 
grey) and in monochromatic regions within carotid ligation induced neointima (dark grey). All data is from high 
density-labelled animals (10x 1 mg tamoxifen). Adapted from Chappell et al., 2016. 
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To determine whether large monochromatic, neointimal, patches are the result of chance merging of 
independent clones of the same colour, carotid ligation was performed on animals injected with lower 
doses of tamoxifen (1x 0.1 and 1x 1 mg per animal), which induces ~40% and ~1% labelling of VSMCs, 
respectively. Compared to high density labelled arteries following carotid ligation, medium and low 
density labelled arteries contained fewer coloured patches (Figure 37, Appendix C), which is expected 
as fewer medial VSMCs are labelled. While patches in the low and medium density labelled arteries 
were similar in size to many of the patches in the high density labelled animals, the mean (363 
cells/patch) and median (98 cells/patch) patch size was lower (Figure 36). This suggests that very large 
patches (>1500 cells) may arise from the chance merging of independent clones of the same colour, 
however, the fact that large isolated patches are still observed in the low density labelled artery 
demonstrates clonality.  
The results from these carotid ligation experiments, therefore, demonstrate that a small subset of 
VSMCs undergo multiple rounds of division (~9 to reach the medium cells/patch) to generate the 
neointima following carotid ligation-induced vascular injury. This is similar to the results observed in 
the ApoE-/- HFD model (Chapter 5), in which few VSMCs clonally expand within atherosclerotic 
plaques. To quantify the proportion of cells that clonally expand in the ligation model, VSMC cellularity 
within the carotid medial layer of 5000 cells/mm2 (Clarke et al. 2006), and carotid artery diameter of 
Figure 36: Patch sizes in remodelled arteries 
Box plot showing the size of individual monochromatic patches. The patch sizes of low density-labelled (blue 
circles), medium density-labelled animals (orange crosses) and high density-labelled animals (green crosses) 
are displayed. Results are from 52 patches from 12 high density-labelled (10x 1 mg), 15 patches from 4 
medium density-labelled (1x 1 mg) and 8 patches from 4 low density-labelled animals (1x 0.1 mg). Adapted 
from Chappell et al., 2017 
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0.47 mm (Lacolley et al. 2001) was used to calculate the number of VSMCs/mm of vessel: 
(2π(0.5*0.47)1)5000 = 7382 cells/mm of vessel. Based on the measurements collected from this study, 
the average number of patches/mm of remodelled artery was 2.7 ± 1.0 (Appendix C), therefore less 
than 0.1% of VSMC are actively expanding to contribute to neointimal formation 28 days post ligation.  
Figure 37: A subset of VSMCs proliferate to form the injury-induced neointima 
A, B (i) Maximal confocal Z-stack projection of whole-mounted ligated left carotid artery from a low density-
labelled (A) and mid density-labelled (B) animals (1x 0.1 mg and 1x 1mg tamoxifen, respectively), analysed 28 
days post-ligation. Region outlined in (B i) is shown as a magnified longitudinal section in (B ii) and (B iii) with 
and without DAP (white). All scale bars are 150 µm. Adapted from Chappell et al., 2016. 
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The results within this section, confirm that in a second model of CVD, few VSMCs respond to an 
environmental stimulus known to elicit a proliferative VSMC response. Importantly, here it is 
demonstrated just how few VSMCs respond in such cases and raises the possibility that this low 
frequency response is an inherent feature of VSMCs.  
 
6.2 Neointimal VSMCs are mostly in a contractile state 28 days post carotid ligation surgery  
To investigate whether clonal proliferation following vascular injury is accompanied by similar 
phenotypic changes to those observed in the atherosclerosis model (i.e. decreased aSma and 
increased Mac3 expression), cross-sections of carotid arteries (which had previously been imaged as 
whole-mount) were stained for aSma and Mac3. Control staining in non-ligated right carotid arteries 
showed that all VSMCs stained positive for the contractile marker aSma while no Mac3 staining was 
detected (Figure 38).  
 
Serial sections from the ligated left carotid artery stained for aSma and Mac3 showed that while the 
majority of Confetti+ cells were aSma+ (68%) a proportion of the VSMC-derived cells had 
downregulated their expression of this contractile protein (Figure 39 B, E). Other studies examining 
earlier stages following carotid ligation suggest that the majority of VSMCs within the ligated artery 
downregulate aSma (Yoshida et al. 2013; B. Paul Herring et al. 2017). It is, therefore, possible that 
Figure 38: Right carotid artery immunostaining controls 
A-D, Single confocal scans from Z-stacks of 14 µm cryo-sections from the control right carotid artery of a high 
density-labelled (10x 1 mg tamoxifen) animal, 28 days after ligation of the left carotid artery stained for aSma 
(A) or Mac-3 (B). Panels (ii-iv) are magnified images of the regions outlined in (i). Signals for fluorescent 
proteins, DAPI (white), aSma (magenta) and Mac3 (magenta) are shown as indicated on each image. Scale bars 
are 50 µm. Adapted from Chappell et al., 2016. 
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aSma downregulation in VSMCs following ligation-surgery is transient, returning to near normal levels 
28 days post-surgery. The proportion of Confetti+ aSma+ cells (68%) seen in carotid arteries 28 days 
post ligation (Figure 39 E) was similar to the proportion of Confetti+ cells within the cap and shoulder 
regions from the ApoE-/- HFD model which were also aSma+ (82 and 62%, respectively, Figure 27). 
There was, however, no specific localisation of Confetti+ aSma+/aSma- cells within the injury-induced 
neo-intima. Mac3 was upregulated in a subset (34%) of VSMC-derived cells within the neointima 
(Figure 39 C, E), however the staining was typically less intense when compared to Mac3 staining 
within atherosclerotic plaques (Figure 28). These results indicate that the injury-induced neointimal 
Confetti+ cells are modulating their phenotype although less severely than the Confetti+ 
atherosclerotic plaque cells. 
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Figure 39: Injury-induced VSMC-derived neointima contains few phenotypically switched VSMCs 
A, Maximal projection of three central scans (7 µm apart) of a confocal Z-stack of a whole-mount ligated left 
carotid artery from a high-density (10x 1 mg tamoxifen) labelled animal, 28 days post-ligation. Scale bar is 300 
µm. B, C, Transverse cryo-sections from the region outlined in (A), stained for aSma (B) or Mac3 (C); the region 
outlined in (i) is magnified in (ii-iv). Arrows point to cells expressing the Confetti reporter (Confetti+) that do 
not stain for aSma (B) and Confetti+ Mac3+ cells (C) within the neointima. Arrow heads point to Confetti+ 
aSma+ cells (B) or Confetti+ Mac3- cells (C) within the neointima. Scale bars are 50 µm. Signals for fluorescent 
proteins, nuclear DAPI (white), aSma (magenta, B) and Mac3 (magenta, C) are shown as indicated on each 
image. D, Box plot showing the proportion of all cells (DAPI) within the neointima which express the Confetti 
reporter (Confetti+). E, Box plot displaying the proportion of Confetti+ neointimal cells that stain positive for 
aSma or Mac3 (Stain+) (based on 5 regions from 4 animals). All data is from high density-labelled (10x 1 mg 
tamoxifen) animals. From Chappell et al., 2016. 
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To further test the phenotypic modulation of VSMC-derived cells in the injury-induced neointimal 
model, cryo-sections were stained with Smmhc, which marks fully differentiated VSMCs and is 
downregulated in the earliest stages of phenotypic switching (Rensen, Doevendans, and van Eys 
2007).  Results showed that Smmhc staining in the neointima is similar to that in the control right 
carotid artery, with only few Confetti+ cells showing no staining for Smmhc (Figure 40), further 
suggesting that within the carotid ligation model, VMSCs exist primarily in a contractile state at day 
28 post ligation.  
 
The contractile phenotype seen here is likely only seen in the latter stage post-injury. For example, 
Herring et al. (2017), observed  that 3 days post-ligation there was an almost complete loss of 
contractile markers accompanied by an increase in inflammatory markers such as Spp1, Il1β and Il6. 
Their study determined this using qPCR following mRNA extraction from all cells in the left carotid 
artery post injury, therefore indicating that the majority of VSMCs first respond by modulating their 
gene expression away from the contractile phenotype and towards a synthetic phenotype. Baetta et 
al. (2000) also observed, 6 and 12 hours post carotid artery injury (using a perivascular collar in 
rabbits), that the majority of VSMCs within the injured carotid artery had upregulated expression of 
Figure 40: Smmhc immuno-staining in a control right carotid artery and ligated left carotid artery 
A, B, Single confocal scans from Z-stacks of 14 µm cryo-sections from the control right carotid artery (A) and 
left carotid artery 28 days post-ligation (B) in high density-labelled (10x 1 mg tamoxifen) animals, stained for 
Smmhc. Panels (ii-iv) are magnified regions outlined in (i). Arrows point to cells co-expressing the Confetti 
reporter and Smmhc, whereas arrow heads point to cells that express the Confetti reporter, but do not stain 
for Smmhc. Signals for fluorescent proteins, DAPI (white) and Smmhc (magenta) are shown as indicated on 
each image. Scale bars are 50 µm. Adapted from Chappell et al., 2016. 
 
A B 
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signal transducers and activators of transcription 6 (Stat6), further supporting the idea that the 
majority of VSMCs phenotypically switch following injury.  
 
6.3 Migration of VSMCs, independent of proliferation, into injury-induced neointima is not observed   
The neointimal patches formed from VSMC-derived cells in the ligation model were always connected 
to medial patches of the same colour (Figure 41) suggesting that VSMC proliferation initially occurs 
within the media and that progeny then migrate through the elastic laminae where they continue 
dividing to form the neointima. This is consistent with time course studies that have determined a 
high rate of medial proliferation soon after injury (Kumar and Lindner 1997). Coherent neointimal 
patches did not contain singlet VSMCs of a different colour (Figures 34 and 41), which would be 
observed if many randomly labelled cells migrated from the medial wall, suggesting that migration of 
VSMCs independent of proliferation does not significantly contribute to neointimal growth. Similarly, 
within the ApoE-/- HDF model, monochromatic patches within atherosclerotic plaques did not contain 
singlet cells of a different colour (Figures 20 and 22), suggesting that only proliferative VSMCs are able 
to enter and/or survive the neointima/plaque environment.  
 
 
 
 
 
 
 
 
 
 
The observation made in this section that VSMCs do not migrate into the neointima independent of 
subsequent proliferation is in direct contradiction to several previous studies (section 1.7, Zahradka 
Figure 41: Clonal VSMC-derived patches span both media and neointima 
Longitudinal cross section of the left carotid artery from animals labelled at high density (10x 1 mg tamoxifen, 
i) or low density (1x 0.1 mg tamoxifen, ii), which were analysed 28 days post-surgery, showing that individual 
VSMC-derived clones are “anchored” in the medial layer. A single scan of a confocal Z-stack, which intersects 
the middle of the vessel, is shown. Signals for fluorescent proteins and DAPI (white) are shown. Scale bars are 
100 µm. From Chappell et al., 2016. 
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et al. 2004; Yu et al. 2011; Clowes and Schwartz 1985). For example, Yu et al. (2011) suggest that 
approximately 40% of neointimal cells migrate independent of proliferation following carotid ligation, 
this observation is based on the detection of the thymidine analogue BrdU, which was diluted in the 
animals drinking water for the entire 28 days post-surgery. Furthermore, Clowes and Schwartz (1985), 
using a carotid balloon injury model in rats, also observed that 40% of neointimal cells had not 
proliferated, based on 3H-thymidine detection, which was delivered using osmotic pumps following 
surgery. However, even if 1% of VSMCs migrated into the neointima and survived independent of 
proliferation, singlet VSMCs would be detected in neointimal, monochromatic patches of a different 
colour. Two possible explanation for why Clowes and Schwartz (1985) and Yu et al. (2011) detected 
such a high number of cells that were negative for proliferation markers within the neointima are: (1) 
as neither study used lineage tracing methods to accurately identify the progeny of VSMCs, they may 
be detecting blood- or adventitial-derived cells which invade the neointima; and (2) that methods to 
label proliferating VSMCs are not 100% efficient.   
To test what the proliferative index is within this study, mice were injected with EdU 5 days a week 
following carotid ligation surgery. Results showed that a high proportion of Confetti+ VSMCs were 
EdU+ (47% ±2, Figure 42), although many cells were EdU-negative, suggesting that they did not 
proliferate. However, given that the neointima in monochromatic patches are derived from the clonal 
expansion of a single VSMC, the EdU method used here to label proliferating VSMCs cannot be 100% 
efficient. It is possible that this is also the case for the 3H-thymidine and BrdU methods used by Clowes 
and Schwartz (1985) and Yu et al. (2011), respectively, explaining why they also see such a high 
number of non-labelled neointimal cells. There are several reasons why strategies for labelling 
proliferating cells may not be 100% efficient. For instance, the use of 3H-thymidine suffers from poor 
resolution and a low signal-to-noise ratio, which makes detecting positive cells challenging (Salic and 
Mitchison 2008). BrdU methods may also suffer from antibody penetration issues and the harsh 
staining conditions necessary to denature double stranded DNA (Rakic 2002; Salic and Mitchison 
2008).  
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6.4 Conclusions from the carotid ligation experiments  
The carotid ligation model of neointimal growth was performed here to determine whether, similar 
to the ApoE-/- HFD model of atherosclerosis (Chapter 5), a few original VSMCs proliferate in response 
to arterial injury/disease. Results within this Chapter show that when carotid ligation is performed on 
high density labelled Myh11-CreER(T2); R26R-Confetti animals, large (mean=962 and median=436 
cell) contiguous monochromatic patches of VSMC-derived cells make up the newly formed neointima 
(Figures 34 and 36). Reducing the labelling frequency of Confetti+ VSMCs resulted in fewer isolated 
monochromatic patches, which confirm that these regions are derived from the clonal expansion of 
single VSMCs (Figures 36 and 37). Based on the number of medial cells and neointimal patches/mm 
of artery, less than 0.1% of medial VSMCs clonally expand to remodel the artery and form the newly 
derived neointima. The low proportion of VSMCs which proliferate in response to the ligation model 
is, therefore, similar to what was previously seen in the ApoE-/- HFD model of atherosclerosis (Chapter 
5), suggesting that the low frequency response to injury/disease could be an inherent feature of 
VSMCs.  
In contrast to the ApoE-/- HFD model (Chapter 5), fewer VSMC-derived cells observed in injury-induced 
neointima, 28 days post injury, present a synthetic phenotype (i.e. irregular morphology and 
expression of the macrophage marker Mac3, Figures 28, 29 and 39), which was more typical of VSMCs 
located to the cap of an atherosclerotic plaque (i.e. elongated and aSma+, Figures 26, 27 and 39). 
Figure 42: EdU staining in carotid ligation-induced neointima 
A, B, Single confocal scans from Z-stacks of 14 μm cryo-sections from the control right carotid artery (A) and 
the left carotid artery (B) 28 days post-ligation in high density-labelled animals (10x 1mg tamoxifen) stained for 
EdU. For each cryo-section, the region outlined in (i) is magnified in (ii-iv). Arrows point to cells co-expressing 
the Confetti reporter and EdU, whereas arrow heads point to cells that express the Confetti reporter, but do 
not stain for EdU. Signals for the fluorescent proteins, DAPI (white) and EdU (magenta) are shown as indicated 
on each image. Scale bars are 50 μm. From Chappell et al., 2016. 
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However, studies examining phenotypic switching of VSMCs just days after carotid ligation showed 
that all VSMCs within an injured artery downregulate contractile markers and upregulate markers of 
inflammation (Yoshida et al. 2013; Herring et al. 2017). It is therefore possible that following surgery 
the initial phenotypic switch of VSMCs away from the contractile phenotype is transient, with VSMC-
derived cells returning to a more contractile phenotype once the neointima is fully formed.  
Both, the carotid ligation experiments performed here and the atherosclerosis experiments in Chapter 
5 show that no monochromatic VSMC-derived patches within a plaque or injury-induced neointima 
contain singlet cells of another colour. This suggests that migration of VSMCs from the media into the 
neointima does not happen independently of proliferation, otherwise singlet cells would be observed. 
This is in direct contrast to observations made by (Yu et al. 2011; Clowes and Schwartz 1985) who 
suggest, based on in vivo methods to label proliferative cells, that up to 40% of non-proliferative, 
migratory VSMCs form the injury-induced neointima. To test the proportion of VSMCs-derived cells 
that were positive for proliferation within the neo-intima, EdU was injected into mice 5 days a week 
following carotid ligation surgery. Results demonstrated that less than 50% of VSMC-derived cells 
within a monochromatic patch were EdU+. However, as these patches were derived from the 
expansion of single VSMCs, this suggests that the EdU labelling strategy used here is not 100% 
efficient, which could be the case for labelling strategies used by Yu et al. (2011), and Clowes and 
Schwartz (1985). 
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Chapter 7: VSMC proliferation and plasticity in the Ang II perfusion model of AAA 
 
Models of AAA have been intensely studied to understand the sequence of cellular events leading to 
aortic aneurysm and rupture (Daugherty and Casis, 2004, and discussed in sections 1.9, 1.10 and 2.4). 
Important steps in the progression of AAA are noted as: (1) the medial accumulation of macrophages 
and degradation of elastin; (2) Dissection of the vascular wall and appearance of vascular haematoma; 
and (3) A profound inflammatory response, including the infiltration of B and T lymphocytes (Saraff et 
al., 2003). VSMCs are typically described in regard to their apoptosis, which is increased in models of 
AAA, along with elastin break-down this leads to the degeneration of the vascular wall (Thompson 
1996; López-Candales et al. 1997; Rowe et al. 2000). Several studies have reported that VSMCs 
phenotypically switch in AAA, downregulating the contractile proteins aSma and Sm22a (Ailawadi et 
al., 2009) and upregulating production of MMPs (Airhart et al., 2014). However, to date no studies 
have specifically lineage traced VSMCs within AAA. Given the known potential for VSMCs to 
phenotypically switch and be unidentifiable by traditional contractile markers (e.g. Myh11 and aSma, 
Gomez and Owens, 2012) there is a possibility that previous studies have missed an important role of 
VSMCs in the progression of AAA. Particularly as, in late stages of AAA there is often prominent 
remodelling and neovascularisation of aneurysmal tissue (Saraff et al., 2003) which, in other models 
of CVD, is often supported by/involves VSMCs, for example the HFD/carotid ligation models (Chapter’s 
5 and 6).         
The work within this Chapter was initiated following experiments performed by Dr. Marc Clement, in 
which, the Ang II infusion model of AAA (described in sections 2.4 and 3.13) resulted in the 
appearance of large, coherent regions of aSma+ cells within the intraluminal thrombus of the 
aneurysm. To understand whether these aSma+ cells are VSMC-derived and to see if VSMCs clonally 
proliferate within AAA, the Myh11CreER(T2); R26R-Confetti mice were subjected to the Ang II infusion 
protocol for 28 days (section 2.4) and the tissue was analysed by confocal microscopy of cryo-sections.  
This results chapter is based on a collaboration between the groups of Dr. Helle Jorgensen and Prof. 
Ziad Mallet. Mini-pump surgery and tissue removal was performed by Dr. Marc Clement while cryo-
sectioning, immuno-staining and imaging was performed by Joel Chappell.  
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Aims 
1. Determine if the observed aSma+ population of cells within the intraluminal thrombus, 
following the Ang II perfusion model of AAA, are VSMC-derived  
2. Determine if VSMCs clonally proliferate in AAA 
3. Examine potential molecular mechanisms leading to the proliferative response of VSMCs 
 
7.1 The Ang II, anti-TGF-β model of AAA induces an outward clonal expansion of VSMCs at thrombotic 
sites and medial proliferation at sites of elastic lamina breaks  
To test if VSMCs proliferate within AAA, 6-week-old Myh11CreER(T2); R26R-Confetti mice were 
labelled at high density (10x 1 mg tamoxifen), and subjected to mini-pump surgery in which an Ang II 
loaded mini-pump was inserted subcutaneously into each mouse, this was followed by 3 injections 
per week of anti-TGF-β for 28 days. The Ang II/anti-TGF-β protocol used here caused the development 
of aneurysms primarily within the abdominal region of the aorta, which macroscopically appeared as 
small bulges along the length of the aorta (data not shown). To investigate VSMC involvement in the 
development of these aneurysms the abdominal aorta was cryo-sectioned and imaged by confocal 
microscopy (Figure 43 A).  
Imaged cryo-sections showed that within the developed intraluminal thrombus, Confetti+ cells were 
frequently (in 3/5 mice, Appendix D) detected in large patches (Figure 43 B). VSMC-derived patches 
within the thrombus were typically composed of several coherent patches expressing different 
colours, suggesting that several VSMCs clonally expand to remodel the aneurysmal tissue. Compared 
to the VSMC-derived patches observed in the HFD atherosclerosis/carotid ligation models of CVD they 
were, typically more heterogeneous, containing more colours within a given region with more 
intermingling of colours. For example, Figure 43 (B ii) shows a large region containing VSMC-derived 
cells, RFP expression is predominant, with some interspersed yellow cells, suggesting that a red and 
yellow clone have merged. Furthermore, where VSMCs had not entered the thrombus/where no 
thrombus had developed, there was frequently large medial patches with multiple cells of the same 
colour, indicating that a single cell had expanded within a particular medial layer (Figure 43 C). This 
could suggest that, at least in some cases, VSMCs proliferate within the media prior to invading the 
thrombus.  
The observation that large VSMC-derived, monochromatic patches within the thrombus and media 
exist following the Ang II/anti-TGF-β protocol clearly show that VSMCs proliferate within AAA through 
massive clonal expansion. This phenomenon has not yet been reported within in the literature, with 
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the majority of studies regarding apoptosis as the key VSMC event (Thompson 1996; López-Candales 
et al. 1997; Rowe et al. 2000). Some studies have however reported highly proliferative/migratory 
VSMCs taken from AAA tissue when analysed in culture (Patel et al. 1996). Out of the five mice 
analysed, three contained VSMC-derived outgrowths and all contained medial monochromatic 
patches and breaks within the elastic lamina (Appendix D). However, similar to other studies there 
was a large degree of heterogeneity between mice in terms of phenotype severity (Daugherty, 
Manning, and Cassis 2001), and is likely the result of a combination of factors, including where initial 
micro-tears occur within the aortic wall (Trachet et al. 2017).  
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Figure 43: VSMCs clonally expand in the Ang II + anti-TGF-β model of AAA 
A, Experimental protocol for the Ang II + anti-TGF-β, AAA studies. B and C, AAA cryo-sections from high 
density-labelled animals (10x 1 mg tamoxifen) presenting outward remodelling of VSMCs within the 
aneurysmal tissue of the abdominal aorta into the thrombus (B) and within the media (C). The regions 
outlined in (i) are magnified in (ii). Dashed white lines in (C ii) encircle VSMC-derived cells of the same 
colour expanded within a single medial layer. Fluorescent protein and DAPI (grey) is shown as indicated. 
Scale bars are 100 µm. 
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To determine if the VSMC-derived outgrowths were aSma+, and therefore related to the original 
observation by Dr. Clement (discussed above), cryo-sections were stained for aSma. Results showed 
that aSma staining co-localised with the Confetti+ outgrowths, although staining was typically less 
intense compared to the media, indicating that some downregulation of aSma had occurred within 
these cells (Figure 44). Furthermore, no aSma+ patches were detected which were not Confetti+. 
Confetti- aSma- cells were detected within the Confetti+ outgrowths, and are likely the results of 
invading macrophages and resident adventitial cells, which are similarly observed in other studies 
(Saraff et al. 2003; Rateri et al. 2011). These results confirm that the aSma+ patches observed by Dr. 
Clement are VSMC-derived.  
Figure 44: VSMC-derived patches within the Ang II + anti-TGF-β model of AAA co-localise with aSma 
A, AAA cryo-section from high density-labelled animals (10x 1 mg tamoxifen) presenting outward remodelling 
of VSMCs into the thrombus with aSma staining. The region outlined in (A) is magnified in (B, C and D) 
fluorescent protein, DAPI (grey) and aSma (magenta) is indicated at the top of each panel. Arrows point to 
Confetti+ aSma+ cells, arrow heads point to Confetti- aSma- cells. Scale bars are 100 µm. 
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Also observed within cryo-sections from all mice with AAA were dilated areas within the media 
containing Confetti+ monochromatic patches, Confetti-negative cells and even regions containing no 
cells at all (Figure 45). While VSMC death, infiltration of immune cells and medial degradation is known 
to occur in AAA (Saraff et al. 2003; Rateri et al. 2011), proliferation of VSMCs to fill these dilated 
regions is not documented. Whether VSMCs which proliferate in response to their environment fill a 
space in which other VSMC have left empty through apoptosis, or if proliferating VSMCs invade the 
space around them killing less fit cells is undetermined. Experiments which lineage trace VSMCs in 
early stages of AAA could be used to determine the sequence of events by which monochromatic 
patches grow and single non-proliferative VSMCs die. 
Figure 45: Medial dilation in AAA 
A and B, AAA cryo-sections from high density-labelled animals (10x 1 mg tamoxifen) presenting medial 
dilation. Dilated areas are either filled with Confetti+ or Confetti- cells (A) or contain no cells (B). The 
region outlined in (i) is magnified in (ii). Arrows in (A i) point to Confetti-negative cells and the white 
dashed line in (B ii) encircles areas containing no cells. Fluorescent protein and DAPI (grey) is indicated at 
the top of each panel. Scale bars are 100 µm. 
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7.2 anti-TGF-β is not responsible for the VSMC response in the Ang II perfusion model on an ApoE-/- 
background  
 
To further understand the proliferative response from VSMC-derived cells it is important to consider 
the factors causing this response. Both Ang II and TGF-β are known to affect VSMCs, for example  Ang 
II has been shown to increase VSMC contractility (Dostal, Murahashi, and Peach 1990) but can also 
contribute to the proliferative phenotype of VSMCs (Zhang et al. 2012). In contrast, TGF-β is vital for 
the development and maturation of VSMCs from pre-cursor cells (Sinha et al. 2004) but can promote 
the proliferative and migratory phenotype of mature VSMCs (Zhu et al. 2015). To investigate whether 
VSMC proliferation within AAA results from the artificial blocking of TGF-β signalling, which might 
directly induce VSMC phenotypic switching, Ang II mini-pumps were inserted into ApoE-/- mice which 
were divided into two groups. One group received no anti-TGF-β while the other was injected with 
anti-TGF-β two weeks following Ang II mini-pump insertion.  
Of the nine mice which did not receive anti-TGF-β only one contained a thrombotic outgrowth of 
VSMCs (Appendix D) which demonstrated large monochromatic regions, suggesting massive clonal 
expansion of multiple cells (Figure 46 A). All nine of these mice, however, contained breaks within the 
elastic lamina along with medial patches of VSMC-derived cells (Appendix D, Figure 46 B). Zero out of 
five animals receiving anti-TGF-β had an outgrowth of VSMCs, but similar to mice which did not receive 
anti-TGF-β, all contained elastic lamina breaks and medial proliferation (Appendix D, Figure 47). It 
should be noted that medial proliferation occurred in relatively healthy-looking media (Figure 46 B) 
and dilated media (Figure 47) in both mice which received and did not receive anti-TGF-β. The similar 
phenotypes observed between the two groups of animals (i.e. +/- anti-TGF-β) is expected, as previous 
studies have shown that while anti-TGF-β increases severity of the AAA phenotype in wildtype mice it 
has little effect in ApoE-/- mice (Wang et al. 2010). Furthermore, the observation that anti-TGF-β 
administration has little effect on the AAA-VSMC phenotype in Ang II infused ApoE-/- animals suggests 
that factors other than those directly related to TGF-β are causing VSMCs to proliferate.    
One possible reason for the lack of VSMC outgrowths in the ApoE-/- mice (1/14) compared to the wild 
type mice (3/5) is that the ApoE-/- AAA phenotype was typically, in these experiments, not severe 
enough to develop a thrombus in which VSMCs could grow into. Given that there was still substantial 
medial proliferation of VSMCs within the ApoE-/- mice this suggests that thrombus formation is reliant 
on other factors than VSMC proliferation, although this is expected as thrombus formation is known 
to occur in response to platelet activation (Liu et al. 2012).  
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Figure 46: VSMC clonal expansion in the Ang II model of AAA on the ApoE-/- background 
A and B, AAA cryo-sections from high density-labelled animals (10x 1 mg tamoxifen) presenting VSMC 
outgrowth (A) and medial expansion of VSMCs (B). The region outlined in (B i) is magnified in (B ii and iii). 
Coloured and white dashed lines in (A and B ii and iii) encircle VSMC-derived patches. Fluorescent protein and 
DAPI (grey) is indicated at the top of each panel. Scale bars are 150 µm. 
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Figure 47: VSMC clonal expansion in the Ang II + anti-TGF-β model of AAA on the ApoE-/- background 
A, AAA cryo-sections from a high density-labelled animal (10x 1 mg tamoxifen) presenting medial 
expansion of VSMCs. The region outlined in (A) is magnified in (B), coloured dashed lines in (B) encircle 
VSMC-derived medial patches. Fluorescent protein and DAPI (grey) is indicated at the top of each panel. 
Scale bars are 100 µm. 
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7.3 Proliferating VSMC-derived cells in AAA, frequently co-localise with the platelet marker CD41 
 
To investigate potential mechanisms behind VSMC proliferation within the the AAA model, and 
whether VSMC proliferation follows or causes elastic lamina breaks, leading to subsequent infiltration 
by blood cells, cryo-sections were stained for the platelet marker CD41. Platelets are known to release 
PDGF-BB, which is a potent activator of the VSMC phenotypic switch to a synthetic state (Li et al. 1997; 
Hao, Gabbiani, and Bochaton-Piallat 2003), and could therefore be causing VSMCs to proliferate.  
All models of AAA used in these studies showed that where breaks occurred to the elastic lamina, the 
media was often observed to be positive for CD41, indicating medial infiltration of platelets and likely 
other blood-derived cells. CD41 often co-localised with Confetti+ monochromatic patches within the 
media and thrombus, however, there were some Confetti+ patches which did not co-localise with 
CD41 but were close to an area positive for CD41 (Figure 48). Furthermore, CD41 frequently located 
to medial areas which were occupied by Confetti-negative cells (Figure 48), indicating that medial 
VSMCs may also be dying when exposed to platelets and other inflammatory cells.  
Given that certain Confetti+ monochromatic patches exist which do not stain positive for CD41 (white 
dashed line in Figure 48 B) this could suggest that VSMCs are phenotypically switching/proliferating 
in response to other signals, for example the systemic circulation of Ang II.  However, large Confetti+ 
patches in dilated medial layers and within thrombus were always CD41+ or surrounded by CD41+ 
cells, suggesting that platelets may have a role in the vast expansion of VSMC-derived clones. While 
there is no published data on the role of platelets within AAA specifically regarding VSMCs, one study 
has found that by blocking platelet activation using a P2Y(12) receptor antagonist; thrombus 
development, inflammatory cell infiltration and MMP-9 expression was reduced (Dai et al. 2009). 
Importantly VSMCs are known to upregulate MMP-9 in AAA (Airhart et al. 2014), which may indeed 
be induced by PDGF-BB release from platelets, as it is known to potently switch VSMCs to a synthetic 
phenotype (Yoshida et al. 2007).   
 
 
 
 
 
 
112 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48: CD41 staining in AAA 
A, AAA cryo-sections from a high density-labelled animal (10x 1 mg tamoxifen) presenting medial expansion of 
VSMCs. The regions outlined in (A) are shown in (B and C). Yellow dashed lines in (B) encircle a Confetti+ 
monochromatic patch which is CD41+. White dashed lines in (B) encircle a VSMC-derived patch which is CD41-
negative. Yellow dashed lines in (C) encircle Confetti- CD41+ cells. Fluorescent protein and DAPI (grey) is 
indicated at the top of each panel. Scale bars are 100 µm. 
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7.4 A high proportion of VSMCs phenotypically modulate/proliferate within the AAA model   
 
The Ang II models of AAA presented here show similar results in regard to VSMC oligo-clonality when 
compared to the HFD atherosclerosis (Chapter 5) and carotid ligation (Chapter 6) models (i.e. large 
monochromatic VSMC-derived patches are observed within the remodelling vasculature). A 
noticeable difference however is the proportion of VSMCs which are responding to disease in AAA. As 
discussed previously in the HFD atherosclerosis model, plaques were typically derived from one or 
two cells, and this was not accompanied by multiple small VSMC-derived patches within the media 
(section 5.2). Furthermore, within the carotid ligation model it was determined that <0.1% of cells 
proliferated in response to surgery to form the neo-intima (section 6.1). Within the Ang II models of 
AAA however, multiple large patches can be observed in the thrombus (Figure 46 A), furthermore the 
media typically contains many small patches of cells (Figure 46 B). This shows that the AAA model is 
able to push a higher proportion of VSMCs to proliferate and suggests that more if not all VSMCs have 
the potential for this response. It should, however, be noted that only the abdominal aorta was 
examined within the AAA studies compared to the descending thoracic aorta, aortic arch and carotid 
arteries in the ApoE-/- HFD studies (Chapter 5) and the left carotid artery in the carotid ligation studies 
(Chapter 6). As VSMCs within different regions are derived from different embryological pre-cursor 
cells (Wang et al. 2015), there may be regional differences in the proportion of VSMCs which  
respond/are capable of responding. Given that medial monochromatic, VSMC-derived, patches within 
AAA are typically space restrained this could explain the small numbers of cells in each patch, and only 
when full medial break down, platelet release of Pdgf-β and thrombus formation occurs, can these 
VSMCs truly expand to their full potential.  
As discussed previously VSMCs are not usually noted for their proliferative role within AAA, and in fact 
most studies talk about their apoptosis and role in the degeneration of the vascular wall (Thompson 
1996; López-Candales et al. 1997; Rowe et al. 2000). Whether the proliferation of VSMCs seen here is 
an attempt to: (1) repair the injured vasculature/replace apoptosed VSMCs; or (2) an aberrant loss of 
control by the proliferating VSMC-derived cells which contribute to degeneration of the vascular wall 
through, for example, MMP production is unknown, and will be investigated further in subsequent 
experiments. The former is however perhaps more likely as VSMCs would provide structural integrity 
to the vasculature which is undergoing extreme pressure not to break apart. Supporting this notion is 
work by Park et al. (2013) who implanted VSMC-like progenitor cells (muscle-derived stem cells 
stimulated with Pdgf-B in vitro) into elastase-induced AAA in rats, and found a decreased rate of 
aneurysm and MMP expression suggesting that VSMC have a role in protecting from the severe AAA 
disease phenotype.     
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7.5 Conclusions from the AAA experiments  
Results from this section suggest that, within the Ang II + anti-TGF-β model of AAA, VSMCs clonally 
expand within the aneurysmal, intraluminal thrombus and media of tissue experiencing breaks within 
the elastic lamina and other characteristics of AAA such as medial dilation and infiltration of non-
VSMC-derived cells (Figures 43 and 45). Furthermore, VSMC-derived clones within the intraluminal 
thrombus co-localise with aSma (Figure 44), confirming that the aSma+ regions observed previously 
(data not shown) are VSMC-derived.  No literature has specifically studied VSMC proliferation in AAA 
and VSMCs have not been lineage traced within AAA until now. 
When anti-TGF-β was removed from the Ang II/anti-TGF-β model of AAA and mice were placed on the 
ApoE-/- background there wes no observed difference in VSMC proliferative phenotype (Figure 46), 
suggesting that anti-TGF-β has no significant effect on the proliferative phenotype of VSMCs in this 
model. There was however a less severe phenotype in general with fewer occurrences of an 
intraluminal thrombus. 
VSMC-derived patches typically co-localised with the platelet marker CD41 (yellow dashed lines in 
Figure 48), however there were exceptions (white dashed lines in Figure 48), suggesting mechanisms 
other than platelet-release of Pdgf-B is acting to phenotypically switch VSMCs. Furthermore, it is not 
clear whether VSMCs cause the breakdown of the elastic lamina and degradation of the vascular wall 
as some have suggested through their upregulation of MMPs (Airhart et al. 2014), or if VSMC are 
responding to elastic breaks to try to repair and remodel the tissue.  
Lastly a higher proportion of VSMCs are observed to proliferate in AAA compared to the previously 
discussed HFD/carotid ligation models of CVD, resulting in the formation of many small medial patches 
(Figure 46). This suggests that given the right environment a high proportion/all VSMCs can 
phenotypically switch and proliferate. 
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Chapter 8: Optimisation of scRNA-seq techniques for VSMCs 
 
The emergence of tools capable of profiling cells at the single cell level is revolutionising the way in 
which scientists can study the complexity of an organism. scRNA-seq has emerged as the most 
sensitive genome wide method to analyse the transcriptome of a single cell as it typically attempts to 
sequence every ploy(A) tailed mRNA sequence within each cell (Saliba et al., 2014). Multiple scRNA-
seq platforms are currently available, including the C1, Smart-seq2, MARS-seq, Drop-seq, Chromium 
10x and CEL-seq methods, within a field which is developing quickly (Haque et al. 2017). Each of these 
methods are different in the way they collect and process cells, be it using microfluidics, plate or 
droplet based systems, which can affect the throughput and quality of the generated data (Haque et 
al. 2017). scRNA-seq techniques are not, currently, conventionally applied to studying VSMCs, but 
could potentially reveal information regarding the heterogeneity of this population and provide 
detailed information regarding their phenotypic transition. Indeed, immunohistochemistry has 
already revealed that expression of contractile markers, as well as adhesion molecules and gap 
junctional proteins can differ between adjacent VSMCs (Christen et al. 2001; Frid, Moiseeva, and 
Stenmark 1994; Moiseeva 2001). A literature search reveals only one published paper using scRNA-
seq to study VSMCS, and looks at cultured VSMCs from two different passages (P1 and P2) using the 
Fluidigm C1 method to isolate and analyse individual cells (Adhikari et al. 2015). Very little analysis of 
sequencing data was presented within this paper, but Adhikari et al. (2015) do suggest that there is a 
great deal of heterogeneity between individual cells within P1 and P2 regarding conventional 
contractile markers (Myh11, Tagln, Acta2, Cnn1, Smtn and Cald1). 
Current single cell methods are technically sensitive and therefore require a degree of optimisation 
for each cell type. The objective of this Chapter is, therefore, to optimise two methods of scRNA-seq 
for use on VSMCs, which will be further used to answer particular questions (described below) in 
future experiments/analyses. Previous experiments within our group used the C1 microfluidics system 
to capture and sequence single VSMCs in an attempt to identify a small sub-population of VSMCs. 
However, this method suffered from several issues, including large batch effects and problems with 
capturing VSMCs of different sizes (data not show). To overcome these problems, the scRNA-seq 
method Smart-seq2 (section 2.5) was chosen for optimisation for use on individual VSMCs. This 
method relies on a plate based protocol in which single cells are isolated via FACS into single wells of 
a 96 well plate. Advantageously, isolating using FACS does not bias against VSMCs of different sizes 
and allows cells to be index sorted, which provides additional information on cell size and level of 
marker expression if cells are stained for a particular antibody of interest. Subsequent RT-PCR and 
cDNA amplification takes place within the 96-well plate (Picelli et al. 2013). Smart-seq2 experiments 
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performed here, were used to isolate and analyse a VSMC sub-population which express Sca1, as 
preliminary studies by our group have shown that these cells exist within the media but only very 
rarely (data not shown). This observation is supported by other studies which previously identified 
Sca1+ medial cells (Sainz et al. 2005). Sca1 is an interesting marker to study regarding VSMCs as it is 
typically associated with adult murine haematopoietic stem cells (Spangrude, Heimfeld, and 
Weissman 1988), with studies identifying Sca1+ adventitial cells, capable of differentiating into VSMCs 
and contributing to injury the response (Hu et al. 2004; Yu et al. 2016). Sca1 therefore represent the 
kind of marker which could be expressed by a population of VSMCs likely to proliferate in response to 
injury/disease.  
In the past, studying heterogeneity within a cellular population, in a high-throughput manner, relied 
on methods such as multi-colour flow cytometry and multiplexed mass cytometry, which are able to 
profile unlimited cell numbers but are limited to the number of proteins which can be identified 
(Giesen et al. 2014). scRNA-seq techniques such as/similar to Smart-seq2 are unbiased, able to detect 
heterogeneity regarding unknown factors, and allow a higher resolution of analysis into single cells by 
attempting to sequence the entire transcriptome of each cell. However, they make the profiling of 
thousands of cells difficult/impossible due to high labour costs. To truly examine the heterogeneity of 
a cellular population at high resolution, a scRNA-seq method which is able to process thousands of 
cells at a time is required. The second method chosen to profile the transcriptome of individual VSMCs 
in this Chapter, is the Chromium 10x system for scRNA-seq, as it able to sequence up to 10,000 
individual cells in one experiment, thus, making it a relatively high throughput method while requiring 
very little manual work (Zheng et al. 2017). The 10x system will be used to profile the heterogeneity 
of the VSMC population, this information will then be used to map cells onto the contractile-synthetic 
spectrum (discussed in section 1.3, Figure 3), search for rare sub-populations and examine 
heterogeneity in VSMC response following injury/disease.  
The work within this Chapter is primarily performed as a proof of concept study to show that these 
scRNA-seq methods are able to analyse the transcriptome of individual VSMCs. The data generated in 
these experiments will be used in future analyses to profile VSMC heterogeneity and identify VSMC 
sub-populations. This results chapter is based on a collaboration between the groups of Dr. Helle 
Jorgensen and Dr. Mikhail Spivakov, future data analysis will be led by Lina Dobnikar. 
Aims: 
1. Optimise Smart-seq2 for analysis of VSMCs  
2. Sequence and compare Confetti+ Sca1- and Confetti+ Sca1+ cells 
3. Sequence healthy VSMCs using the 10x Chromium system  
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8.1 Smart-seq2 optimisation for VSMCs 
 
Smart-seq2 is a sensitive technique for full-length transcriptome profiling in single cells, which is 
necessary when working with such small amounts of RNA, and requires careful optimisation for each 
cell type used. The main step requiring optimisation is the number of PCR cycles used to amplify the 
cDNA; amplification is needed to generate sufficient quantities of cDNA for subsequent reactions. Too 
little amplification will result in the loss of rare transcripts whilst too much will lead to amplification 
bias of more common transcripts. To optimise the number of PCR cycles to sufficiently amplify cDNA 
from a single VSMC, aortas from Myh11-CreER(T2); R26R-Confetti mice labelled at high density (10 x 
1 mg tamoxifen) were enzymatically dissociated to a single cell suspension and Confetti+ cells were 
FACS sorted into a 96 well plate so that each well contains a single cell. The cells then underwent lysis 
and RT-PCR using the Smart-seq2 protocol (sections 2.5 and 3.18) to create cDNA. At this point 
different numbers of PCR cycles (22, 24 and 26) were used to amplify cDNA from individual cells. 
Samples were then analysed using an Agilent Bioanalyzer to test if cDNA was detectable. Bioanalyzer 
traces show that with 22 cycles cDNA was barely detectable and often no cDNA was detected at all, 
however 24 and 26 cycles showed consistently detectable quantities of cDNA (Figure 49).  
 
 
 
 
 
 
 
 
 
 
 
 
Amplified cDNA of 10 single cells from 2 separate batches (i.e. different mice, FACS sort and RT-PCR) 
with 24 cycles and 2 cells from a batch with 26 cycles were further processed using the Nextera XT 
Figure 49: Bioanalyzer plots showing 
cDNA signal intensity from Smart-seq2 
samples subjected to different PCR cycle 
numbers 
RNA from single VSMCs went through the 
Smart-seq2 protocol, however, different 
PCR cycle numbers (22 (A), 24 (B) and 26 
(C)) were used to amplify the cDNA. The 
graphs show signal intensity (fluorescence 
units, FU) over time in seconds (s) from 
the Agilent Bioanalyzer high-sensitivity 
DNA chips, for individual samples. Arrows 
point to peaks representing cDNA. Peaks 
at 43 and 113 (s) are internal control 
markers. Peaks at 50 (s) is primer dimer.  
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tagmentation kit in order to index individual transcripts so they can be matched back to their cell of 
origin in later analysis. Samples were then pooled together and sequenced using Illumina NextSeq 500 
Mid Output 75 bp paired end sequencing. Read counts were typically between 2-6 million reads/cell 
for 24 cycles and 14 million for those which underwent 26 cycles of amplification (Figure 50 A). Gene 
counts, however, were similar for all cells (excluding one of low quality) with between 4000-5000 
genes detected (Figure 50 B). Given that 26 cycles only increased the number of reads per cell and not 
the number of genes detected, 24 cycles were chosen for all future experiments. The number of genes 
detected here is comparable to the number of genes detected using Smart-seq2 in a study by 
Macaulay et al. (2016) which analysed hematopoietic stem cells and uses 25 PCR cycles for cDNA 
amplification. Other studies have detected >9000 genes/cell using Smart-seq2 when analysing 
embryonic stem cells (Ziegenhain et al. 2017). However, as VSMCs are typically a quiescent cell type, 
the number of genes detected per cell is expected to be lower compared to other cell types.   
 
 
 
 
 
 
 
 
The second factor that required optimisation concerns the concentration of ERCC spike-in controls, a 
common set of external RNA controls developed by the External RNA Controls Consortium. ERCC 
controls are a set of 92 unlabelled, poly(A) transcripts which are added to each sample after cell 
isolation in order to evaluate sensitivity and dynamic range of an experiment and allow differential 
gene expression analysis. ERCC transcripts are designed to be 250-2000 nucleotides in length and 
cover a concentration range of 6 logs, representing the distribution of endogenous transcript signals 
(Lemire et al., 2011). If, for example, too many reads from a cell map to ERCCs this suggest that the 
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Figure 50: Total read and gene counts from single VSMCs subjected to different numbers of cDNA 
PCR cycles 
Graphs showing the read (left panel) and gene (right panel) counts for twelve individual VSMCs which 
underwent the smart-seq2 protocol, each batch relates to a separate experiment. The number of 
cDNA amplification cycles each cell underwent is displayed in the legend. 
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endogenous mRNA was likely of poor quality and this cell should be excluded from further analysis. 
To determine the optimal amount of ERCCs to mix with each sample, different amounts of ERCC Spike-
In Mix (Thermo Fischer Scientific, Cat. no. 4456740) was added to each well of a 96 well plate, already 
containing the RT-PCR reagents and a single VSMC. Following RT-PCR and cDNA amplification, samples 
were then analysed using an Agilent Bioanalyzer. As shown in Figure 51 (B), addition of ERCCs at 
1:10,000,000 resulted in detection of peaks corresponding to the size of prominent ERCC transcripts, 
whereas the broad peak resulting from cDNA generated from endogenous transcripts was barely 
detectable. In contrast, Figure 51 (E) shows that a ERCCs diluted at 1:80,000,000 are only just 
detectable over the endogenous RNA on the Bioanalyzer trace.  
 
 
 
 
 
 
 
 
 
 
 
 
 
To further test which of the ERCC dilutions were optimal, eight single cells containing three different 
ERCC dilutions (1:20,000,000; 1:40,000,000; 1:80,000,000) were analysed by high-throughput 
Figure 51: Bioanalyzer plots showing cDNA intensity generated from endogenous and ERCC transcripts 
from Smart-seq2 samples 
RNA from single VSMCs went through the Smart-seq2 protocol containing different quantities of ERCC 
controls. A = 0; B = 1:10,000000; C = 1:20,000,000; D = 1:40,000,000; E = 1:80,000,000. The graphs show 
signal intensity (fluorescence units, FU) over time in seconds (s) observed using the Agilent Bioanalyzers 
high-sensitivity DNA chips, for individual VSMCs. Arrows point to peaks representing ERCC spikes, 
surrounded by the endogenous cDNA signal. 
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sequencing to detect the proportion of reads which mapped to ERCC transcripts compared to 
endogenous RNA transcripts. As shown in Figure 52, addition of ERCCs at 1:20,000,000 resulted in 
approximately 600,000 reads mapping to ERCC transcripts which equates to 20% of the total reads 
per cell, these values halved as the dilution halved (Figure 52). Other studies typically use ERCCs at a 
dilution which results in between 2-10% of total reads mapping to ERCC transcripts as this provides 
adequate coverage to detect lowly expressed ERCC transcripts without reducing the number of 
endogenous genes detected (Achim et al. 2015; Tung et al. 2017). Therefore, as a dilution of 
1:40,000,000 gave between 7-10% of total reads mapped to ERCC transcripts, this dilution was chosen 
for subsequent experiments.  
 
 
 
 
 
 
 
 
8.2 Smart-seq2 experiment: Sca1+ VSMCs 
 
Next, the ability of the Smartseq2 protocol to identify cell-to-cell variations between VSMC 
populations is tested. Prior to these experiments, our group had identified a population of Sca1+ 
VSMCs (data not shown), this is unexpected as Sca1 is a stem cell marker typically associated with 
haematopoietic cells (Spangrude, Heimfeld, and Weissman 1988). Sca1+ medial cells had previously 
been identified by Sainz et al. (2005) but were not confirmed to be VSMCs in their study. To 
demonstrate the proportion of Sca1+ VSMCs, aortas from high-density labelled Myh11-CreER(T2); 
R26R-Confetti mice were dissociated to single cells and stained with a near infra-red viability dye and 
a Sca1 antibody conjugated to the APC fluorophore. These cells were then analysed by flow cytometry. 
Gating for singlet, live, Confetti+, Sca1+ cells revealed that approximately 0.14% of Confetti+ cells 
Figure 52: Total ERCC reads and the proportion of reads per cell which map to ERCC controls. 
Graphs showing the number (left panel) and proportion (right panel) of reads which map to ERCCs for eight 
single VSMCs which underwent the Smart-seq2 protocol. The dilution of ERCC into the RT-PCR mix for each 
cell is displayed in the legend. 
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stained positive for Sca1 (Figure 53). For comparison, this gating strategy with cells stained with the 
corresponding IgG control conjugated to APC gave a Confetti+ APC+ rate of 0.06% of cells (data not 
shown) suggesting that approximately 0.1% of VSMCs are Sca1+. 
 
 Events % of parent 
All events 10,000 100 
R1 (cells) 9,743 97.43 
R2 (singlets) 8,431 86.53 
R3 (live cells) 8,144 96.60 
R4+R5+R6 (Confetti+ cells) 6,436 79.03 
R7 (Confetti+ Sca1+) 9 0.14 
 
Previous results presented within the thesis, for example from the carotid ligation model (Chapter 6), 
suggest that generation of the injury-induced neointima results from the clonal expansion of very few 
VSMCs (<0.1%), indicating that activation of proliferation is a rare event. The observed, low proportion 
of cells which activate proliferation following injury raises questions regarding heterogeneity of 
VSMCs. For example, whether there exists a progenitor-like cell population which responds to injury 
or whether all cells are equi-potent, capable of responding. If the former is true, then Sca1 could 
Figure 53: Flow cytometry analysis of Confetti+ Sca1+ cells 
VSMCs from Myh11-CreER(T2); R26R-Confetti mice were stained with a near infrared viability dye and a 
anit-Sca1 antibody conjugated to APC before analysis by flow cytometry. Graphs show the gates (R) used to 
isolate live Confetti+ Sca1+ cells. The table shows the number of events recorded in each gate (R) and the 
percent of cells carried on from the previous (parent) gate.  
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potentially be the type of gene which may mark a progenitor-like population. In order to further profile 
this cell type and compare them to Sca1-negative VSMCs, single cells from the aortas of nine (4 in the 
first batch and 5 in the second batch) Myh11-CreER(T2); R26R-Confetti mice were first dissociated to 
single cells. These cells were then stained with a cell viability dye and the Sca1-APC antibody and then 
FACS sorted into individual wells of a 96 well plate (2x plates from two different days). In total 88 
Confetti+ Sca1+ (C+S+), 70 Confetti+ Sca1- (C+S-) and 26 Confetti- Sca1- (C-S-) cells were collected. All 
cells were subjected to the Smart-seq2 protocol (Batch 1 and 2 were processed on different days). 
After initial quality control, where cells were excluded if no cDNA was detected using the Quant-iT™ 
PicoGreen™ assay kit (section 3.18), 158 (84 C+S+, 48 C+S- and 26 C-S+) cells were analysed by high-
throughput sequencing.  
Total number of reads per cell was typically between 1-4 million (Figure 54) and total number of genes 
detected per cell was typically between 2000-8000 per cell, with a mean of 3964 (Figure 55). The 
number of ERCC reads per cell was typically between 100,000-1,000,000 with approximately 5-30% of 
all reads mapping to ERCCs (Figure 56). All cells which achieved either <100,000 reads, <1500 detected 
genes or where >30% of reads mapped to ERCCs were excluded from subsequent analysis, as these 
samples were likely of poor quality. In total, therefore, 128 cells (66 C+S+, 42 C+S- and 20 C-S+) were 
used for further analysis.    
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Figure 54: Total read counts from scRNA-seq analysis of sorted cell populations 
Single cells from the aortas of nine Myh11-CreER(T2); R26R-Confetti mice were FACS sorted prior to 
scRNA-seq using the Smart-seq2 protocol. In total 154 cells were collected. Phenotype status is displayed 
in the legend. The red dashed line indicates a read count of 100,000, all cells below this read count were 
excluded from subsequent analysis. C+S+ = Confetti+ Sca1+; C-S+ = Confetti- Sca1+; C+S- = Confetti+ Sca1-. 
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Figure 55: Total gene counts from scRNA-seq analysis of sorted cell populations 
Single cells from the aortas of nine Myh11-CreER(T2); R26R-Confetti mice were FACS sorted prior to scRNA-
seq using the Smart-seq2 protocol. In total 154 cells were collected. Phenotype status is displayed in the 
legend. The red dashed line indicates a gene count of 1500 genes, all cells below this gene count were 
excluded from subsequent analysis. C+S+ = Confetti+ Sca1+; C-S+ = Confetti- Sca1+; C+S- = Confetti+ Sca1-. 
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To investigate the sensitivity, defined here as the ability to detect ERCC control transcripts, of the 
Smart-seq2 method in these experiments, the number and type of ERCCs detected was analysed. 
Typically, between 25-45 ERCCs were detected per cell (Figure 57), which equates to approximately 
half the total number of ERCCs. This is similar to other studies using a variety of methods, including 
Smart-seq2, CEL-seq and Drop-seq, to sequence embryonic stem cells (Ziegenhain et al., 2017). When 
analysing the proportion of cells containing each individual ERCC, it was found that typically the very 
lowly expressed transcripts are not detected and that transcript length appears to have no difference 
on which transcripts are detected (Figure 58). While ERCC detection is a good gauge for how sensitive 
the experiment was it will likely differ regarding endogenous mRNA, as ERCCs are typically shorter 
compared to mammalian genes, have a shorter poly(A) tails and do not possess a 5’ cap (Risso et al. 
2014; Grun and van Oudenaarden 2015).  
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Figure 56: Total number of ERCC reads and the proportion of reads which map to ERCCs from scRNA-seq 
analysis of sorted cell populations 
Single cells from the aortas of nine Myh11-CreER(T2); R26R-Confetti mice were FACS sorted prior to scRNA-
seq using the Smart-seq2 protocol. In total 154 cells were collected. Phenotype status is displayed in the 
legend. The red dashed line indicates 30% of reads mapped to ERCCs, all cells above this percentage were 
excluded from subsequent analysis. C+S+ = Confetti+ Sca1+; C-S+ = Confetti- Sca1+; C+S- = Confetti+ Sca1-. 
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Figure 57: Number of ERCCs detected from scRNA-seq analysis of sorted cell populations 
Single cells from the aortas of nine Myh11-CreER(T2); R26R-Confetti mice were FACS sorted prior to scRNA-
seq using the Smart-seq2 protocol. After initial quality control 128 cells remained. In total 92 ERCCs were 
diluted into each cell RT-PCR mix. Phenotype status is displayed in the legend. C+S+ = Confetti+ Sca1+; C-S+ 
= Confetti- Sca1+; C+S- = Confetti+ Sca1-. 
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Following the initial filtering of low quality cells, the sequence data was normalised using the 
Bioconductor scran package (Lun, Bach, and Marioni, 2016), and genes with a mean expression value 
below one were excluded from further analyses. Normalisation ensures that cell-to-cell differences in 
capture efficiency, sequencing depth and other confounding factors (for example, high dropout rates 
of lowly expressed genes) are accounted for, allowing for valid analysis of relative gene expression 
between cells (Lun, Bach, and Marioni, 2016). Myh11 and Sca1 expression was then evaluated to test 
if selected cell populations expressed the appropriate genes. As shown in Figure 59, the C+S- cells 
contained relatively high, normalised counts for Myh11 expression. C+S+ cells have a lower mean 
Figure 58: Number of times each ERCC is detected, their concentration and transcript length 
Graph displaying the number of times each ERCC is detected at least once in all 128 cells sequenced. Each 
ERCC has a different transcript length and concentration, the concentration displayed here represents the 
concentration of each ERCC within the ERCC stock mix. Size of each point on the graph represents the 
number of cells each ERCC is detected in, as indicated by the legend.  
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expression of Myh11 compared to C+S-  with a few cells expressing very low levels of Myh11. The 
majority of C-S+ cells express low levels of Myh11 compared to either Confetti+ group, however a few 
cells have high, normalised Myh11 counts. In contrast, Figure 60 shows that Sca1 is more highly 
expressed in C-S+ cells which decreases in C+S+ cells and is almost completely undetectable in the 
majority of C+S- cells. Both these results are expected given the cell types sequenced and, importantly, 
these results and the quality control steps discussed above demonstrate that Smart-seq2 method is 
working and can be used to detect differences in gene expression between individual VSMCs. Further 
detailed analysis profiling each cell type is currently ongoing, and beyond the scope of this thesis. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 59: Normalised Myh11 counts from scRNA-seq analysis of sorted cell populations 
Box plots showing the number of normalised counts for the Myh11 gene from 128 single cells using the 
Smart-seq2 method of scRNA-seq. C+S+ = Confetti+ Sca1+; C-S+ = Confetti- Sca1+; C+S- = Confetti+ Sca1-. 
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8.3 Chromium 10x experiment: VSMC heterogeneity 
 
As discussed previously, VSMCs form a heterogeneous population (section 1.3), differing in regards to 
their expression of particular proteins, including VSMCs contractile markers (Christen et al. 2001; Frid, 
Moiseeva, and Stenmark 1994; Moiseeva 2001), with studies identifying different sub-populations of 
VSMCs (Bochaton-Piallat et al. 1996; Christen et al. 2001; Li et al. 2001). VSMCs are also hypothesised 
to differ in their placement on a proposed, phenotypic spectrum which ranges from contractile to 
synthetic (Figure 3, Rensen et al., 2007). Considering these ideas and given what has been shown 
within the HFD atherosclerosis/carotid ligation experiments (i.e. that few VSMCs respond to disease, 
Chapters 5 and 6), it is possible that heterogeneity has a functional consequence when it comes to 
VSMC response to disease. For example, VSMCs which proliferate to form the neo-
intima/atherosclerotic plaques observed in Chapters 5 and 6 may belong to a pre-determined 
response population with a distinct transcriptional profile within the healthy vascular wall. 
Alternatively, all cells may be capable of the proliferative response but stochastic activation of a few 
cells may result in the observed oligo-clonal response. To detect rare sub-populations and profile 
heterogeneity within the VSMC population it is necessary to capture and analyse thousands of 
Figure 60: Normalised Sca1 counts from scRNA-seq analysis of sorted cell populations 
Box plots showing the number of normalised counts for the Sca1 gene from 128 single cells using the 
Smart-seq2 method of scRNA-seq. C+S+ = Confetti+ Sca1+; C-S+ = Confetti- Sca1+; C+S- = Confetti+ Sca1-. 
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individual cells, which (as discussed above and in section 2.5) can be achieved using the Chromium 
10x system, which is tested here.  
To profile heterogeneity within VSMCs, the aortas of five Myh11-CreER(T2); R26R-Confetti mice 
labelled at high density (10 x 1 mg tamoxifen) were enzymatically dissociated to a single cell 
suspension and Confetti+ cells were isolated by FACS to ensure only VSMCs are analysed. The 10x 
system has a variable capture efficiency which will likely differ depending on the cell type used. As no 
information was known regarding VSMC capture efficiency in the 10x system, a predicted capture 
efficiency of ~50% was used based on previous experiments using other cell types (Zheng et al. 2017). 
Therefore, 6000 VSMC were loaded into the 10x machine with the goal of capturing 3000 cells for 
analysis by high-throughput sequencing. The capture efficiency was however only 12%, with only 725 
cells being captured. The number of reads per cell averaged at 431,227, and typically between 1300-
2500 genes were detected per cell with a mean of 2164 (Figure 61), however in total 14,821 different 
genes were detected. Compared to the Smart-seq2 method (section 8.2) the mean number of genes 
detected per cell are ~50% lower (2164/cell for 10x and 3964/cell for Smart-seq2, Figures 55 and 61). 
This was, however, not a result of the lower read counts per cell in the 10x data compared to the 
Smart-seq2 data, as sequencing saturation occurred at 97.4% of reads within the 10x experiments. 
Other studies using the 10x system to profile blood mononuclear cells and intestinal stem cells 
demonstrated a median of ~4500 genes per cell with a read depth of 100,000 reads per cell (Zheng et 
al., 2017) and ~2500 genes per cell with a read depth of 45,000-86,000 per cell (Yan et al. 2017), 
respectively. The lower gene counts seen when sequencing VSMCs is likely due to their quiescent 
phenotype.  
Expression of aSma/Acta2 across the population reveals that the detected gene expression values are 
very variable (Figure 62), indicating that VSMCs are heterogeneous even in expression of one of their 
classical marker genes. This is similar to what was suggested by (Adhikari et al. 2015) in their 
experiments using the Fluidigm C1 to sequence cultured single VSMCs. However, this data requires 
further processing and statistical analysis to reveal a more detailed profile of heterogeneity as a 
degree of this variation will be technical noise. Importantly, the 10x system for scRNA-seq was 
successfully performed on VSMCs which will allow the detailed analysis of thousands of individual 
VSMCs in future experiments.  
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Figure 61: Number of Genes detected per cell in the 10x experiment 
Graph showing the number of genes detected per cell in 725 individual VSMCs which underwent scRNA-
seq using the Chromium 10x system 
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Figure 62: Number of read counts for aSma in the 10x experiment 
Graph showing the number of aSma/Acta2 reads per cell in 725 individual VSMCs which underwent scRNA-
seq using the Chromium 10x system 
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8.4 Conclusions from the scRNA-seq experiments  
 
The observations made in Chapter’s 5, 6 and 7, raise the question why, in a population made up of 
thousands of VSMCs, all of which are in close proximity to each other, did only a few cells respond 
proliferatively to the ApoE-/- HFD, carotid ligation and Ang II infusion disease models, resulting in the 
observed oligo-clonality. While multiple methods can be employed to answer these questions, scRNA-
seq has the potential to provide detailed information regarding cell-cell heterogeneity and potentially 
reveal VSMC sub-populations and how they differ, which could be key in answering questions 
regarding oligo-clonality. As scRNA-seq methods are sensitive techniques and often require cell 
specific optimisations, two methods were chosen for this purpose with VSMCs.  
The first method, Smart-seq2, allows specific selection of up to 96 cells per experiment using single 
cell FACS sorting. The work carried out within this Chapter optimised (1) the number of PCR 
amplification cycles (Figures 49 and 50), necessary to achieve sufficient amounts of cDNA for 
subsequent reactions; and (2) the dilution of ERCC controls (Figures 51 and 52), which act as an 
internal control within scRNA-seq experiments and can aid downstream statistical analysis. Following 
optimisation, the Smart-seq2 method was employed to analyse a rare population of Sca1+ VSMCs 
(account for ~0.1% of the entire VSMC population) and Sca1- VSMCs for comparison. In total 184 cells 
were collected, the dropout rate due to low quality samples was 30% meaning that 128 cells were 
analysed. Genes detected in each single cell typically ranged between 2000-8000 (Figure 55) which is 
comparable to other studies using scRNA-seq (Macaulay et al. 2016; Ziegenhain et al. 2017). The 
number of ERCCs detected was also similar to studies which have employed Smart-seq2 to sequence 
other cell types (Ziegenhain et al., 2017), confirming that this method is working correctly on single 
VSMCs.  
Finally, the Chromium 10x system, which allows simultaneous processing of up to 10,000 single cells 
was used in order to profile VSMC heterogeneity and detect rare sub-populations. In total, 725 
individual VSMCs were analysed, the number of genes detected per cell was typically between 1300-
2500, which is ~50% lower than the Smart-seq2 method. The number of genes detected per cell was 
also lower when compared to other studies using the 10x system to analyse other cell types (Zheng et 
al., 2017) which may be due to VSMCs being a quiescent cell type. Further detailed analysis will 
hopefully allow new insights into the heterogeneity of VSMCs from healthy vasculature.   
The Smart-seq2 and 10x methods detailed here to perform scRNA-seq can now be used to perform 
different experiments/analyses on VSMCs. The Smart-seq2 method will be used to investigate 
transcriptional changes in VSMCs in the early stages post carotid ligation. Specifically, carotid ligation 
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will be performed on Myh11-CreER(T2); Rosa26-STOP-floxedYFP mice which also contain a Ki67-RFP 
knock-in reporter (Basak et al. 2014). Proliferating (RFP+) VSMCs-derived (YFP+) cells will then be 
isolated by FACS 1-5 days post-surgery and analysed by Smart-seq2 to reveal early transcriptional 
changes in VSMCs which proliferate in response to injury. The 10x system will be used to analyse 
VSMC-derived cells from entire plaques to assess the transcriptional programmes in the 
phenotypically different, trans-differentiated, VSMCs-derived cells which are known to occupy 
atherosclerotic plaques (Shankman et al. 2015).  
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CHAPTER 9: Discussion  
 
9.1 The confetti system for CVD analysis  
 
Chapter’s 4-7 within this thesis were based on analysis using multi-colour, VSMC specific, stable 
lineage labelling. This lineage tracing system, was successfully combined with three models of CVD, 
and analysed with conventional immuno-staining of cryo-sections. Additionally, a method to image 
whole-mount, cleared carotid arteries after carotid ligation was developed (Chapter 6). Which allowed 
detailed analysis of remodelled surfaces (i.e. neointimal patches) by rendering the imaged arteries in 
3D, using the software Imaris. As expected based on previous studies using the same Cre, 
recombination was specific to VSMCs for all tissues analysed (Gomez et al. 2013).  A potential caveat 
is that, as noted in section 2.1, the Myh11-Cre is not driven by the endogenous Myh11 Gene. While 
studies suggest that this Cre-transgene faithfully recapitulates endogenous gene expression (Wirth et 
al. 2008; Nemenoff et al. 2011), differences under certain circumstances/the extent to which it may 
be active in cells which express very low levels of Myh11 are difficult to determine. Importantly, 
however, recombination of the confetti reporter was not detected in bone marrow cells (Table 3), 
which are the only other cell type know to express Myh11, seen only in cultured cells treated with 
PDGF (Wu et al. 2007).        
The method for analysing whole-mount carotid arteries was developed by combining multiple 
techniques necessary for clearing and mounting the tissue, imaging large samples with multiple 
fluorescent molecules and analysing data in 3D. This method proved advantageous over standard 
techniques which rely on sectioning tissue, primarily because it allows quantification of the number 
and size of neointimal patches throughout the whole artery (Figures 34, 36, 37), instead of a few 
sections which are assumed to be the average across the whole tissue. Furthermore, the number of 
VSMC-derived cells within a contiguous, mono-chromatic, neointimal patch could also be analysed, 
which would be technically challenging/impossible using sectioning alone. The method used here for 
whole-mount analysis would be useful in future studies, to quantify and compare phenotypic 
parameters (such as size and cellularity) of the neointima between mice under different physiological 
conditions, throughout the whole artery. For example, to test the effects of gene knockout/drug 
treatment in reducing the size of the neointima. While the whole-mount method was also tried for 
atherosclerotic plaque samples it was not possible to image through the dense, lipid-laden, core. To 
compensate, thick vibratome sections (Figure 22) allowed visualisation of how far monochromatic 
regions could extend throughout the artery while thin cryo-sections (Figures 20, 26 and 28) taken from 
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multiple vascular regions within each mouse allowed for immuno-staining. To avoid false positive cell 
scoring while analysing immuno-stained cryo-sections, all quantification was performed within Imaris 
in 3D, which allows section manipulation to ensure all cells were scored accurately. 
 
9.2 VSMC oligo-clonality in models of CVD       
 
Studies described in Chapters 5 and 6 identified that VSMC-derived cells, which make up the majority 
of cells within injury-induced neointima and HFD-induced atherosclerotic plaques, are typically oligo-
clonally derived. As discussed (section 5.2) this observation extends and supports the previous 
hypothesis/studies of Benditt and Benditt (1973) and Feil et al. (2014) who suggest that plaques could 
be mono-clonally derived. While the studies within this thesis are performed in mice, Benditt and 
Benditt (1973) originally tested human atherosclerotic plaques by detecting X-inactivation patterns, 
however, for technical reasons, this study was not able to definitively confirm that plaques were 
mono-clonal (section 1.6). It is tempting to extrapolate the oligo-clonality result from this thesis to 
human plaques especially given the evidence from Benditt and Benditt (1973). However, given that 
human plaques will likely be larger than those in mice and differences exist between mouse and 
human physiology, for example humans contain VSMCs within the intima at certain points in the 
vasculature (Doran, Meller, and McNamara 2008), this may not be the case. To definitively confirm 
mono/oligo-clonality within humans, this may require deep sequencing of atherosclerotic plaques 
combined with statistical analysis, such as that developed by Simons (2016) to detect clonal 
architecture of the epidermis in human. 
The oligo-clonality seen in both the carotid ligation and HFD models suggest that the number of VSMCs 
which proliferate in response to disease is extremely low and that these cells go through multiple 
rounds of proliferation to form such large monochromatic regions (Figures 20, 22, 34, 37, 39). These 
observations could therefore explain findings which suggest that replicative exhaustion, telomere 
shortening and senescent cells are a prominent feature in human atherosclerotic plaques (Gardner et 
al. 2015; Matthews et al. 2006). Senescence and telomere shortening of VSMCs are highly correlated 
with increasing severity of atherosclerosis. Furthermore, the inability of VSMCs to proliferate and 
subsequent thinning of the VSMC-derived fibrous cap can result in plaque rupture (Newby, Libby, and 
van der Wal 1999; Matthews et al. 2006). As discussed by Braganza and Bennett (2001), prevention of 
deaths from atherosclerosis is shifting from controlling the absolute size of a plaque to the improving 
the stability of plaques by increasing the VSMC/fibrous content of a plaque. Based on the studies 
describe here, an increase in VSMC plaque content could be achieved in three ways: (1) preventing 
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the death of VSMCs (e.g. by reducing oxidative stress which is known to cause senescence/cell death, 
Matthews et al. 2006); (2) decreasing the proportion of non-VSMC/lipid content of the plaque; and 
(3) increasing the proportion of VSMCs which respond to disease. The first two suggestions have been 
studied, for example, statins capable of lowering cholesterol have reduced clinical events and have 
been shown to increase collagen, decrease lipid content and decrease VSMC death within 
atherosclerotic plaques (Sacks et al. 1996; Crisby et al. 2001). The third suggestion, is counter-intuitive 
as it may result in larger plaques, however in the long term this may be beneficial if the large 
monochromatic regions which contain thousands of cells are experiencing replicative exhaustion and 
can no longer proliferate. Reducing the size of monochromatic regions while increasing their number 
may therefore be beneficial, how this could be achieved though is not yet obvious.  
The observation that the progeny of only a few cells exist within the diseased site in the carotid ligation 
and HFD atherosclerosis models suggests this ‘low frequency response’ could be an inherent feature 
of VSMCs. One possible explanation for this is the potential existence of a specialised ‘response’ 
population of medial VSMCs. This idea has previously been discussed regarding MVSMCs, in which 
non-Myh11 expressing medial cells are responsible for proliferating and remodelling injured arteries 
(Tang et al. 2012). However this view has been widely disputed as lineage tracing has definitively 
shown that mature Myh11-expressing cells can proliferate and trans-differentiate in response to 
disease (Gomez et al. 2013; Herring et al. 2014; Feil et al. 2014; Chappell et al. 2016). One study has, 
however, demonstrated that within the pulmonary vasculature there exists a mature Myh11-
expressing VSMC progenitor population located at the pulmonary arteriole muscular-unmuscular 
border (Sheikh et al. 2015). Unlike other VSMCs, these cells express platelet-derived growth factor 
receptor-β (PDGFR-β) and are said to be ‘primed’ for phenotypic modulation/proliferation, as 
following hypoxia-induced pulmonary hypertension they express Klf4. In each arteriole a single primed 
cell then migrates, dedifferentiates and clonally expands to give rise to VSMCs within the distal region 
of the arteriole, which is normally only occupied by ECs, thus contributing to the pulmonary 
hypertension disease phenotype (Sheikh et al. 2015). It is tempting to expand their result to the result 
seen within this thesis as it would explain the observed oligo-clonal phenotype, however the necessary 
studies using the PDGFR-β–CreER(T2) mice have yet to be performed. Furthermore, it is worth noting 
that, unlike the pulmonary arterioles, within the vascular regions studied here (aortic arch, carotid 
arteries and descending aorta) there is no specific niche, such as the arterial muscular-unmuscular 
junction for these cells to exist. Preliminary studies, within our group, to test if PDGFR-β+ cells exist 
within the media of the aorta have identified that a low proportion of medial cells stain-positive with 
an anti-PDGFR-β antibody (data not shown). However, further tests are needed to show this 
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conclusively, and whether these PDGFR-β+ cells are primed for proliferation, as in the study by Sheikh 
et al. (2015).   
As monochromatic regions within plaques/neointima did not contain singlet cells expressing a 
different confetti colour (Figures 20, 22, 34, 37, 39), this work strongly suggests that cell migration 
independent of proliferation is not frequent in either the HFD or carotid ligation models of CVD. As 
discussed previously (section 6.3), this is in contrast to studies which suggest that up to 40% of VSMC-
derived cells in neointima and plaques have migrated independent of proliferation (Clowes and 
Schwartz 1985; Yu et al. 2011). One possible reason for these contrasting results is that methods for 
labelling and detecting proliferating cells is not 100% efficient. Indeed, the EdU method used in this 
study only labelled 47% of cells which had proliferated in the ligation model (Figure 42, section 6.3), 
which is likely due to inefficiencies in the methods used to perform EdU labelling/detection. While 
only the progeny of few cells form the, relatively, late stage plaques/neointima observed in Chapters 
5 and 6, it is possible that a higher proportion of VSMCs initially proliferate in the early stages of these 
disease models. For example, as discussed by both Chappell et al. (2016) and Gomez and Owens 
(2016), more VSMCs may proliferate early on in disease development but through processes such as 
clonal selection or cell competition the progeny of only a few cells/clones survive. Selection of 
dominant clones may manifest in several different ways: (1) it may be the result of a few hyper-
proliferative cells which simply outcompete other clones; (2) the expansion of particular clones may 
relate to not only a clone’s ability to proliferate but also survive the plaque environment; and (3) a 
few VSMC-derived clones may inhibit the clonal expansion of surrounding VSMCs. Without further 
studies, these questions relating to the initial response will remain unanswered. However, addressing 
these questions can potentially be done using the Confetti system by analysing clones in earlier stages 
of disease to see if, for example, the neointima/media contains a greater number of smaller clones 
compared to the late stage neointima.  
Another possible explanation for oligo-clonality is that all VSMCs have the same potential to 
phenotypically switch and contribute to disease but only those cells in the right position within this 
environment respond. For example, Lu et al. (2017) suggest that VSMC clonality could, in part, be 
explained by the difficult process which VSMCs undertake when migrating through small fenestrations 
within the elastic laminae, which only appear in regions where ECs have taken on an athero-prone 
phenotype. Therefore, it is possible that only a few VSMCs make it into the plaque in the first place, 
and once they begin to proliferate they might reduce the probability that other VSMCs can migrate 
into the plaque.  
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The Ang II model of AAA complicates the hypothesis that only few VSMCs proliferate in response to 
injury/disease. While large outgrowths of clonally derived-VSMCs are observed within the thrombus, 
within the media there seems to be a more general response from VSMCs, noted in their morphology 
(i.e. VSMCs appear larger and more irregularly shaped) and the occurrence of many small (4-5 cell) 
patches (Figures 44 and 46). The more general response within the media might be a result of the 
systemic administration of Ang II and anti-TGF-B, and/or the subsequent breaks within the elastic 
lamina which allows infiltration of blood components, including platelets. Therefore, many cells within 
the media may be more directly exposed to signals known to potently induce VSMC proliferation (e.g. 
Pdgf-BB, Blank and Owens 1990), compared to VSMCs within the media of arteries which have 
undergone the ligation or HFD models of CVD. It therefore appears that a larger proportion of cells 
are capable of phenotypic switching than eluded to in the carotid ligation and HFD models. However, 
the reason why only a few cells go on to massive expansion within the thrombus is still unresolved, 
but could partially relate to the clonal selection hypotheses discussed above. Another explanation for 
why so few cells expand into the thrombus of AAA animals relates back to the hypothetical spectrum 
of phenotypes, formulated by Rensen, Doevendans, and van Eys (2007), on which VSMCs lie. Each 
position on this hypothesised spectrum contains VSMCs with a different propensity and possible range 
of phenotypic switching (Figure 3, section 1.3).  Therefore, it is possible that, due to the inherent 
heterogeneity within this population, those VSMCs which have only proliferated to a small degree are 
not capable of the massive proliferation seen by cells forming the large mono-chromatic patches.  
  
9.3 Potential molecular mechanisms for the low frequency response 
 
Regardless of the proportion of VSMCs which are capable of initial or minor responses and whether 
clonal competition etc. is involved in this response, only a few medial cells go through massive 
proliferation and survive compared to VSMCs in close proximity. All cells within diseased regions are 
likely exposed to a similar environment (e.g. hypercholesterolemia, oscillating blood flow or systemic 
Ang II exposure), this therefore raises questions regarding mechanisms which prime VSMCs to expand 
and become dominant (Gomez and Owens 2016).   
Possible mechanism may rely on genetic and/or epigenetic priming of individual VSMCs. For example, 
Jaiswal et al. (2014) showed that somatic mutations in a subset of myeloid cells resulted in clonal 
expansion of these cells and correlated with an increased incidence of CVD. Furthermore, the genes 
noted to contain these mutations were typically genes responsible for epigenetic alterations (e.g. DNA 
(cytosine-5)-methyltransferase 3A, Tet methylcytosine dioxygenase 2 and Additional Sex Combs Like 
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1, Transcriptional Regulator). If similar mechanisms are present within VSMCs, somatic mutations in a 
very small number of VSMCs could confer proliferative/survival advantages which would result in the 
observed oligo-clonal phenotype (Gomez and Owens 2016). Indeed, somatic mutations, as a cause of 
VSMC-proliferation, have been discussed multiple times in the history of research into atherosclerosis. 
This is primarily due to the monoclonal hypothesis (Benditt and Benditt 1973, discussed in section 1.6) 
and other similarities atherosclerosis appears to share with cancer (Andreassi et al. 2000; Weakley et 
al. 2010). For example, Penn et al. (1986) showed that when DNA taken from human atherosclerotic 
plaques is transfected into a fibroblast cell line and injected into nude mice, these mice develop 
tumours which contain human DNA. Furthermore, the reason Benditt and Benditt (1973) first tested 
plaques for their mono-clonality was due to their similarity with uterine leiomyomas (benign smooth 
muscle tumours of the uterus) known to be mono-clonally derived, and like atherosclerotic plaques 
are present in all, female, adults (Mashal et al. 1994; Schwartz and Murry 1998). Similar to how uterine 
leiomyomas have been found to contain chromosomal rearrangements, unstable atherosclerotic 
plaques have been observed which contain chromosome 7 trisomy and tetrasomy (Schwartz and 
Murry 1998; Matturri et al. 2001).  
Distinct epigenetic programmes within VSMCs could also be responsible for the differences in how 
VSMCs respond to their environment. Given the known VSMC heterogeneity (section 1.3) and the 
importance of epigenetic modulation in phenotypic switching (section 1.11) it is highly plausible that 
epigenetic programmes exist which regulate lineage memory creating a ‘response like-population’. 
Cherepanova et al. (2016), for example, show that hydroxymethylation of the Oct4 promoter within 
VSMCs activates this pluripotency factor which seems to be necessary for VSMC 
migration/proliferation, as VSMC-specific Oct4 knockout mice contain atherosclerotic plaques with 
fewer VSMC-derived cells. While the frequency of DNA hydroxmethylation of the Oct4 gene within 
medial VSMCs is not known, such mechanisms could be responsible for the observed low frequency 
response (Gomez and Owens 2016).    
However, differences in how cells respond to an environmental stimulus may not necessarily be the 
result of distinct genetic/epigenetic programmes. Within an organism there is an interplay between 
random biochemical interactions and precise deterministic processes such as those underlying 
development. To reconcile this interplay the statistical law of large numbers can be applied and in a 
sense, remove the significance of single particles/molecules (Raj and van Oudenaarden 2008). 
However, as DNA (and the genes encoded within) is present in such low numbers within a single cell 
and gene transcription and translation are inherently random processes, involving the movement and 
interaction of a host of molecules, this statistical ‘averaging out’ cannot take place. Random gene 
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fluctuations can, therefore, lead to vast cellular differences between otherwise identical populations 
of cells (Raj and Oudenaarden, 2008). Indeed, Sigal et al. (2006) suggest that stochastic processes can 
cause a large degree of human cell to cell variability regarding protein levels, which can persist as what 
they define as “memory noise” for several days. The transcriptional and translation variability, caused 
by stochastic processes within a single cell, can thus generate phenotypic variability and the potential 
for differences in the responses to an identical stimulus between cells of the same population (Sigal 
et al. 2006).    
 
9.4 Multi-potent VSMCs 
 
Results from Chapter 5 demonstrate that VSMCs belonging to the same clone, and therefore derived 
from a single VSMC, contribute to aSma+ cap cells (Figures 26 and 27) and Mac3+ core cells (Figures 
28 and 29). Given that large plaques were observed containing single coloured clones (Figures 20, 22 
and 23) it is also likely that a single VSMC can contribute to the other cell types which VSMCs are 
capable of turning in to within the plaque environment, for example mesenchymal stem cell-like cells 
and myofibroblasts like-cells (Shankman et al. 2015). This suggests that single VSMCs, capable of 
responding to injury, are multi-potent and that trans-differentiation into distinct VSMC-derived cell 
types does not rely on specific subpopulations of VSMCs. The order in which VSMCs trans-differentiate 
into different cell types is not yet known, nor whether they can switch phenotype once they have 
acquired a specific state. As a small proportion of aSma+ Mac3+ VSMC-derived cells were observed 
(Figure 30), typically within the border region between the cap and the core, this suggests that VSMCs 
could inter-convert between phenotypes depending on the environment they are exposed to. Opitz 
et al. (2007) have similarly observed that VSMCs which have switched to a synthetic phenotype in vitro 
are able to return to a contractile state under physiological conditions of shear stress. These studies 
therefore suggest that plaque stabilisation may be achieved if therapeutics are able to bias 
proliferating VSMCs towards the, contractile, protective cap phenotype.  
  
9.5 VSMCs in AAA   
 
The Ang II model of AAA was discussed in section 2.5. Early studies suggested that this model has 
many similarities with AAA seen in humans, for example, accumulation of macrophages, medial 
dissection and thrombus development (Saraff et al. 2003; Barisione et al. 2006; Rateri et al. 2011). A 
few differences are also noted, including the location of aneurysms. Within the Ang II model they 
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typically locate to the suprarenal compared to infrarenal region of the aorta (Saraff et al. 2003). 
However, Trachet et al (2017) suggest that Ang II induced AAA is actually a model of aortic dissection 
rather than aneurysm, based on their observation of the sequence of events, starting with medial 
micro tears and finishing in the development of an intramural haematoma. Within the literature, the 
distinction between AAA and aortic dissection is not always clear and is confounded by the fact that 
dissection can occur within AAA (Saraff et al. 2003). However, these diseases can be separated in their 
pathophysiology. Aortic dissections occur when there is a tear in the aortic wall which results in the 
splitting of wall layers and haemorrhaging, whereas AAA is the result of a degenerative, proteolytic 
and inflammatory phenotype (Baumann et al., 2013). One major difference between these two 
diseases is the involvement of VSMCs. In AAA, VSMCs death contributes to the degeneration of the 
medial wall (Raffort et al., 2017), whereas VSMC phenotypic switching and proliferation is often noted 
as an integral part in the pathophysiology of aortic dissection (Feng et al., 2016; An et al., 2017).  
The AAA studies presented within this thesis (Chapter 7) identified that a large proportion of VSMCs 
phenotypically switch, that many small patches within the media are generated and in some instances 
large medial patches or patches within the thrombus are observed. Given that many VSMCs proliferate 
in response to Ang II infusion, this further raises questions regarding how similar Ang II infusion reflects 
aneurysm, particularly as lineage tracing of VSMCs has not been performed in other models of AAA. 
Phenotypic switching (i.e. VSMCs with a synthetic phenotype) is often observed in aortic dissection 
(Feng et al. 2016; An et al. 2017) but again, there are no studies which specifically lineage trace VSMCs, 
detailing their proliferation. The results from Chapter 7 are therefore difficult to put into definitive 
context, for example VSMC proliferation could be a common feature of both AAA and aortic dissection 
or only one of these diseases. Indeed, the degeneration of the vascular wall may require an initial 
proliferation of VSMCs, followed by the upregulation of VSMC MMP production leading to further 
break down of the elastin/collagen structures supporting the wall. Before VSMC proliferation can be 
classified as an actual stage in the cellular progression of either disease, more work needs to be 
performed to definitively classify what the Ang II infusion model represents and if the VSMC response 
can be demonstrated in other models of AAA and/or aortic dissection. Most importantly studies need 
to examine the role of VSMCs in human AAA and determine if VSMC proliferation occurs.  
It will also be interesting to see whether the proliferating VSMCs seen in the Ang II infusion model are 
attempting to remodel the vascular wall (i.e. by trying to prevent the breakdown of the wall and 
provide structural support) or if indeed VSMC MMP production/trans-differentiation into, for 
example, macrophage-like cells contributes to disease development. 
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9.6 scRNA-seq techniques – what they will be used for now  
 
In response to the lineage tracing which was carried out in this thesis, methods were required which 
allow the investigation of individual cells at high resolution. This is in order to identify possible sub-
populations which might act as a ‘response’ population following disease and to map differential 
VSMC responses to injury/disease. scRNA-seq was chosen as this approach analyses the transcriptome 
of individuals cells, which will allow the investigation of VSMC heterogeneity.  
There are an abundant number of scRNA-seq protocols, each using slightly different methods and 
machinery. Due to the high technical sensitivity of these methods they require careful optimisation 
for each cell type used. Two methods of scRNA-seq were therefore chosen to optimise for the use 
with VSMCs and perform preliminary experiments to check their efficiency/performance. The first, 
Smart-seq2, is a manual method for scRNA-seq which is relatively inexpensive, this method is usually 
performed for 96 cells at a time and is therefore relatively low-throughput. However, Smart-seq2 is a 
very sensitive method regarding the number of genes it can detect, relative to other techniques (Picelli 
et al. 2014; Ziegenhain et al. 2017). The second method uses the Chromium 10x protocol, an 
automated system than can sequence thousands of individual cells, but is relatively costly and can 
suffer from cell capture inefficiencies. Both methods were able to generate transcriptional data from 
individual VSMCs, discussed in Chapter 8, with information being gained regarding the optimal PCR 
cycle number required to amplify cDNA within the Smart-seq2 method (Figure 50) and the cell capture 
efficiency of VSMCs using the 10x system (section 8.3).  
Importantly these methods have now generated data from a large number of healthy VSMCs and the 
rare population of Sca1+ VSMCs. The aim is to now use these data to answer some of the questions 
asked throughout this thesis. Firstly, data from healthy VSMCs will be analysed to reveal heterogeneity 
within this population and determine if sub-populations exist which could act as a ‘response 
population’. Subsequent lineage tracing and gene knock out studies could then be employed to test 
physiological function/relevance of observed cell populations, which is important as scRNA-seq 
analysis can be complicated by the inherent noise within single cell techniques (Brennecke et al. 2013). 
It will also be interesting to see whether a picture emerges which is suggestive of the phenotypic 
spectrum hypothesis (Figure 3, section 1.3), i.e. VSMC profiles which represent different positions 
along the spectrum, functional studies could then be used to determine the potential for VSMCs at 
different starting positions to move up or down this spectrum. Importantly once VSMC population 
heterogeneity is understood, this will provide a baseline for comparisons to future studies which will 
sequence phenotypically modulated VSMCs within injury-induced neointima and atherosclerotic 
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plaques. Indeed, understanding the early transcriptional changes in VSMCs which are phenotypically 
switching could, potentially, provide valuable information regarding ways in which therapeutics could 
bias proliferating VSMCs towards a desired fate or stop them from proliferating in the first place.  
Applying scRNA-seq analyses to study VSMCs has the potential to revolutionise our understanding of 
this heterogeneous cell type and reveal the molecular mechanisms responsible for their ability to 
trans-differentiate/phenotypically switch, which if nothing else, is an exciting prospect.   
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Appendices  
 
Appendix A. Experimental animals used for atherosclerosis studies  
 
Animal no. Back-crosses* Tamoxifen 
dose (mg) 
HFD (weeks) Plaques 
analysed 
Analysis 
method 
1 2 10 17 4 vibratome 
2 2 10 12† 2 vibratome 
3 2 10 19 10 vibratome 
4 2 10 18 8 cryo 
5 2 10 18 8 cryo 
6 2 10 18 7 cryo 
7 2 10 14† 9 cryo 
8 2 10 18 8 cryo 
9 2 10 17 10 cryo 
10 2 10 17 1 vibratome 
11 2 10 16 2 cryo 
12 2 10 16 2 cryo 
13 2 10 16 4 cryo 
14 2 10 16 3 cryo 
15 2 10 16 3 cryo 
16 2 10 16 1 cryo 
17 2 1 16 2 cryo 
18 2 1 16 3 cryo 
19 2 1 16 4 cryo 
20 2 1 16 4 cryo 
21 2 1 16 1 cryo 
22 2 0.1 13† 0‡ vibratome 
23 2 0.1 11† 0 vibratome 
24 2 0.1 14 0 vibratome 
25 2 0.1 14 0 vibratome 
 
* Number of backcrosses to C57bl/6. 
† Animals were analysed prematurely due to health issues unrelated to cardiovascular defects (e.g.  
fighting or warts). 
‡ One monochromatic region was observed, but this was not included in analysis.  
Adapted from Chappell et al., 2016 
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Appendix B. Plaque information  
Animal 
no. 
Plaque 
no. 
Tamoxifen 
dose (mg) 
Vascular 
region* 
Colours per plaque aSma Mac3 DS† EdU 
1 1 10 CA 2 (RFP, YFP) - - - - 
1 2 10 DA 2 (RFP, YFP) - - - - 
1 3 10 AA 1 (RFP) - - - - 
1 4 10 CA 2 (YFP, nGFP) - - - - 
2 5 10 AA 2 (RFP, mCFP) - - - - 
2 6 10 AA 2 (nGFP, RFP) - - - - 
3 7 10 CA 2 (nGFP, RFP) - - - - 
3 8 10 CA 2 (YFP, nGFP) - - - - 
3 9 10 AA 2 (RFP, mCFP) - - - - 
3 10 10 AA 2 (RFP, YFP) - - - - 
3 11 10 AA 2 (RFP, mCFP) - - - - 
3 12 10 CA 1 (RFP) - - - - 
3 13 10 CA 1 (RFP) - - - - 
3 14 10 CA 2 (RFP, YFP) - - - - 
3 15 10 CA 1 (YFP) - - - - 
3 16 10 AA 2 (RFP, nGFP) - - - - 
4 17 10 CA 1 (YFP) - - - - 
4 18 10 CA 2 (mCFP, nGFP) + + - - 
4 19 10 AA 2 (RFP, mCFP) - - - - 
4 20 10 AA 2 (RFP, YFP) - - - - 
4 21 10 AA 1 (RFP) + + + - 
4 22 10 AA 1 (YFP) - - - - 
4 23 10 DA 1 (RFP) + + + - 
4 24 10 ? 1 (RFP) - - - - 
5 25 10 DA 3 (RFP, YFP, mCFP) + + - - 
5 26 10 CA 1 (RFP) + + - - 
5 27 10 AA 2 (RFP, mCFP) - - - - 
5 28 10 CA 1 (RFP) + + - - 
5 29 10 AA 1 (mCFP) + + - - 
5 30 10 AA 1 (RFP) + + - - 
5 31 10 ? 1 (RFP) - - - - 
5 32 10 ? 1 (RFP) - - + - 
6 33 10 CA 1 (RFP) - - - - 
6 34 10 CA 1 (mCFP) - - - - 
6 35 10 CA 1 (mCFP) + + - - 
6 36 10 AA 1 (RFP) - - + - 
6 37 10 DA 1 (RFP)§ + + - - 
6 38 10 AA 1 (mCFP) + + - - 
6 39 10 DA 1 (RFP) + + - - 
7 40 10 DA 1 (mCFP) - - - - 
7 41 10 DA 1 (mCFP) - - - - 
7 42 10 DA 1 (RFP) - - + - 
7 43 10 CA 2 (RFP, YFP) + + - - 
7 44 10 AA 2 (RFP, YFP) + + - - 
7 45 10 ? 4 (RFP, YFP, mCFP, nGFP) + + - - 
7 46 10 CA 1 (YFP) - - - - 
7 47 10 AA 2 (RFP, mCFP) + + + - 
7 48 10 ? 2 (RFP, nGFP) - - - - 
8 49 10 DA 1 (RFP) - - - - 
8 50 10 DA 1 (mCFP) + + - - 
8 51 10 ?? 1 (RFP) - - - - 
8 52 10 AA 2 (RFP, mCFP) - - - - 
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8 53 10 AA 1 (RFP) + + + - 
8 54 10 DA 2 (RFP, mCFP) + + - - 
8 55 10 CA 2 (RFP, YFP) + + - - 
8 56 10 AA 2 (mCFP, RFP) - - - - 
9 57 10 AA 3 (RFP, YFP, mCFP) - - - - 
9 58 10 AA 1 (RFP)  - - - - 
9 59 10 DA 1 (RFP) - - - - 
9 60 10 AA 2 (mCFP, RFP) + + + - 
9 61 10 AA 1 (YFP) - - - - 
9 62 10 AA 1 (RFP) - - - - 
9 63 10 AA 2 (RFP, YFP) + + - - 
9 64 10 DA 1 (RFP) - - - - 
9 65 10 ? 3 (mCFP, RFP, YFP) - - - - 
9 66 10 DA 1 (mCFP) - - - - 
10 67 10 DA 1 (YFP) - - - - 
11 68 10 CA 3 (RFP, YFP, mCFP) - - - - 
11 69 10 CA 1 (RFP) - - - + 
12 70 10 AA 2 (RFP, YFP) - - - + 
12 71 10 DA 1 (YFP) - - - - 
13 72 10 AA 2 (RFP, nGFP) - - - + 
13 73 10 DA 2 (RFP, mCFP) - - - + 
13 74 10 AA 1 (RFP) - - - + 
13 75 10 DA 2 (YFP, nGFP) - - - + 
14 76 10 AA 1 (RFP) - - - + 
14 77 10 CA 2 (RFP, YFP) - - - - 
14 78 10 CA 3 (mCFP, RFP, YFP) - - - + 
15 79 10 AA 1 (RFP) - - - - 
15 80 10 CA 2 (RFP, mCFP) - - - + 
15 81 10 CA 1 (RFP) - - - - 
16 82 10 CA 1 (YFP) - - - - 
17 83 1 AA 1 (RFP) - - - - 
17 84 1 AA 2 (RFP, YFP) - - - - 
18 85 1 AA 1 (RFP) - - - - 
18 86 1 CA 1 (RFP) - - - - 
18 87 1 DA 1 (YFP) - - - - 
19 88 1 AA 1 (RFP) - - - - 
19 89 1 AA 2 (RFP, YFP) - - - - 
19 90 1 XA 1 (RFP) - - - - 
19 91 1 CA 1 (RFP) - - - - 
20 92 1 CA 1 (RFP) - - - - 
20 93 1 DA 2 (RFP, YFP) - - - - 
20 94 1 CA 1 (RFP) - - - - 
20 95 1 AA 1 (RFP) - - - - 
21 96 1 AA 1 (RFP) - - - - 
 
* AA: ascending aorta or aortic arch. DA: descending aorta. CA: carotid artery or brachiocephalic 
artery. Plaques at borders between vascular regions are indicated with a question mark.  
† DS: double staining for aSma and Mac3. Only done in plaques that did not contain nGFP or YFP 
positive cells. 
§ One YFP-expressing cell was observed in this plaque.  
Adapted from Chappell et al., 2016 
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Appendix C. Experimental animals used for carotid ligation surgery  
 
* Number of backcrosses to C57Bl/6. † A small subset of patches was not quantified due to technical issues, such as high auto-fluorescence, which impeded 
surface modelling in Imaris.  
 NA, not applicable. 
Adapted from Chappell et al., 2016 
Animal 
no. 
Tamoxifen 
dose (mg) 
Back-
crosses* 
nGFP YFP RFP mCFP Confetti 
patches 
Measured 
patches† 
Patch size (cell number) Remodelled 
area (µm) 
1 10 1 3 6 7 4 20 17 48, 52, 149, 156, 227, 375, 425, 522, 585, 872, 
950, 981, 1040, 1990, 2290, 3140, 3450 
4517 
2 10 1 1 2 1 3 7 7 171, 409, 666, 849, 940, 1470, 3610 2391 
3 10 1 1 1 0 1 3 1 178 1301 
4 10 1 0 2 2 0 4 4 174, 332, 415, 508 1878 
5 10 1 0 1 1 1 3 3 66, 360, 3090 1276 
6 10 1 0 1 2 0 3 3 125, 151, 329 1130 
7 10 1 0 2 1 1 4 3 128, 234, 7480 1609 
8 10 1 0 3 3 1 7 3 52, 149, 446 2128 
9 10 1 0 2 2 2 6 3 125, 805, 1495 1345 
10 10 1 0 2 1 1 4 3 96, 115, 1490 1503 
11 10 6 0 1 1 1 3 3 565, 612, 3200 1994 
12 10 6 0 1 1 1 3 2 1097, 2827 2816 
13 1 6 0 3 1 2 6 4 35, 63, 689, 1073 NA 
14 1 5 2 2 2 0 6 6 50, 55, 81, 98, 148, 225 NA 
15 1 6 0 1 1 0 2 2 9, 64 NA 
16 1 6 0 1 1 1 3 3 24, 153, 410 NA 
17 0.1 1 0 0 0 0 0 0 NA NA 
18 0.1 1 0 1 0 1 2 2 45, 170 NA 
19 0.1 1 0 0 0 0 0 0 NA NA 
20 0.1 1 0 2 1 0 3 3 65, 192, 749 NA 
21 0.1 1 0 0 0 0 0 0 NA NA 
22 0.1 5 0 1 0 0 1 1 32 NA 
23 0.1 6 0 1 1 0 2 2 59, 592 NA 
 
 
Appendix D. Experimental animals used for AAA studies  
 
Animal 
no. 
Genotype 
background 
Tamoxifen 
dose (mg) 
Anti-
TGF-β 
Thrombus 
VSMC 
outgrowth 
Medial VSMC-
derived 
patches 
Breaks in 
elastic 
lamina 
1 Wild type 10 Yes Yes Yes Yes 
2 Wild type 10 Yes No Yes Yes 
3 Wild type 10 Yes No Yes Yes 
4 Wild type 10 Yes Yes Yes Yes 
5 Wild type 10 Yes Yes Yes Yes 
6 ApoE-/- 10 No No Yes Yes 
7 ApoE-/- 10 No No Yes Yes 
8 ApoE-/- 10 No No Yes Yes 
9 ApoE-/- 10 No No Yes Yes 
10 ApoE-/- 10 No No Yes Yes 
11 ApoE-/- 10 No Yes Yes Yes 
12 ApoE-/- 10 No No Yes Yes 
13 ApoE-/- 10 No No Yes Yes 
14 ApoE-/- 10 No No Yes Yes 
15 ApoE-/- 10 Yes No Yes Yes 
16 ApoE-/- 10 Yes No Yes Yes 
17 ApoE-/- 10 Yes No Yes Yes 
18 ApoE-/- 10 Yes No Yes Yes 
19 ApoE-/- 10 Yes No Yes Yes 
 
 
 
 
 
 
 
 
 
 
 
148 
 
References 
 
Achim, Kaia, Jean-Baptiste Pettit, Luis R Saraiva, Daria Gavriouchkina, Tomas Larsson, Detlev Arendt, 
and John C Marioni. “High-Throughput Spatial Mapping of Single-Cell RNA-Seq Data to Tissue of 
Origin.” Nature Biotechnology 33, no. 5 (April 2015): 503–509. 
https://doi.org/10.1038/nbt.3209. 
Adhikari, Neeta, Kadambari Chandra Shekar, Rodney Staggs, Zaw Win, Kerianne Steucke, Yi-Wei Lin, 
Li-Na Wei, Patrick Alford, Jennifer L. Hall, and International Society of Cardiovascular 
Translational Research. “Guidelines for the Isolation and Characterization of Murine Vascular 
Smooth Muscle Cells. A Report from the International Society of Cardiovascular Translational 
Research.” Journal of Cardiovascular Translational Research 8, no. 3 (April 2015): 158–163. 
https://doi.org/10.1007/s12265-015-9616-6. 
Ailawadi, Gorav, Jonathan L Eliason, and Gilbert R Upchurch. “Current Concepts in the Pathogenesis 
of Abdominal Aortic Aneurysm.” Journal of Vascular Surgery 38, no. 3 (September 2003): 584–
588. https://doi.org/10.1016/S0741-5214(03)00324-0. 
Ailawadi, Gorav, Christopher W Moehle, Hong Pei, Sandra P Walton, Zequan Yang, Irving L Kron, 
Christine L Lau, and Gary K Owens. “Smooth Muscle Phenotypic Modulation Is an Early Event in 
Aortic Aneurysms.” The Journal of Thoracic and Cardiovascular Surgery 138, no. 6 (December 
2009): 1392–9. https://doi.org/10.1016/j.jtcvs.2009.07.075. 
Airhart, Nathan, Bernard H Brownstein, J Perren Cobb, William Schierding, Batool Arif, Terri L Ennis, 
Robert W Thompson, and John A Curci. “Smooth Muscle Cells from Abdominal Aortic 
Aneurysms Are Unique and Can Independently and Synergistically Degrade Insoluble Elastin.” 
Journal of Vascular Surgery 60, no. 4 (October 2014): 1033–41; discussion 1041–2. 
https://doi.org/10.1016/j.jvs.2013.07.097. 
Albarrán-Juárez, Julián, Harmandeep Kaur, Myriam Grimm, Stefan Offermanns, and Nina 
Wettschureck. “Lineage Tracing of Cells Involved in Atherosclerosis.” Atherosclerosis 251 
(August 2016): 445–453. https://doi.org/10.1016/j.atherosclerosis.2016.06.012. 
Alexander, Matthew R., and Gary K. Owens. “Epigenetic Control of Smooth Muscle Cell 
Differentiation and Phenotypic Switching in Vascular Development and Disease.” Annual 
Review of Physiology 74, no. 1 (2012): 13–40. https://doi.org/10.1146/annurev-physiol-
012110-142315. 
Alexander, Matthew R, and Gary K Owens. “Epigenetic Control of Smooth Muscle Cell Differentiation 
and Phenotypic Switchingin Vascular Development and Disease.” Annual Review of Physiology, 
2011. https://doi.org/10.1146/annurev-physiol-012110-142315. 
An, Zhao, Yang Liu, Zhi-Gang Song, Hao Tang, Yang Yuan, and Zhi-Yun Xu. “Mechanisms of Aortic 
Dissection Smooth Muscle Cell Phenotype Switch.” The Journal of Thoracic and Cardiovascular 
Surgery, May 2017. https://doi.org/10.1016/j.jtcvs.2017.05.066. 
Andreassi, M G, N Botto, M G Colombo, A Biagini, and A Clerico. “Genetic Instability and 
Atherosclerosis: Can Somatic Mutations Account for the Development of Cardiovascular 
Diseases?” Environmental and Molecular Mutagenesis 35, no. 4 (2000): 265–9. 
Annabi, Borhane, Daniel Shédid, Pierre Ghosn, Rhoda L. Kenigsberg, Richard R. Desrosiers, Michel W. 
Bojanowski, Édith Beaulieu, Edgar Nassif, Robert Moumdjian, and Richard Béliveau. 
“Differential Regulation of Matrix Metalloproteinase Activities in Abdominal Aortic 
Aneurysms.” Journal of Vascular Surgery 35, no. 3 (March 2002): 539–546. 
https://doi.org/10.1067/mva.2002.121124. 
Baetta, R, M Soma, C De Fraja, C Comparato, C Teruzzi, L Magrassi, and E Cattaneo. “Upregulation 
and Activation of Stat6 Precede Vascular Smooth Muscle Cell Proliferation in Carotid Artery 
Injury Model.” Arteriosclerosis, Thrombosis and Vascular Biology 20, no. 4 (2000): 931–939. 
Barisione, Chiara, Richard Charnigo, Deborah A. Howatt, Jessica J. Moorleghen, Debra L. Rateri, and 
Alan Daugherty. “Rapid Dilation of the Abdominal Aorta during Infusion of Angiotensin II 
149 
 
Detected by Noninvasive High-Frequency Ultrasonography.” Journal of Vascular Surgery 44, no. 
2 (August 2006): 372–376. https://doi.org/10.1016/j.jvs.2006.04.047. 
Basak, O., M. van de Born, J. Korving, J. Beumer, S. van der Elst, J. H. van Es, and H. Clevers. 
“Mapping Early Fate Determination in Lgr5+ Crypt Stem Cells Using a Novel Ki67-RFP Allele.” 
The EMBO Journal 33, no. 18 (September 2014): 2057–2068. 
https://doi.org/10.15252/embj.201488017. 
Basnyat, P. S., A. H. B. Biffin, L. G. Moseley, A. R. Hedges, and M. H. Lewis. “Mortality from Ruptured 
Abdominal Aortic Aneurysm in Wales.” British Journal of Surgery 86, no. 6 (June 1999): 765–
770. https://doi.org/10.1046/j.1365-2168.1999.01170.x. 
Baumann, F., V. Makaloski, and N. Diehm. “Aortenaneurysma Und -Dissektion.” Der Internist 54, no. 
5 (May 2013): 535–542. https://doi.org/10.1007/s00108-012-3217-0. 
Beery, Annaliese K, and Irving Zucker. “Sex Bias in Neuroscience and Biomedical Research.” 
Neuroscience and Biobehavioral Reviews 35, no. 3 (January 2011): 565–72. 
https://doi.org/10.1016/j.neubiorev.2010.07.002. 
Bellairs, Ruth, and Mark Osmond. The Atlas of Chick Development, 2009. 
Benditt, E P, and J M Benditt. “Evidence for a Monoclonal Origin of Human Atherosclerotic Plaques.” 
Proceedings of the National Academy of Sciences of the United States of America 70, no. 6 
(1973): 1753–6. 
Bennett, M R. “Apoptosis of Vascular Smooth Muscle Cells in Vascular Remodelling and 
Atherosclerotic Plaque Rupture.” Cardiovascular Research 41, no. 2 (February 1999): 361–8. 
Bennett, M R, G I Evan, and S M Schwartz. “Apoptosis of Human Vascular Smooth Muscle Cells 
Derived from Normal Vessels and Coronary Atherosclerotic Plaques.” The Journal of Clinical 
Investigation 95, no. 5 (May 1995): 2266–74. https://doi.org/10.1172/JCI117917. 
Bennett, Martin R. “Apoptosis in the Cardiovascular System.” Heart (British Cardiac Society) 87, no. 5 
(May 2002): 480–7. 
Bennett, Martin R., Sanjay Sinha, and Gary K. Owens. “Vascular Smooth Muscle Cells in 
Atherosclerosis.” Circulation Research 118, no. 4 (February 2016): 692–702. 
https://doi.org/10.1161/CIRCRESAHA.115.306361. 
Bheda, Poonam, and Robert Schneider. “Epigenetics Reloaded: The Single-Cell Revolution.” Trends in 
Cell Biology 24, no. 11 (November 2014): 712–723. https://doi.org/10.1016/j.tcb.2014.08.010. 
Blank, Randal S., and Gary K. Owens. “Platelet-Derived Growth Factor Regulates Actin Isoform 
Expression and Growth Factor Regulates Actin Isoform Expression and Growth State in Cultured 
Rat Aortic Smooth Muscle Cells.” Journal of Cellular Physiology 142, no. 3 (March 1990): 635–
642. https://doi.org/10.1002/jcp.1041420325. 
Blatnik, Jeffrey S., Geert W. Schmid-Schönbein, and Lanping Amy Sung. “The Influence of Fluid Shear 
Stress on the Remodeling of the Embryonic Primary Capillary Plexus.” Biomechanics and 
Modeling in Mechanobiology 4, no. 4 (December 2005): 211–220. 
https://doi.org/10.1007/s10237-005-0001-2. 
Bochaton-Piallat, M L, P Ropraz, F Gabbiani, and G Gabbiani. “Phenotypic Heterogeneity of Rat 
Arterial Smooth Muscle Cell Clones - Implications for the Development of Experimental Intimal 
Thickening.” Arteriosclerosis Thrombosis and Vascular Biology 16, no. 6 (1996): 815–820. 
Braganza, D M, and M R Bennett. “New Insights into Atherosclerotic Plaque Rupture.” Postgraduate 
Medical Journal 77, no. 904 (February 2001): 94–8. https://doi.org/10.1136/PMJ.77.904.94. 
Brennecke, Philip, Simon Anders, Jong Kyoung Kim, Aleksandra A Ko\lodziejczyk, Xiuwei Zhang, 
Valentina Proserpio, Bianka Baying, et al. “Accounting for Technical Noise in Single-Cell RNA-
Seq Experiments.” Nature Methods 10, no. 11 (September 2013): 1093–1095. 
https://doi.org/10.1038/nmeth.2645. 
Cai, H, and D G Harrison. “Endothelial Dysfunction in Cardiovascular Diseases: The Role of Oxidant 
Stress.” Circulation Research 87, no. 10 (November 2000): 840–4. 
Cambridge Clinical School. Clinical and Biomedical Computing Unit. Expert Reviews in Molecular 
Medicine. Published by Cambridge University Press in association with the Clinical and 
150 
 
Biomedical Computing Unit of the University of Cambridge School of Clinical Medicine, 1997. 
http://journals.cambridge.org/fulltext_content/ERM/ERM4_01/S1462399402004039sup006.ht
m. 
Campbell, Gordon R., Yasuo Uehara, Torbjorn Malmfors, and Geoffrey Burnstock. “Degeneration and 
Regeneration of Smooth Muscle Transplants in the Anterior Eye Chamber.” Cell & Tissue 
Research 117, no. 2 (1971): 155–175. 
Cao, D., Z. Wang, C.-L. Zhang, J. Oh, W. Xing, S. Li, J. A. Richardson, D.-Z. Wang, and E. N. Olson. 
“Modulation of Smooth Muscle Gene Expression by Association of Histone Acetyltransferases 
and Deacetylases with Myocardin.” Molecular and Cellular Biology 25, no. 1 (January 2005): 
364–376. https://doi.org/10.1128/MCB.25.1.364-376.2005. 
Cao, Richard Y, Tim Amand, Matthew D Ford, Ugo Piomelli, and Colin D Funk. “The Murine 
Angiotensin II-Induced Abdominal Aortic Aneurysm Model: Rupture Risk and Inflammatory 
Progression Patterns.” Frontiers in Pharmacology 1 (2010): 9. 
https://doi.org/10.3389/fphar.2010.00009. 
Chamley-Campbell, J H, and G R Campbell. “What Controls Smooth Muscle Phenotype?” 
Atherosclerosis 40, no. 3–4 (1981): 347–57. https://doi.org/0021-9150(81)90145-3 [pii]. 
Chappell, Joel, Jennifer L. Harman, Vagheesh M. Narasimhan, Haixiang Yu, Kirsty Foote, Benjamin D. 
Simons, Martin R. Bennett, and Helle F. Jørgensen. “Extensive Proliferation of a Subset of 
Differentiated, yet Plastic, Medial Vascular Smooth Muscle Cells Contributes to Neointimal 
Formation in Mouse Injury and Atherosclerosis ModelsNovelty and Significance.” Circulation 
Research 119, no. 12 (December 2016): 1313–1323. 
https://doi.org/10.1161/CIRCRESAHA.116.309799. 
Chen, Z., and E. Tzima. “PECAM-1 Is Necessary for Flow-Induced Vascular Remodeling.” 
Arteriosclerosis, Thrombosis, and Vascular Biology 29, no. 7 (July 2009): 1067–1073. 
https://doi.org/10.1161/ATVBAHA.109.186692. 
Cheng, Y., X. Liu, J. Yang, Y. Lin, D.-Z. Xu, Q. Lu, E. A. Deitch, Y. Huo, E. S. Delphin, and C. Zhang. 
“MicroRNA-145, a Novel Smooth Muscle Cell Phenotypic Marker and Modulator, Controls 
Vascular Neointimal Lesion Formation.” Circulation Research 105, no. 2 (July 2009): 158–166. 
https://doi.org/10.1161/CIRCRESAHA.109.197517. 
Cherepanova, Olga A, Delphine Gomez, Laura S Shankman, Pamela Swiatlowska, Jason Williams, 
Olga F Sarmento, Gabriel F Alencar, et al. “Activation of the Pluripotency Factor OCT4 in 
Smooth Muscle Cells Is Atheroprotective.” Nature Medicine 22, no. 6 (May 2016): 657–665. 
https://doi.org/10.1038/nm.4109. 
Chiu, Jeng-Jiann, and Shu Chien. “Effects of Disturbed Flow on Vascular Endothelium: 
Pathophysiological Basis and Clinical Perspectives.” Physiological Reviews 91, no. 1 (2011): 
327–387. https://doi.org/10.1152/physrev.00047.2009. 
Choke, E., G. Cockerill, W.R.W. Wilson, S. Sayed, J. Dawson, I. Loftus, and M.M. Thompson. “A 
Review of Biological Factors Implicated in Abdominal Aortic Aneurysm Rupture.” European 
Journal of Vascular and Endovascular Surgery 30, no. 3 (September 2005): 227–244. 
https://doi.org/10.1016/j.ejvs.2005.03.009. 
Christen, T, V Verin, M Bochaton-Piallat, Y Popowski, F Ramaekers, P Debruyne, E Camenzind, G van 
Eys, and G Gabbiani. “Mechanisms of Neointima Formation and Remodeling in the Porcine 
Coronary Artery.” Circulation 103, no. 6 (2001): 882–888. 
https://doi.org/10.1161/01.CIR.103.6.882. 
Cines, D B, E S Pollak, C a Buck, J Loscalzo, G a Zimmerman, R P McEver, J S Pober, et al. “Endothelial 
Cells in Physiology and in the Pathophysiology of Vascular Disorders.” Blood 91, no. 10 (1998): 
3527–3561. 
Clarke, Murray C H, Nichola Figg, Janet J Maguire, Anthony P Davenport, Martin Goddard, Trevor D 
Littlewood, and Martin R Bennett. “Apoptosis of Vascular Smooth Muscle Cells Induces 
Features of Plaque Vulnerability in Atherosclerosis.” Nature Medicine 12, no. 9 (September 
2006): 1075–1080. https://doi.org/10.1038/nm1459. 
151 
 
Clowes, A W, and S M Schwartz. “Significance of Quiescent Smooth Muscle Migration in the Injured 
Rat Carotid Artery.” Circulation Research 56, no. 1 (1985). 
http://circres.ahajournals.org/content/56/1/139. 
Collin, J, L Araujo, J Walton, and D Lindsell. “Oxford Screening Programme for Abdominal Aortic 
Aneurysm in Men Aged 65 to 74 Years.” Lancet (London, England) 2, no. 8611 (September 
1988): 613–5. 
Cordes, Kimberly R., Neil T. Sheehy, Mark P. White, Emily C. Berry, Sarah U. Morton, Alecia N. Muth, 
Ting-Hein Lee, Joseph M. Miano, Kathryn N. Ivey, and Deepak Srivastava. “MiR-145 and MiR-
143 Regulate Smooth Muscle Cell Fate and Plasticity.” Nature 460, no. 7256 (July 2009): 705. 
https://doi.org/10.1038/nature08195. 
Crisby, M, G Nordin-Fredriksson, P K Shah, J Yano, J Zhu, and J Nilsson. “Pravastatin Treatment 
Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, 
and Cell Death in Human Carotid Plaques: Implications for Plaque Stabilization.” Circulation 
103, no. 7 (February 2001): 926–33. 
Dai, Jianping, Liliane Louedec, Monique Philippe, Jean-Baptiste Michel, and Xavier Houard. “Effect of 
Blocking Platelet Activation with AZD6140 on Development of Abdominal Aortic Aneurysm in a 
Rat Aneurysmal Model.” Journal of Vascular Surgery 49, no. 3 (March 2009): 719–727. 
https://doi.org/10.1016/j.jvs.2008.09.057. 
Daugherty, A, M W Manning, and L A Cassis. “Antagonism of AT2 Receptors Augments Angiotensin 
II-Induced Abdominal Aortic Aneurysms and Atherosclerosis.” British Journal of Pharmacology 
134, no. 4 (October 2001): 865–70. https://doi.org/10.1038/sj.bjp.0704331. 
Daugherty, Alan, and Lisa Cassis. “Angiotensin II and Abdominal Aortic Aneurysms.” Current 
Hypertension Reports 6, no. 6 (November 2004): 442–446. https://doi.org/10.1007/s11906-
004-0038-0. 
Daugherty, Alan, and Lisa Cassis. “Chronic Angiotensin II Infusion Promotes Atherogenesis in Low 
Density Lipoprotein Receptor -/- Mice.” Annals of the New York Academy of Sciences 892, no. 1 
THE METABOLIC (November 1999): 108–118. https://doi.org/10.1111/j.1749-
6632.1999.tb07789.x. 
Daugherty, Alan, Lisa A. Cassis, and Hong Lu. “Complex Pathologies of Angiotensin II-Induced 
Abdominal Aortic Aneurysms.” Journal of Zhejiang University SCIENCE B 12, no. 8 (August 
2011): 624–628. https://doi.org/10.1631/jzus.B1101002. 
Daugherty, Alan, Michael W. Manning, and Lisa A. Cassis. “Angiotensin II Promotes Atherosclerotic 
Lesions and Aneurysms in Apolipoprotein E–deficient Mice.” Journal of Clinical Investigation 
105, no. 11 (June 2000): 1605–1612. https://doi.org/10.1172/JCI7818. 
Davis, P H, J D Dawson, W a Riley, and R M Lauer. “Carotid Intimal-Medial Thickness Is Related to 
Cardiovascular Risk Factors Measured from Childhood through Middle Age: The Muscatine 
Study.” Circulation 104, no. 23 (2001): 2815–2819. https://doi.org/10.1161/hc4601.099486. 
Davies, M J, P D Richardson, N Woolf, D R Katz, and J Mann. “Risk of Thrombosis in Human 
Atherosclerotic Plaques: Role of Extracellular Lipid, Macrophage, and Smooth Muscle Cell 
Content.” British Heart Journal 69, no. 5 (1993): 377–381. 
https://doi.org/10.1136/hrt.69.5.377. 
De Caterina, R, P Libby, H B Peng, V J Thannickal, T B Rajavashisth, M A Gimbrone, W S Shin, J K Liao, 
and J K Liao. “Nitric Oxide Decreases Cytokine-Induced Endothelial Activation. Nitric Oxide 
Selectively Reduces Endothelial Expression of Adhesion Molecules and Proinflammatory 
Cytokines.” The Journal of Clinical Investigation 96, no. 1 (July 1995): 60–8. 
https://doi.org/10.1172/JCI118074. 
De Donatis, Alina, Giusy Comito, Francesca Buricchi, Maria C. Vinci, Astrid Parenti, Anna Caselli, 
Guido Camici, Giampaolo Manao, Giampietro Ramponi, and Paolo Cirri. “Proliferation versus 
Migration in Platelet-Derived Growth Factor Signaling: The Key Role of Endocytosis.” Journal of 
Biological Chemistry 283, no. 29 (2008): 19948–19956. 
https://doi.org/10.1074/jbc.M709428200. 
152 
 
DeBakey, M E, G M Lawrie, and D H Glaeser. “Patterns of Atherosclerosis and Their Surgical 
Significance.” Annals of Surgery 201, no. 2 (February 1985): 115–31. 
Dekker, Rob J., Johannes V. van Thienen, Jakub Rohlena, Saskia C. de Jager, Yvonne W. Elderkamp, 
Jurgen Seppen, Carlie J.M. de Vries, et al. “Endothelial KLF2 Links Local Arterial Shear Stress 
Levels to the Expression of Vascular Tone-Regulating Genes.” The American Journal of 
Pathology 167, no. 2 (August 2005): 609–618. https://doi.org/10.1016/S0002-9440(10)63002-
7. 
Dilley, R J, and S M Schwartz. “Vascular Remodeling in the Growth Hormone Transgenic Mouse.” 
Circulation Research 65, no. 5 (1989): 1233–40. 
Dimmeler, S, C Hermann, J Galle, and A M Zeiher. “Upregulation of Superoxide Dismutase and Nitric 
Oxide Synthase Mediates the Apoptosis-Suppressive Effects of Shear Stress on Endothelial 
Cells.” Arteriosclerosis, Thrombosis, and Vascular Biology 19, no. 3 (March 1999): 656–64. 
Doran, Amanda C, Nahum Meller, and Coleen a McNamara. “Role of Smooth Muscle Cells in the 
Initiation and Early Progression of Atherosclerosis.” Arteriosclerosis, Thrombosis, and Vascular 
Biology 28, no. 5 (2008): 812–9. https://doi.org/10.1161/ATVBAHA.107.159327. 
Dostal, D E, T Murahashi, and M J Peach. “Regulation of Cytosolic Calcium by Angiotensins in 
Vascular Smooth Muscle.” Hypertension (Dallas, Tex. : 1979) 15, no. 6 Pt 2 (June 1990): 815–22. 
https://doi.org/10.1161/01.hyp.30.2.222. 
Dourron, H. M., Gary M Jacobson, James L Park, Jianhua Liu, Daniel J Reddy, Maria L Scheel, and 
Patrick J Pagano. “Perivascular Gene Transfer of NADPH Oxidase Inhibitor Suppresses 
Angioplasty-Induced Neointimal Proliferation of Rat Carotid Artery.” AJP: Heart and Circulatory 
Physiology 288, no. 2 (October 2004): H946–H953. 
https://doi.org/10.1152/ajpheart.00413.2004. 
Du, Kevin L, Hon S Ip, Jian Li, Mary Chen, Frederic Dandre, William Yu, Min Min Lu, Gary K Owens, 
and Michael S Parmacek. “Myocardin Is a Critical Serum Response Factor Cofactor in the 
Transcriptional Program Regulating Smooth Muscle Cell Differentiation.” Molecular and 
Cellular Biology 23, no. 7 (April 2003): 2425–37. 
Elmore, James R., Bonnie F. Keister, David P. Franklin, Jerry R. Youkey, and David J. Carey. 
“Expression of Matrix Metalloproteinases and TIMPs in Human Abdominal Aortic Aneurysms.” 
Annals of Vascular Surgery 12, no. 3 (May 1998): 221–228. 
https://doi.org/10.1007/s100169900144. 
Espagnolle, Nicolas, Fabien Guilloton, Frédéric Deschaseaux, Mélanie Gadelorge, Luc Sensébé, and 
Philippe Bourin. “CD146 Expression on Mesenchymal Stem Cells Is Associated with Their 
Vascular Smooth Muscle Commitment.” Journal of Cellular and Molecular Medicine 18, no. 1 
(January 2014): 104–114. https://doi.org/10.1111/jcmm.12168. 
Faury, Gilles, Mylène Pezet, Russell H. Knutsen, Walter A. Boyle, Scott P. Heximer, Sean E. McLean, 
Robert K. Minkes, et al. “Developmental Adaptation of the Mouse Cardiovascular System to 
Elastin Haploinsufficiency.” Journal of Clinical Investigation 112, no. 9 (November 2003): 1419–
1428. https://doi.org/10.1172/JCI19028. 
Feil, Susanne, Birgit Fehrenbacher, Robert Lukowski, Frank Essmann, Klaus Schulze-Osthoff, Martin 
Schaller, and Robert Feil. “Transdifferentiation of Vascular Smooth Muscle Cells to 
Macrophage-like Cells during Atherogenesis.” Circulation Research, 2014, 662–667. 
https://doi.org/10.1161/CIRCRESAHA.115.304634. 
Feng, J, S Ge, L Zhang, H Che, and C Liang. “Aortic Dissection Is Associated with Reduced Polycystin-1 
Expression, an Abnormality That Leads to Increased ERK Phosphorylation in Vascular Smooth 
Muscle Cells.” European Journal of Histochemistry : EJH 60, no. 4 (December 2016): 2711. 
https://doi.org/10.4081/ejh.2016.2711. 
Filardo, Giovanni, Janet T Powell, Melissa Ashley-Marie Martinez, and David J Ballard. “Surgery for 
Small Asymptomatic Abdominal Aortic Aneurysms.” In Cochrane Database of Systematic 
Reviews, edited by Giovanni Filardo, CD001835. 3. Chichester, UK: John Wiley & Sons, Ltd, 
2012. https://doi.org/10.1002/14651858.CD001835.pub3. 
153 
 
Frid, M G, E P Moiseeva, and K R Stenmark. “Multiple Phenotypically Distinct Smooth Muscle Cell 
Populations Exist in the Adult and Developing Bovine Pulmonary Arterial Media in Vivo.” 
Circulation Research 75, no. 4 (1994): 669–81. https://doi.org/10.1161/01.RES.75.4.669. 
Fuster, V. “Lewis A. Conner Memorial Lecture. Mechanisms Leading to Myocardial Infarction: 
Insights from Studies of Vascular Biology.” Circulation 90 (1994): 2126–2146. 
https://doi.org/10.1161/01.CIR.90.4.2126. 
Galkina, Elena, Alexandra Kadl, John Sanders, Danielle Varughese, Ian J. Sarembock, and Klaus Ley. 
“Lymphocyte Recruitment into the Aortic Wall before and during Development of 
Atherosclerosis Is Partially L-Selectin Dependent.” The Journal of Experimental Medicine 203, 
no. 5 (May 2006): 1273–1282. https://doi.org/10.1084/jem.20052205. 
Galley, H. F., and N R Webster. “Physiology of the Endothelium.” British Journal of Anaesthesia 93, 
no. 1 (July 2004): 105–113. https://doi.org/10.1093/bja/aeh163. 
Gardner, Sarah E., Melanie Humphry, Martin R. Bennett, and Murray C.H. Clarke. “Senescent 
Vascular Smooth Muscle Cells Drive Inflammation Through an Interleukin-1α–Dependent 
Senescence-Associated Secretory PhenotypeSignificance.” Arteriosclerosis, Thrombosis, and 
Vascular Biology 35, no. 9 (September 2015): 1963–1974. 
https://doi.org/10.1161/ATVBAHA.115.305896. 
Geng, Y J, and P Libby. “Evidence for Apoptosis in Advanced Human Atheroma. Colocalization with 
Interleukin-1 Beta-Converting Enzyme.” The American Journal of Pathology 147, no. 2 (August 
1995): 251–66. 
Giesen, Charlotte, Hao A O Wang, Denis Schapiro, Nevena Zivanovic, Andrea Jacobs, Bodo 
Hattendorf, Peter J Schüffler, et al. “Highly Multiplexed Imaging of Tumor Tissues with 
Subcellular Resolution by Mass Cytometry.” Nature Methods 11, no. 4 (March 2014): 417–422. 
https://doi.org/10.1038/nmeth.2869. 
Gomez, D., and G. K. Owens. “Smooth Muscle Cell Phenotypic Switching in Atherosclerosis.” 
Cardiovascular Research 95, no. 2 (July 2012): 156–164. https://doi.org/10.1093/cvr/cvs115. 
Gomez, Delphine, and Gary K Owens. “Reconciling Smooth Muscle Cell Oligoclonality and 
Proliferative Capacity in Experimental Atherosclerosis.” Circulation Research 119, no. 12 
(December 2016): 1262–1264. https://doi.org/10.1161/CIRCRESAHA.116.310104. 
Gomez, Delphine, Laura S Shankman, Anh T Nguyen, and Gary K Owens. “Detection of Histone 
Modifications at Specific Gene Loci in Single Cells in Histological Sections.” Nature Methods 10, 
no. 2 (2013): 171–7. https://doi.org/10.1038/nmeth.2332. 
Gomez, Delphine, Pamela Swiatlowska, and Gary K. Owens. “Epigenetic Control of Smooth Muscle 
Cell Identity and Lineage Memory.” Arteriosclerosis, Thrombosis, and Vascular Biology 35, no. 
12 (December 2015): 2508–2516. https://doi.org/10.1161/ATVBAHA.115.305044. 
Grobbee, D.E., and M.L. Bots. “Carotid Artery Intima-Media Thickness as an Indicator of Generalized 
Atherosclerosis.” Journal of Internal Medicine 236 (1994): 567–573. 
Grun, D, and A van Oudenaarden. “Design and Analysis of Single-Cell Sequencing Experiments.” Cell 
163, no. 4 (2015). 
Guo, Dong-Chuan, Hariyadarshi Pannu, Van Tran-Fadulu, Christina L Papke, Robert K Yu, Nili Avidan, 
Scott Bourgeois, et al. “Mutations in Smooth Muscle α-Actin (ACTA2) Lead to Thoracic Aortic 
Aneurysms and Dissections.” Nature Genetics 39, no. 12 (December 2007): 1488–1493. 
https://doi.org/10.1038/ng.2007.6. 
Gutterman, D D. “Adventitia-Dependent Influences on Vascular Function.” The American Journal of 
Physiology 277, no. 4 Pt 2 (October 1999): H1265–72. 
Haimovici, H, and N Maier. “Experimental Canine Atherosclerosis in Autogenous Abdominal Aortic 
Grafts Implanted into the Jugular Vein.” Atherosclerosis 13, no. 3 (May 1971): 375–84. 
https://doi.org/10.1016/0021-9150(71)90080-3. 
Hao, H., Giulio Gabbiani, and Marie-Luce Bochaton-Piallat. “Arterial Smooth Muscle Cell 
Heterogeneity: Implications for Atherosclerosis and Restenosis Development.” Arteriosclerosis, 
154 
 
Thrombosis, and Vascular Biology 23, no. 9 (September 2003): 1510–1520. 
https://doi.org/10.1161/01.ATV.0000090130.85752.ED. 
Hao, Hiroyuki, Patricia Ropraz, Vitali Verin, Edoardo Camenzind, Antoine Geinoz, Michael S. Pepper, 
Giulio Gabbiani, and Marie Luce Bochaton-Piallat. “Heterogeneity of Smooth Muscle Cell 
Populations Cultured from Pig Coronary Artery.” Arteriosclerosis, Thrombosis, and Vascular 
Biology 22, no. 7 (2002): 1093–1099. https://doi.org/10.1161/01.ATV.0000022407.91111.E4. 
Haque, Ashraful, Jessica Engel, Sarah A. Teichmann, and Tapio Lönnberg. “A Practical Guide to 
Single-Cell RNA-Sequencing for Biomedical Research and Clinical Applications.” Genome 
Medicine 9, no. 1 (December 2017): 75. https://doi.org/10.1186/s13073-017-0467-4. 
Hashimshony, Tamar, Florian Wagner, Noa Sher, and Itai Yanai. “CEL-Seq: Single-Cell RNA-Seq by 
Multiplexed Linear Amplification.” Cell Reports 2, no. 3 (September 2012): 666–673. 
https://doi.org/10.1016/j.celrep.2012.08.003. 
Haurani, M, P PAGANO, Ruperez M., Suzuki Y., Egido J., Kübler W., Kita T., and Yokode M. 
“Adventitial Fibroblast Reactive Oxygen Species as Autacrine and Paracrine Mediators of 
Remodeling: Bellwether for Vascular Disease?” Cardiovascular Research 75, no. 4 (September 
2007): 679–689. https://doi.org/10.1016/j.cardiores.2007.06.016. 
Herring, B. Paul, April M. Hoggatt, Sarah L. Griffith, Jeanette N. McClintick, and Patricia J. Gallagher. 
“Inflammation and Vascular Smooth Muscle Cell Dedifferentiation Following Carotid Artery 
Ligation.” Physiological Genomics 49, no. 3 (2017). 
http://physiolgenomics.physiology.org/content/49/3/115?hwshib2=authn%3A1505408047%3
A20170913%253A9f5d9f7c-6515-4636-8895-
7c6af22ba2bc%3A0%3A0%3A0%3AG1XGk%2B9pHF8OYAEYkj3gOw%3D%3D. 
Herring, Brian Paul, April M Hoggatt, Christopher Burlak, and Stefan Offermanns. “Previously 
Differentiated Medial Vascular Smooth Muscle Cells Contribute to Neointima Formation 
Following Vascular Injury.” Vascular Cell 6 (2014): 21. https://doi.org/10.1186/2045-824X-6-21. 
Hiltunen, Mikko O, Mikko P Turunen, Tomi P Häkkinen, Juha Rutanen, Maria Hedman, Kimmo 
Mäkinen, Anna-Mari Turunen, Katriina Aalto-Setälä, and Seppo Ylä-Herttuala. “DNA 
Hypomethylation and Methyltransferase Expression in Atherosclerotic Lesions.” Vascular 
Medicine (London, England) 7 (2002): 5–11. https://doi.org/10.1191/1358863x02vm418oa. 
Hofnagel, O., Birgit Luechtenborg, Katrin Stolle, Stefan Lorkowski, Heike Eschert, Gabriele Plenz, and 
Horst Robenek. “Proinflammatory Cytokines Regulate LOX-1 Expression in Vascular Smooth 
Muscle Cells.” Arteriosclerosis, Thrombosis, and Vascular Biology 24, no. 10 (August 2004): 
1789–1795. https://doi.org/10.1161/01.ATV.0000140061.89096.2b. 
Howard, E W, E C Bullen, and M J Banda. “Preferential Inhibition of 72- and 92-KDa Gelatinases by 
Tissue Inhibitor of Metalloproteinases-2.” The Journal of Biological Chemistry 266, no. 20 (July 
1991): 13070–5. 
Hu, Yanhua, Zhongyi Zhang, Evelyn Torsney, Ali R Afzal, Fergus Davison, Bernhard Metzler, and 
Qingbo Xu. “Abundant Progenitor Cells in the Adventitia Contribute to Atherosclerosis of Vein 
Grafts in ApoE-Deficient Mice.” The Journal of Clinical Investigation 113, no. 9 (2004): 1258–
1265. https://doi.org/10.1172/JCI200419628. 
Ishibashi, S, M S Brown, J L Goldstein, R D Gerard, R E Hammer, and J Herz. “Hypercholesterolemia in 
Low Density Lipoprotein Receptor Knockout Mice and Its Reversal by Adenovirus-Mediated 
Gene Delivery.” The Journal of Clinical Investigation 92, no. 2 (August 1993): 883–93. 
https://doi.org/10.1172/JCI116663. 
Iwata, Hiroshi, Ichiro Manabe, Katsuhito Fujiu, Tetsufumi Yamamoto, Norifumi Takeda, Kosei Eguchi, 
Akiko Furuya, Makoto Kuro-o, Masataka Sata, and Ryozo Nagai. “Bone Marrow-Derived Cells 
Contribute to Vascular Inflammation but Do Not Differentiate into Smooth Muscle Cell 
Lineages.” Circulation 122, no. 20 (2010): 2048–2057. 
https://doi.org/10.1161/CIRCULATIONAHA.110.965202. 
155 
 
Jacobs, M L, A J Chin, J Rychik, J M Steven, S C Nicolson, and W I Norwood. “Interrupted Aortic Arch. 
Impact of Subaortic Stenosis on Management and Outcome.” Circulation 92, no. 9 Suppl 
(November 1995): II128–31. 
Jaitin, Diego Adhemar, Ephraim Kenigsberg, Hadas Keren-Shaul, Naama Elefant, Franziska Paul, Irina 
Zaretsky, Alexander Mildner, et al. “Massively Parallel Single-Cell RNA-Seq for Marker-Free 
Decomposition of Tissues into Cell Types.” Science (New York, N.Y.) 343, no. 6172 (February 
2014): 776–9. https://doi.org/10.1126/science.1247651. 
Jaulmes, A., Sylvain Thierry, Brigitte Janvier, Michel Raymondjean, and Vincent Maréchal. “Activation 
of SPLA2-IIA and PGE2 Production by High Mobility Group Protein B1 in Vascular Smooth 
Muscle Cells Sensitized by IL-1.” The FASEB Journal 20, no. 10 (August 2006): 1727–1729. 
https://doi.org/10.1096/fj.05-5514fje. 
Jiang, X, D H Rowitch, P Soriano, a P McMahon, and H M Sucov. “Fate of the Mammalian Cardiac 
Neural Crest.” Development (Cambridge, England) 127, no. 8 (2000): 1607–1616. 
Johnsen, S. H., S. H. Forsdahl, K. Singh, and B. K. Jacobsen. “Atherosclerosis in Abdominal Aortic 
Aneurysms: A Causal Event or a Process Running in Parallel? The Tromso Study.” 
Arteriosclerosis, Thrombosis, and Vascular Biology 30, no. 6 (June 2010): 1263–1268. 
https://doi.org/10.1161/ATVBAHA.110.203588. 
Johnston, K W, R B Rutherford, M D Tilson, D M Shah, L Hollier, and J C Stanley. “Suggested 
Standards for Reporting on Arterial Aneurysms. Subcommittee on Reporting Standards for 
Arterial Aneurysms, Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery 
and North American Chapter, International Society for Cardiovascular Surgery.” Journal of 
Vascular Surgery 13, no. 3 (March 1991): 452–8. 
Kim, S, H S Ip, M M Lu, C Clendenin, and M S Parmacek. “A Serum Response Factor-Dependent 
Transcriptional Regulatory Program Identifies Distinct Smooth Muscle Cell Sublineages.” 
Molecular and Cellular Biology 17, no. 4 (April 1997): 2266–78. 
King, V. L., A. Y. Lin, F. Kristo, T. J. T. Anderson, N. Ahluwalia, G. J. Hardy, A. P. Owens, et al. 
“Interferon- and the Interferon-Inducible Chemokine CXCL10 Protect Against Aneurysm 
Formation and Rupture.” Circulation 119, no. 3 (January 2009): 426–435. 
https://doi.org/10.1161/CIRCULATIONAHA.108.785949. 
Kinlay, S, and P Ganz. “Role of Endothelial Dysfunction in Coronary Artery Disease and Implications 
for Therapy.” The American Journal of Cardiology 80, no. 9A (1997): 11I–16I. 
Kivioja, Teemu, Anna Vähärautio, Kasper Karlsson, Martin Bonke, Martin Enge, Sten Linnarsson, and 
Jussi Taipale. “Counting Absolute Numbers of Molecules Using Unique Molecular Identifiers.” 
Nature Methods 9, no. 1 (November 2011): 72–74. https://doi.org/10.1038/nmeth.1778. 
Koch, A E, G K Haines, R J Rizzo, J A Radosevich, R M Pope, P G Robinson, and W H Pearce. “Human 
Abdominal Aortic Aneurysms. Immunophenotypic Analysis Suggesting an Immune-Mediated 
Response.” The American Journal of Pathology 137, no. 5 (November 1990): 1199–213. 
Kolodgie, Frank D, Allen P Burke, Gaku Nakazawa, and R Virmani. “Is Pathologic Intimal Thickening 
the Key to Understanding Early Plaque Progression in Human Atherosclerotic Disease?” ATVB 
27 (2007): 986–989. 
Koltsova, Ekaterina K, Catherine C Hedrick, and Klaus Ley. “Myeloid Cells in Atherosclerosis: A 
Delicate Balance of Anti-Inflammatory and Proinflammatory Mechanisms.” Current Opinion in 
Lipidology 24, no. 5 (October 2013): 371–80. 
https://doi.org/10.1097/MOL.0b013e328363d298. 
Korshunov, Vyacheslav a., and Bradford C. Berk. “Flow-Induced Vascular Remodeling in the Mouse: A 
Model for Carotid Intima-Media Thickening.” Arteriosclerosis, Thrombosis, and Vascular Biology 
23 (2003): 2185–2191. https://doi.org/10.1161/01.ATV.0000103120.06092.14. 
Koyama, H, E W Raines, K E Bornfeldt, J M Roberts, and R Ross. “Fibrillar Collagen Inhibits Arterial 
Smooth Muscle Proliferation through Regulation of Cdk2 Inhibitors.” Cell 87, no. 6 (December 
1996): 1069–78. 
156 
 
Kramann, Rafael, Rebekka K Schneider, Derek P DiRocco, Flavia Machado, Susanne Fleig, Philip A 
Bondzie, Joel M Henderson, et al. “Perivascular Gli1+ Progenitors Are Key Contributors to 
Injury-Induced Organ Fibrosis.” Cell Stem Cell 16, no. 1 (January 2015): 51–66. 
https://doi.org/10.1016/j.stem.2014.11.004. 
Kumar, A, and V Lindner. “Remodeling with Neointima Formation in the Mouse Carotid Artery after 
Cessation of Blood Flow.” Arteriosclerosis, Thrombosis, and Vascular Biology 17, no. 10 
(October 1997): 2238–44. 
Lacolley, P, P Challande, S Boumaza, G Cohuet, S Laurent, P Boutouyrie, J A Grimaud, D Paulin, J M 
Lamazière, and Z Li. “Mechanical Properties and Structure of Carotid Arteries in Mice Lacking 
Desmin.” Cardiovascular Research 51, no. 1 (July 2001): 178–87. 
Lemire, A. Lea, K. Batten, D. Jian Gu, S. Whitley, P. and Bramlett. K. “Development of ERCC RNA 
Spike-In Control Mixes.” J Biomol Tech 22 (2011). 
Levine, G N, A P Chodos, and J Loscalzo. “Restenosis Following Coronary Angioplasty: Clinical 
Presentations and Therapeutic Options.” Clinical Cardiology 18, no. 12 (December 1995): 693–
703. 
Li, L, J M Miano, B Mercer, and E N Olson. “Expression of the SM22alpha Promoter in Transgenic 
Mice Provides Evidence for Distinct Transcriptional Regulatory Programs in Vascular and 
Visceral Smooth Muscle Cells.” The Journal of Cell Biology 132, no. 5 (March 1996): 849–59. 
Li, S, Y S Fan, L H Chow, C Van Den Diepstraten, E van Der Veer, S M Sims, and J G Pickering. “Innate 
Diversity of Adult Human Arterial Smooth Muscle Cells: Cloning of Distinct Subtypes from the 
Internal Thoracic Artery.” Circulation Research 89, no. 6 (2001): 517–525. 
https://doi.org/10.1161/hh1801.097165. 
Li, Shaohua, Stephen Sims, Yang Jiao, Lawrence H Chow, and J Geoffrey Pickering. “Evidence From a 
Novel Human Cell Clone That Adult Between Noncontractile and Contractile Phenotypes.” 
Circulation Research 85 (1999): 338–348. https://doi.org/10.1161/01.RES.85.4.338. 
Li, X, V Van Putten, F Zarinetchi, M E Nicks, S Thaler, L E Heasley, and R A Nemenoff. “Suppression of 
Smooth-Muscle Alpha-Actin Expression by Platelet-Derived Growth Factor in Vascular Smooth-
Muscle Cells Involves Ras and Cytosolic Phospholipase A2.” The Biochemical Journal 327 ( Pt 3), 
no. Pt 3 (November 1997): 709–16. 
Libby, P. Chapter 241. The Pathogenesis, Prevention, and Treatment of Atherosclerosis | Harrison’s 
Principles of Internal Medicine, 18e | AccessMedicine | McGraw-Hill Medical. (2005).  
Libby, Peter, Paul M Ridker, and Göran K Hansson. “Progress and Challenges in Translating the 
Biology of Atherosclerosis.” Nature 473, no. 7347 (2011): 317–25. 
https://doi.org/10.1038/nature10146. 
Lindner, V, J Fingerle, and M A Reidy. “Mouse Model of Arterial Injury.” Circulation Research 73, no. 
5 (November 1993): 792–6. 
Liu, Chengyu. “Strategies for Designing Transgenic DNA Constructs.” Methods in Molecular Biology 
(Clifton, N.J.) 1027 (2013): 183–201. https://doi.org/10.1007/978-1-60327-369-5_8. 
Liu, Ou, Lixin Jia, Xiaoxi Liu, Yueli Wang, Xiaolong Wang, Yanwen Qin, Jie Du, and Hongjia Zhang. 
“Clopidogrel, a Platelet P2Y12 Receptor Inhibitor, Reduces Vascular Inflammation and 
Angiotensin II Induced-Abdominal Aortic Aneurysm Progression.” PloS One 7, no. 12 (2012): 
e51707. https://doi.org/10.1371/journal.pone.0051707. 
Liu, Serena, and Cole Trapnell. “Single-Cell Transcriptome Sequencing: Recent Advances and 
Remaining Challenges.” F1000Research 5 (February 2016). 
https://doi.org/10.12688/f1000research.7223.1. 
Livet, Jean, Tamily A. Weissman, Hyuno Kang, Ryan W. Draft, Ju Lu, Robyn A. Bennis, Joshua R. Sanes, 
and Jeff W. Lichtman. “Transgenic Strategies for Combinatorial Expression of Fluorescent 
Proteins in the Nervous System.” Nature 450, no. 7166 (November 2007): 56–62. 
https://doi.org/10.1038/nature06293. 
157 
 
López-Candales, A, D R Holmes, S Liao, M J Scott, S A Wickline, and R W Thompson. “Decreased 
Vascular Smooth Muscle Cell Density in Medial Degeneration of Human Abdominal Aortic 
Aneurysms.” The American Journal of Pathology 150, no. 3 (March 1997): 993–1007. 
Lu, Yao Wei, Anthony M. Lowery, Li-Yan Sun, Harold A. Singer, Guohao Dai, Alejandro P. Adam, Peter 
A. Vincent, and John J. Schwarz. “Endothelial Myocyte Enhancer Factor 2c Inhibits Migration of 
Smooth Muscle Cells Through Fenestrations in the Internal Elastic LaminaHighlights.” 
Arteriosclerosis, Thrombosis, and Vascular Biology 37, no. 7 (2017). 
http://atvb.ahajournals.org/content/37/7/1380. 
Lun, L. Aaron T., Karsten Bach, and John C. Marioni. “Pooling across Cells to Normalize Single-Cell 
RNA Sequencing Data with Many Zero Counts.” Genome Biology 17, no. 1 (December 2016): 75. 
https://doi.org/10.1186/s13059-016-0947-7. 
Maaten, Laurens van der. “Barnes-Hut-SNE,” January 2013. http://arxiv.org/abs/1301.3342. 
Macaulay, Iain C., Valentine Svensson, Charlotte Labalette, Lauren Ferreira, Fiona Hamey, Thierry 
Voet, Sarah A. Teichmann, and Ana Cvejic. “Single-Cell RNA-Sequencing Reveals a Continuous 
Spectrum of Differentiation in Hematopoietic Cells.” Cell Reports 14, no. 4 (February 2016): 
966–977. https://doi.org/10.1016/j.celrep.2015.12.082. 
Macaulay, IC, V Svensson, C Labalette, L Ferreira, F Hamey, T Voet, SA Teichmann, and A Cvejic. “No 
Title.” Cell Reports 14, no. 4 (2016). 
Mack, C P, and G K Owens. “Regulation of Smooth Muscle Alpha-Actin Expression in Vivo Is 
Dependent on CArG Elements within the 5’ and First Intron Promoter Regions.” Circulation 
Research 84, no. 7 (April 1999): 852–61. 
Madsen, C S, C P Regan, J E Hungerford, S L White, I Manabe, and G K Owens. “Smooth Muscle-
Specific Expression of the Smooth Muscle Myosin Heavy Chain Gene in Transgenic Mice 
Requires 5’-Flanking and First Intronic DNA Sequence.” Circulation Research 82, no. 8 (May 
1998): 908–17. 
Majesky, M. W., X. R. Dong, J. N. Regan, and V. J. Hoglund. “Vascular Smooth Muscle Progenitor 
Cells: Building and Repairing Blood Vessels.” Circulation Research 108, no. 3 (February 2011): 
365–377. https://doi.org/10.1161/CIRCRESAHA.110.223800. 
Majesky, Mark W. “Developmental Basis of Vascular Smooth Muscle Diversity.” Arteriosclerosis, 
Thrombosis, and Vascular Biology 27, no. 6 (2007): 1248–1258. 
https://doi.org/10.1161/ATVBAHA.107.141069. 
Manabe, I, and G K Owens. “Recruitment of Serum Response Factor and Hyperacetylation of 
Histones at Smooth Muscle-Specific Regulatory Regions during Differentiation of a Novel P19-
Derived in Vitro Smooth Muscle Differentiation System.” Circulation Research 88, no. 11 (June 
2001): 1127–34. 
Manning, Michael W, Lisa A Cassis, Jing Huang, Stephen J Szilvassy, and Alan Daugherty. “Abdominal 
Aortic Aneurysms: Fresh Insights from a Novel Animal Model of the Disease.” Vascular 
Medicine 7, no. 1 (February 2002): 45–54. https://doi.org/10.1191/1358863x02vm413ra. 
Marx, Steven O, Hana Totary-Jain, and Andrew R Marks. “Vascular Smooth Muscle Cell Proliferation 
in Restenosis.” Circulation. Cardiovascular Interventions 4, no. 1 (February 2011): 104–11. 
https://doi.org/10.1161/CIRCINTERVENTIONS.110.957332. 
Mashal, R D, M L Fejzo, A J Friedman, N Mitchner, R A Nowak, M S Rein, C C Morton, and J Sklar. 
“Analysis of Androgen Receptor DNA Reveals the Independent Clonal Origins of Uterine 
Leiomyomata and the Secondary Nature of Cytogenetic Aberrations in the Development of 
Leiomyomata.” Genes, Chromosomes & Cancer 11, no. 1 (September 1994): 1–6. 
Mathers, Colin D, and Dejan Loncar. “Updated Projections of Global Mortality and Burden of 
Disease, 2002-2030: Data Sources, Methods and Results.” World Health, no. October (2005): 
2002–2030. https://doi.org/10.1371/journal.pmed.0030442. 
Mathers, Colin D, Dejan Loncar, J Boreham, M Thun, JC Heath, and R Doll. “Projections of Global 
Mortality and Burden of Disease from 2002 to 2030.” Edited by Jon Samet. PLoS Medicine 3, 
no. 11 (November 2006): e442. https://doi.org/10.1371/journal.pmed.0030442. 
158 
 
Matthews, Charles, Isabelle Gorenne, Stephen Scott, Nicola Figg, Peter Kirkpatrick, Andrew Ritchie, 
Martin Goddard, and Martin Bennett. “Vascular Smooth Muscle Cells Undergo Telomere-Based 
Senescence in Human Atherosclerosis: Effects of Telomerase and Oxidative Stress.” Circulation 
Research 99, no. 2 (2006): 156–164. https://doi.org/10.1161/01.RES.0000233315.38086.bc. 
Matturri, L, A Cazzullo, P Turconi, A M Lavezzi, P L Vandone, L Gabrielli, G Fernández Alonso, D 
Grana, and J Milei. “Chromosomal Alterations in Atherosclerotic Plaques.” Atherosclerosis 154, 
no. 3 (February 2001): 755–61. https://doi.org/10.1016/S0021-9150(00)00488-3. 
Mayor, R., and E. Theveneau. “The Neural Crest.” Development 140, no. 11 (June 2013): 2247–2251. 
https://doi.org/10.1242/dev.091751. 
McDonald, O. G., Brian R Wamhoff, Mark H Hoofnagle, and Gary K Owens. “Control of SRF Binding to 
CArG Box Chromatin Regulates Smooth Muscle Gene Expression in Vivo.” Journal of Clinical 
Investigation 116, no. 1 (December 2005): 36–48. https://doi.org/10.1172/JCI26505. 
McDonald, Oliver G, Brian R Wamhoff, Mark H Hoofnagle, and Gary K Owens. “Control of SRF 
Binding to CArG Box Chromatin Regulates Smooth Muscle Gene Expression in Vivo.” The 
Journal of Clinical Investigation 116, no. 1 (2006): 36–48. https://doi.org/10.1172/JCI26505. 
McEniery, Carmel M, Ian B Wilkinson, and Albert P Avolio. “AGE, HYPERTENSION AND ARTERIAL 
FUNCTION.” Clinical and Experimental Pharmacology and Physiology 34, no. 7 (July 2007): 665–
671. https://doi.org/10.1111/j.1440-1681.2007.04657.x. 
Meir, Karen S, and Eran Leitersdorf. “Atherosclerosis in the Apolipoprotein-E-Deficient Mouse: A 
Decade of Progress.” Arteriosclerosis, Thrombosis, and Vascular Biology 24, no. 6 (2004): 1006–
14. https://doi.org/10.1161/01.ATV.0000128849.12617.f4. 
Mericskay, Mathias, Ara Parlakian, Arlette Porteu, Frédéric Dandré, Jacques Bonnet, Denise Paulin, 
and Zhenlin Li. “An Overlapping CArG/Octamer Element Is Required for Regulation of Desmin 
Gene Transcription in Arterial Smooth Muscle Cells.” Developmental Biology 226, no. 2 (2000): 
192–208. https://doi.org/10.1006/dbio.2000.9865. 
Moiseeva, E P. “Adhesion Receptors of Vascular Smooth Muscle Cells and Their Functions.” 
Cardiovascular Research 52, no. 3 (2001): 372–386. 
Mozaffarian, Dariush, Emelia J. Benjamin, Alan S. Go, Donna K. Arnett, Michael J. Blaha, Mary 
Cushman, Sandeep R. Das, et al. “Heart Disease and Stroke Statistics—2016 Update.” 
Circulation, 2015. 
http://circ.ahajournals.org/content/early/2015/12/16/CIR.0000000000000350. 
Nakahashi, Takeshi K, Katsuyuki Hoshina, Philip S Tsao, Eiketsu Sho, Mien Sho, John K Karwowski, 
Cory Yeh, Ruey-Bing Yang, James N Topper, and Ronald L Dalman. “Flow Loading Induces 
Macrophage Antioxidative Gene Expression in Experimental Aneurysms.” Arteriosclerosis, 
Thrombosis, and Vascular Biology 22, no. 12 (December 2002): 2017–22. 
Nakashima, Yutaka, Andrew S Plump, Elaine W Raines, Jan L Breslow, and Russell Ross. “ApoE-
Deficient Mice Develop Lesions of All Phases of Atherosclerosis throughout the Arterial Tree.” 
Arteriosclerosis and Thrombosis : A Journal of Vascular Biology / American Heart Association 
14, no. 1 (1994): 133–40. https://doi.org/10.1161/01.ATV.14.1.133. 
Nam, Douglas, Chih-Wen Ni, Amir Rezvan, Jin Suo, Klaudia Budzyn, Alexander Llanos, David Harrison, 
Don Giddens, and Hanjoong Jo. “Partial Carotid Ligation Is a Model of Acutely Induced 
Disturbed Flow, Leading to Rapid Endothelial Dysfunction and Atherosclerosis.” American 
Journal of Physiology. Heart and Circulatory Physiology 297, no. 4 (2009): H1535–43. 
https://doi.org/10.1152/ajpheart.00510.2009. 
Neese, R. A., L. M. Misell, S. Turner, A. Chu, J. Kim, D. Cesar, R. Hoh, et al. “Nonlinear Partial 
Differential Equations and Applications: Measurement in Vivo of Proliferation Rates of Slow 
Turnover Cells by 2H2O Labeling of the Deoxyribose Moiety of DNA.” Proceedings of the 
National Academy of Sciences 99, no. 24 (November 2002): 15345–15350. 
https://doi.org/10.1073/pnas.232551499. 
Nemenoff, R. A., H. Horita, A. C. Ostriker, S. B. Furgeson, P. A. Simpson, V. VanPutten, J. Crossno, S. 
Offermanns, and M. C. M. Weiser-Evans. “SDF-1 Induction in Mature Smooth Muscle Cells by 
159 
 
Inactivation of PTEN Is a Critical Mediator of Exacerbated Injury-Induced Neointima 
Formation.” Arteriosclerosis, Thrombosis, and Vascular Biology 31, no. 6 (June 2011): 1300–
1308. https://doi.org/10.1161/ATVBAHA.111.223701. 
Newby, A C, P Libby, and A C van der Wal. “Plaque Instability–the Real Challenge for Atherosclerosis 
Research in the next Decade?” Cardiovascular Research 41, no. 2 (February 1999): 321–2. 
Newman, W P, D S Freedman, a W Voors, P D Gard, S R Srinivasan, J L Cresanta, G D Williamson, L S 
Webber, and G S Berenson. Relation of Serum Lipoprotein Levels and Systolic Blood Pressure to 
Early Atherosclerosis. The Bogalusa Heart Study. Vol. 314. 3, 1986. 
https://doi.org/10.1056/NEJM198601163140302. 
Nguyen, AT, D Gomez, RD Bell, JH Campbell, AW Clowes, G Gabbiani, CM Giachelli, et al. “Smooth 
Muscle Cell Plasticity: Fact or Fiction?” Circ Res. 112, no. 1 (2013): 17–22. 
Nichterwitz, Susanne, Geng Chen, Julio Aguila Benitez, Marlene Yilmaz, Helena Storvall, Ming Cao, 
Rickard Sandberg, Qiaolin Deng, and Eva Hedlund. “Laser Capture Microscopy Coupled with 
Smart-Seq2 for Precise Spatial Transcriptomic Profiling.” Nature Communications 7 (July 2016): 
12139. https://doi.org/10.1038/ncomms12139. 
Nurnberg, ST, K Cheng, A Raiesdana, R Kundu, CL Miller, JB Kim, K Arora, et al. “Coronary Artery 
Disease Associated Transcription Factor TCF21 Regulates Smooth Muscle Precursor Cells That 
Contribute to the Fibrous Cap.” PLoS Genet. 11, no. 5 (2015). 
Ogeng’o, Julius, Kevin Ongeti, Moses Obimbo, Bedu Olabu, and Phillip Mwachaka. “Features of 
Atherosclerosis in the Tunica Adventitia of Coronary and Carotid Arteries in a Black Kenyan 
Population.” Anatomy Research International Article ID (2014): 5 pages. 
Okura, Yoshifumi, Marijke Brink, Hiroyuki Itabe, Kathrin J. Scheidegger, Afksendiyos Kalangos, and 
Patrice Delafontaine. “Oxidized Low-Density Lipoprotein Is Associated With Apoptosis of 
Vascular Smooth Muscle Cells in Human Atherosclerotic Plaques.” Circulation 102, no. 22 
(2000). http://circ.ahajournals.org/content/102/22/2680.short. 
Opitz, Florian, Katja Schenke-Layland, Tina U. Cohnert, and Ulrich A. Stock. “Phenotypical Plasticity of 
Vascular Smooth Muscle Cells—Effect of \textlessi\textgreaterIn Vitro\textless/I\textgreater 
and \textlessi\textgreaterIn Vivo\textless/I\textgreater Shear Stress for Tissue Engineering of 
Blood Vessels.” Tissue Engineering 13, no. 10 (October 2007): 2505–2514. 
https://doi.org/10.1089/ten.2006.0424. 
Organization, World Health. Global Health Estimates : Death by Cause, Age, Sex and Country, 2000 -
2012. WHO, 2014. 
Owens, G K. “Regulation of Differentiation of Vascular Smooth Muscle Cells.” Physiological Reviews 
75, no. 3 (July 1995): 487–517. 
Owens, G. K., Meena S Kumar, and Brian R Wamhoff. “Molecular Regulation of Vascular Smooth 
Muscle Cell Differentiation in Development and Disease.” Physiological Reviews 84, no. 3 (July 
2004): 767–801. https://doi.org/10.1152/physrev.00041.2003. 
Paigen, B, A Morrow, P A Holmes, D Mitchell, and R A Williams. “Quantitative Assessment of 
Atherosclerotic Lesions in Mice.” Atherosclerosis 68, no. 3 (1987): 231–240. 
https://doi.org/10.1016/0021-9150(87)90202-4. 
Pannu, H., V. Tran-Fadulu, C. L. Papke, S. Scherer, Y. Liu, C. Presley, D. Guo, et al. “MYH11 Mutations 
Result in a Distinct Vascular Pathology Driven by Insulin-like Growth Factor 1 and Angiotensin 
II.” Human Molecular Genetics 16, no. 20 (April 2007): 2453–2462. 
https://doi.org/10.1093/hmg/ddm201. 
Parastatidis, Ioannis, Daiana Weiss, Giji Joseph, and W Robert Taylor. “Overexpression of Catalase in 
Vascular Smooth Muscle Cells Prevents the Formation of Abdominal Aortic Aneurysms.” 
Arteriosclerosis, Thrombosis, and Vascular Biology 33, no. 10 (October 2013): 2389–96. 
https://doi.org/10.1161/ATVBAHA.113.302175. 
Park, Hyung Sub, Geum Hee Choi, Soli Hahn, Young Sun Yoo, Ji Youl Lee, and Taeseung Lee. 
“Potential Role of Vascular Smooth Muscle Cell-like Progenitor Cell Therapy in the Suppression 
of Experimental Abdominal Aortic Aneurysms.” Biochemical and Biophysical Research 
160 
 
Communications 431, no. 2 (February 2013): 326–331. 
https://doi.org/10.1016/j.bbrc.2012.12.099. 
Patel, M. I., P. Ghosh, J. Melrose, and M. Appleberg. “SMOOTH MUSCLE CELL MIGRATION AND 
PROLIFERATION IS ENHANCED IN ABDOMINAL AORTIC ANEURYSMS.” ANZ Journal of Surgery 
66, no. 5 (May 1996): 305–308. https://doi.org/10.1111/j.1445-2197.1996.tb01192.x. 
PDAY research group. “Relationship of Atherosclerosis in Young Men to Serum Lipoprotein 
Cholesterol Concentrations and Smoking. A Preliminary Report from the Pathobiological 
Determinants of Atherosclerosis in Youth (PDAY) Research Group.” JAMA : The Journal of the 
American Medical Association 264, no. 23 (1990): 3018–24. https://doi.org/10.1097/00043764-
199108000-00002. 
Penn, A, S J Garte, L Warren, D Nesta, and B Mindich. “Transforming Gene in Human Atherosclerotic 
Plaque DNA.” Proceedings of the National Academy of Sciences of the United States of America 
83, no. 20 (October 1986): 7951–5. 
Pfaltzgraff, Elise R, and David M Bader. “Heterogeneity in Vascular Smooth Muscle Cell Embryonic 
Origin in Relation to Adult Structure, Physiology, and Disease.” Developmental Dynamics : An 
Official Publication of the American Association of Anatomists 244, no. 3 (2015): 410–6. 
https://doi.org/10.1002/dvdy.24247. 
Picelli, Simone, \AAsa K Björklund, Omid R Faridani, Sven Sagasser, Gösta Winberg, and Rickard 
Sandberg. “Smart-Seq2 for Sensitive Full-Length Transcriptome Profiling in Single Cells.” Nature 
Methods 10, no. 11 (September 2013): 1096–1098. https://doi.org/10.1038/nmeth.2639. 
Picelli, Simone, Omid R Faridani, \AAsa K Björklund, Gösta Winberg, Sven Sagasser, and Rickard 
Sandberg. “Full-Length RNA-Seq from Single Cells Using Smart-Seq2.” Nature Protocols 9, no. 1 
(January 2014): 171–181. https://doi.org/10.1038/nprot.2014.006. 
Piedrahita, Jorge A, Sunny H Zhang, John R Hagaman, Paula M Oliver, and Nobuyo Maeda. 
“Generation of Mice Carrying a Mutant Apolipoprotein E Gene Inactivated by Gene Targeting in 
Embryonic Stem Cells.” Proceedings of the National Academy of Sciences of the United States of 
America 89, no. May (1992): 4471–4475. https://doi.org/10.1073/pnas.89.10.4471. 
Pleumeekers, H.J.C.M., A.W. Hoes, E. van der Does, H. Van Urk, and D.E. Grobbee. “Epidemiology of 
Abdominal Aortic Aneurysms.” European Journal of Vascular Surgery 8, no. 2 (March 1994): 
119–128. https://doi.org/10.1016/S0950-821X(05)80446-3. 
Pouget, C., K. Pottin, and T. Jaffredo. “Sclerotomal Origin of Vascular Smooth Muscle Cells and 
Pericytes in the Embryo.” Developmental Biology 315, no. 2 (March 2008): 437–447. 
https://doi.org/10.1016/j.ydbio.2007.12.045. 
Proweller, Aaron, Lili Tu, John J. Lepore, Lan Cheng, Min Min Lu, John Seykora, Sarah E. Millar, 
Warren S. Pear, and Michael S. Parmacek. “Impaired Notch Signaling Promotes 
\textlessi\textgreaterDe Novo\textless/I\textgreater Squamous Cell Carcinoma Formation.” 
Cancer Research 66, no. 15 (August 2006): 7438–7444. https://doi.org/10.1158/0008-
5472.CAN-06-0793. 
Pugsley, M K, and R Tabrizchi. “The Vascular System. An Overview of Structure and Function.” 
Journal of Pharmacological and Toxicological Methods 44, no. 2 (2000): 333–40. 
Qiu, Ping, and Li Li. “Histone Acetylation and Recruitment of Serum Responsive Factor and CREB-
Binding Protein Onto SM22 Promoter During SM22 Gene Expression.” Circulation Research 90, 
no. 8 (2002). http://circres.ahajournals.org/content/90/8/858. 
R Core Team. R: A Language and Environment for Statistical Computing., 2016. 
Raffort, Juliette, Fabien Lareyre, Marc Clément, Réda Hassen-Khodja, Giulia Chinetti, and Ziad Mallat. 
“Monocytes and Macrophages in Abdominal Aortic Aneurysm.” Nature Reviews Cardiology 14, 
no. 8 (April 2017): 457–471. https://doi.org/10.1038/nrcardio.2017.52. 
Raj, Arjun, and Alexander van Oudenaarden. “Nature, Nurture, or Chance: Stochastic Gene 
Expression and Its Consequences.” Cell 135, no. 2 (2008): 216–26. 
https://doi.org/10.1016/j.cell.2008.09.050. 
161 
 
Rakic, Pasko. “PROGRESSNeurogenesis in Adult Primate Neocortex: An Evaluation of the Evidence.” 
Nature Reviews Neuroscience 3, no. 1 (January 2002): 65–71. https://doi.org/10.1038/nrn700. 
Rastan, S. “Timing of X-Chromosome Inactivation in Postimplantation Mouse Embryos.” Journal of 
Embryology and Experimental Morphology 71 (1982): 11–24. 
Rateri, Debra L., Deborah A. Howatt, Jessica J. Moorleghen, Richard Charnigo, Lisa A. Cassis, and Alan 
Daugherty. “Prolonged Infusion of Angiotensin II in ApoE−/− Mice Promotes Macrophage 
Recruitment with Continued Expansion of Abdominal Aortic Aneurysm.” The American Journal 
of Pathology 179, no. 3 (September 2011): 1542–1548. 
https://doi.org/10.1016/j.ajpath.2011.05.049. 
Rensen, S S M, P a F M Doevendans, and G J J M van Eys. “Regulation and Characteristics of Vascular 
Smooth Muscle Cell Phenotypic Diversity.” Netherlands Heart Journal : Monthly Journal of the 
Netherlands Society of Cardiology and the Netherlands Heart Foundation 15, no. 3 (2007): 100–
108. https://doi.org/10.1007/BF03085963. 
Rhodin, Johannes A. G. “Architecture of the Vessel Wall.” In Comprehensive Physiology, 1–31. 
Hoboken, NJ, USA: John Wiley & Sons, Inc., 1980. https://doi.org/10.1002/cphy.cp020201. 
Risso, Davide, John Ngai, Terence P Speed, and Sandrine Dudoit. “Normalization of RNA-Seq Data 
Using Factor Analysis of Control Genes or Samples.” Nature Biotechnology 32, no. 9 (August 
2014): 896–902. https://doi.org/10.1038/nbt.2931. 
Ross, Russell. “Atherosclerosis — An Inflammatory Disease.” New England Journal of Medicine 340, 
no. 2 (1999): 115–126. https://doi.org/10.1056/NEJM199901143400207. 
Rowe, V L, S L Stevens, T T Reddick, M B Freeman, R Donnell, R C Carroll, and M H Goldman. 
“Vascular Smooth Muscle Cell Apoptosis in Aneurysmal, Occlusive, and Normal Human Aortas.” 
Journal of Vascular Surgery 31, no. 3 (March 2000): 567–76. 
Ruddy, Jean Marie, Jeffrey A. Jones, Francis G. Spinale, and John S. Ikonomidis. “Regional 
Heterogeneity within the Aorta: Relevance to Aneurysm Disease.” The Journal of Thoracic and 
Cardiovascular Surgery 136, no. 5 (November 2008): 1123–1130. 
https://doi.org/10.1016/j.jtcvs.2008.06.027. 
Sacks, Frank M., Marc A. Pfeffer, Lemuel A. Moye, Jean L. Rouleau, John D. Rutherford, Thomas G. 
Cole, Lisa Brown, et al. “The Effect of Pravastatin on Coronary Events after Myocardial 
Infarction in Patients with Average Cholesterol Levels.” New England Journal of Medicine 335, 
no. 14 (October 1996): 1001–1009. https://doi.org/10.1056/NEJM199610033351401. 
Sainz, J., Ayman Al Haj Zen, Giuseppina Caligiuri, Corinne Demerens, Dominique Urbain, Mathilde 
Lemitre, and Antoine Lafont. “Isolation of ‘Side Population’ Progenitor Cells From Healthy 
Arteries of Adult Mice.” Arteriosclerosis, Thrombosis, and Vascular Biology 26, no. 2 (December 
2005): 281–286. https://doi.org/10.1161/01.ATV.0000197793.83391.91. 
Saliba, AE, AJ Westermann, SA Gorski, and J Vogel. “Single-Cell RNA-Seq: Advances and Future 
Challenges.” Nucleic Acids Res. 42, no. 14 (2014). 
Salic, A., and T. J. Mitchison. “A Chemical Method for Fast and Sensitive Detection of DNA Synthesis 
in Vivo.” Proceedings of the National Academy of Sciences 105, no. 7 (February 2008): 2415–
2420. https://doi.org/10.1073/pnas.0712168105. 
Samy, A. K., B. Whyte, and G. Macbain. “Abdominal Aortic Aneurysm in Scotland.” British Journal of 
Surgery 81, no. 8 (August 1994): 1104–1106. https://doi.org/10.1002/bjs.1800810807. 
Sandoo, Aamer, Jet J C S Veldhuijzen van Zanten, George S Metsios, Douglas Carroll, and George D 
Kitas. “The Endothelium and Its Role in Regulating Vascular Tone.” The Open Cardiovascular 
Medicine Journal 4 (December 2010): 302–12. 
https://doi.org/10.2174/1874192401004010302. 
Saraff, K., Fjoralba Babamusta, Lisa A Cassis, and Alan Daugherty. “Aortic Dissection Precedes 
Formation of Aneurysms and Atherosclerosis in Angiotensin II-Infused, Apolipoprotein E-
Deficient Mice.” Arteriosclerosis, Thrombosis, and Vascular Biology 23, no. 9 (September 2003): 
1621–1626. https://doi.org/10.1161/01.ATV.0000085631.76095.64. 
162 
 
Sata, Masataka, Akio Saiura, Atsushi Kunisato, Akihiro Tojo, Seiji Okada, Takeshi Tokuhisa, Hisamaru 
Hirai, Masatoshi Makuuchi, Yasunobu Hirata, and Ryozo Nagai. “Hematopoietic Stem Cells 
Differentiate into Vascular Cells That Participate in the Pathogenesis of Atherosclerosis.” Nat 
Med 8, no. 4 (2002): 403–409. https://doi.org/10.1038/nm0402-403. 
Sato, Yuki. “Dorsal Aorta Formation: Separate Origins, Lateral-to-Medial Migration, and 
Remodeling.” Development, Growth & Differentiation 55, no. 1 (January 2013): 113–129. 
https://doi.org/10.1111/dgd.12010. 
Schindelin, Johannes, Ignacio Arganda-Carreras, Erwin Frise, Verena Kaynig, Mark Longair, Tobias 
Pietzsch, Stephan Preibisch, et al. “Fiji: An Open-Source Platform for Biological-Image Analysis.” 
Nature Methods 9, no. 7 (June 2012): 676–682. https://doi.org/10.1038/nmeth.2019. 
Schwartz, S M, D DeBlois, and E R O’Brien. “The Intima. Soil for Atherosclerosis and Restenosis.” 
Circulation Research 77, no. 3 (September 1995): 445–65. 
Schwartz, S M, and C E Murry. “Proliferation and the Monoclonal Origins of Atherosclerotic Lesions.” 
Annual Review of Medicine 49 (1998): 437–60. https://doi.org/10.1146/annurev.med.49.1.437. 
Schwartz, Stephen M., Renu Virmani, and Michael E. Rosenfeld. “The Good Smooth Muscle Cells in 
Atherosclerosis.” Curr Atheroscler Rep 2, no. 5 (2000): 422–429. 
https://doi.org/10.1007/s11883-000-0081-5. 
Scott, R A, N M Wilson, H A Ashton, and D N Kay. “Influence of Screening on the Incidence of 
Ruptured Abdominal Aortic Aneurysm: 5-Year Results of a Randomized Controlled Study.” The 
British Journal of Surgery 82, no. 8 (August 1995): 1066–70. 
Shang, Yueting, Tadashi Yoshida, Brad A. Amendt, James F. Martin, and Gary K. Owens. “Pitx2 Is 
Functionally Important in the Early Stages of Vascular Smooth Muscle Cell Differentiation.” The 
Journal of Cell Biology 181, no. 3 (May 2008): 461–473. 
https://doi.org/10.1083/jcb.200711145. 
Shankman, Laura S, Delphine Gomez, Olga a Cherepanova, Morgan Salmon, Gabriel F Alencar, Ryan 
M Haskins, Pamela Swiatlowska, et al. “KLF4-Dependent Phenotypic Modulation of Smooth 
Muscle Cells Has a Key Role in Atherosclerotic Plaque Pathogenesis.” Nature Medicine 21, no. 6 
(2015): 628–37. https://doi.org/10.1038/nm.3866. 
Sheikh, Abdul Q, Ashish Misra, Ivan O Rosas, Ralf H Adams, and Daniel M Greif. “Smooth Muscle Cell 
Progenitors Are Primed to Muscularize in Pulmonary Hypertension.” Science Translational 
Medicine 7, no. 308 (October 2015): 308ra159. https://doi.org/10.1126/scitranslmed.aaa9712. 
Shen, Zhuxia, Chao Li, Ryan A Frieler, Alena S Gerasimova, Soo Jung Lee, Jing Wu, Michael M Wang, 
et al. “Smooth Muscle Protein 22 Alpha-Cre Is Expressed in Myeloid Cells in Mice.” Biochemical 
and Biophysical Research Communications 422, no. 4 (June 2012): 639–42. 
https://doi.org/10.1016/j.bbrc.2012.05.041. 
Sheng, Kuanwei, Wenjian Cao, Yichi Niu, Qing Deng, and Chenghang Zong. “Effective Detection of 
Variation in Single-Cell Transcriptomes Using MATQ-Seq.” Nature Methods 14, no. 3 (January 
2017): 267–270. https://doi.org/10.1038/nmeth.4145. 
Sherif L, and Zahradka P. “Vascular Smooth Muscle Cell Motility: From Migration to Invasion.” 
Experimental and Clinical Cardiology 15, no. 4 (2010): 75–85. 
Shikatani, Eric A., Mark Chandy, Rickvinder Besla, Cedric C. Li, Abdul Momen, Omar El-Mounayri, 
Clinton S. Robbins, and Mansoor Husain. “C-Myb Regulates Proliferation and Differentiation of 
Adventitial Sca1 \textlesssup\textgreater+\textless/Sup\textgreater Vascular Smooth Muscle 
Cell Progenitors by Transactivation of MyocardinHighlights.” Arteriosclerosis, Thrombosis, and 
Vascular Biology 36, no. 7 (July 2016): 1367–1376. 
https://doi.org/10.1161/ATVBAHA.115.307116. 
Sigal, Alex, Ron Milo, Ariel Cohen, Naama Geva-Zatorsky, Yael Klein, Yuvalal Liron, Nitzan Rosenfeld, 
Tamar Danon, Natalie Perzov, and Uri Alon. “Variability and Memory of Protein Levels in 
Human Cells.” Nature 444, no. 7119 (2006): 643–646. https://doi.org/10.1038/nature05316. 
163 
 
Simons, Benjamin D. “Deep Sequencing as a Probe of Normal Stem Cell Fate and Preneoplasia in 
Human Epidermis.” Proceedings of the National Academy of Sciences of the United States of 
America 113, no. 1 (January 2016): 128–33. https://doi.org/10.1073/pnas.1516123113. 
Singh, K, K H Bønaa, B K Jacobsen, L Bjørk, and S Solberg. “Prevalence of and Risk Factors for 
Abdominal Aortic Aneurysms in a Population-Based Study : The Tromsø Study.” American 
Journal of Epidemiology 154, no. 3 (August 2001): 236–44. 
Sinha, S., Mark H Hoofnagle, Paul A Kingston, Mary E McCanna, and Gary K Owens. “Transforming 
Growth Factor- 1 Signaling Contributes to Development of Smooth Muscle Cells from 
Embryonic Stem Cells.” AJP: Cell Physiology 287, no. 6 (August 2004): C1560–C1568. 
https://doi.org/10.1152/ajpcell.00221.2004. 
Sinha, Sanjay, Dharini Iyer, and Alessandra Granata. “Embryonic Origins of Human Vascular Smooth 
Muscle Cells: Implications for in Vitro Modeling and Clinical Application.” Cellular and 
Molecular Life Sciences 71, no. 12 (June 2014): 2271–2288. https://doi.org/10.1007/s00018-
013-1554-3. 
Smallwood, Sébastien A, Heather J Lee, Christof Angermueller, Felix Krueger, Heba Saadeh, Julian 
Peat, Simon R Andrews, Oliver Stegle, Wolf Reik, and Gavin Kelsey. “Single-Cell Genome-Wide 
Bisulfite Sequencing for Assessing Epigenetic Heterogeneity.” Nature Methods 11, no. 8 
(August 2014): 817–820. https://doi.org/10.1038/nmeth.3035. 
Snippert, Hugo J, Laurens G van der Flier, Toshiro Sato, Johan H van Es, Maaike van den Born, Carla 
Kroon-Veenboer, Nick Barker, et al. “Intestinal Crypt Homeostasis Results from Neutral 
Competition between Symmetrically Dividing Lgr5 Stem Cells.” Cell 143, no. 1 (2010): 134–44. 
https://doi.org/10.1016/j.cell.2010.09.016. 
Spangrude, G J, S Heimfeld, and I L Weissman. “Purification and Characterization of Mouse 
Hematopoietic Stem Cells.” Science (New York, N.Y.) 241, no. 4861 (July 1988): 58–62. 
Stegemann, Jan P, Helen Hong, and Robert M Nerem. “Mechanical, Biochemical, and Extracellular 
Matrix Effects on Vascular Smooth Muscle Cell Phenotype.” Journal of Applied Physiology 
(Bethesda, Md. : 1985) 98, no. 6 (2005): 2321–2327. 
https://doi.org/10.1152/japplphysiol.01114.2004. 
Stenmark, Kurt R, Michael E Yeager, Karim C El Kasmi, Eva Nozik-Grayck, Evgenia V Gerasimovskaya, 
Min Li, Suzette R Riddle, and Maria G Frid. “The Adventitia: Essential Regulator of Vascular Wall 
Structure and Function.” Annual Review of Physiology 75, no. November 2012 (2013): 23–47. 
https://doi.org/10.1146/annurev-physiol-030212-183802. 
Stringfellow, M M, P F Lawrence, and R G Stringfellow. “The Influence of Aorta-Aneurysm Geometry 
upon Stress in the Aneurysm Wall.” The Journal of Surgical Research 42, no. 4 (April 1987): 
425–33. 
Swedenborg, J., M. I. Mayranpaa, and P. T. Kovanen. “Mast Cells: Important Players in the 
Orchestrated Pathogenesis of Abdominal Aortic Aneurysms.” Arteriosclerosis, Thrombosis, and 
Vascular Biology 31, no. 4 (April 2011): 734–740. 
https://doi.org/10.1161/ATVBAHA.110.213157. 
Tabas, I., G. Garcia-Cardena, and G. K. Owens. “The Cell Biology of Disease: Recent Insights into the 
Cellular Biology of Atherosclerosis.” The Journal of Cell Biology 209, no. 1 (2015): 13–22. 
https://doi.org/10.1083/jcb.201412052. 
Tacke, Frank, David Alvarez, Theodore J Kaplan, Claudia Jakubzick, Rainer Spanbroek, Jaime Llodra, 
Alexandre Garin, et al. “Monocyte Subsets Differentially Employ CCR2, CCR5, and CX3CR1 to 
Accumulate within Atherosclerotic Plaques.” The Journal of Clinical Investigation 117, no. 1 
(January 2007): 185–94. https://doi.org/10.1172/JCI28549. 
Takagi, N, O Sugawara, and M Sasaki. “Regional and Temporal Changes in the Pattern of X-
Chromosome Replication during the Early Post-Implantation Development of the Female 
Mouse.” Chromosoma 85, no. 2 (1982): 275–86. https://doi.org/10.1007/BF00294971. 
164 
 
Tam, Patrick P.L, and Richard R Behringer. “Mouse Gastrulation: The Formation of a Mammalian 
Body Plan.” Mechanisms of Development 68, no. 1–2 (November 1997): 3–25. 
https://doi.org/10.1016/S0925-4773(97)00123-8. 
Tamarina, N A, W D McMillan, V P Shively, and W H Pearce. “Expression of Matrix 
Metalloproteinases and Their Inhibitors in Aneurysms and Normal Aorta.” Surgery 122, no. 2 
(August 1997): 264–71; discussion 271–2. 
Tambyraja, Andrew L., Raymond Dawson, Domenico Valenti, John A. Murie, and Roderick T. 
Chalmers. “Systemic Inflammation and Repair of Abdominal Aortic Aneurysm.” World Journal 
of Surgery 31, no. 6 (May 2007): 1212–1216. https://doi.org/10.1007/s00268-007-9014-6. 
Tang, Fuchou, Catalin Barbacioru, Yangzhou Wang, Ellen Nordman, Clarence Lee, Nanlan Xu, Xiaohui 
Wang, et al. “MRNA-Seq Whole-Transcriptome Analysis of a Single Cell.” Nature Methods 6, no. 
5 (May 2009): 377–382. https://doi.org/10.1038/nmeth.1315. 
Tang, R.-h., X.-L. Zheng, T. E. Callis, W. E. Stansfield, J. He, A. S. Baldwin, D.-Z. Wang, and C. H. 
Selzman. “Myocardin Inhibits Cellular Proliferation by Inhibiting NF- B(P65)-Dependent Cell 
Cycle Progression.” Proceedings of the National Academy of Sciences 105, no. 9 (March 2008): 
3362–3367. https://doi.org/10.1073/pnas.0705842105. 
Tang, Zhenyu, Aijun Wang, Falei Yuan, Zhiqiang Yan, Bo Liu, Julia S. Chu, Jill a. Helms, and Song Li. 
“Differentiation of Multipotent Vascular Stem Cells Contributes to Vascular Diseases.” Nature 
Communications 3 (2012): 875. https://doi.org/10.1038/ncomms1867. 
Tanous, David, Lee N Benson, and Eric M Horlick. “Coarctation of the Aorta: Evaluation and 
Management.” Current Opinion in Cardiology 24, no. 6 (November 2009): 509–515. 
https://doi.org/10.1097/HCO.0b013e328330cc22. 
Tedgui, A, and Z Mallat. “Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways.” Physiol 
Rev 86, no. 2 (2006): 515–581. https://doi.org/86/2/515 [pii]\r10.1152/physrev.00024.2005. 
Thompson, R W. “Basic Science of Abdominal Aortic Aneurysms: Emerging Therapeutic Strategies for 
an Unresolved Clinical Problem.” Current Opinion in Cardiology 11, no. 5 (September 1996): 
504–18. 
Thompson, Robert W. “Reflections on the Pathogenesis of Abdominal Aortic Aneurysms.” 
Cardiovascular Surgery (London, England) 10, no. 4 (August 2002): 389–94. 
Tieu, Brian C., Chang Lee, Hong Sun, Wanda LeJeune, Adrian Recinos, Xiaoxi Ju, Heidi Spratt, et al. 
“An Adventitial IL-6/MCP1 Amplification Loop Accelerates Macrophage-Mediated Vascular 
Inflammation Leading to Aortic Dissection in Mice.” Journal of Clinical Investigation 119, no. 12 
(December 2009): 3637–3651. https://doi.org/10.1172/JCI38308. 
Trachet, Bram, Lydia Aslanidou, Alessandra Piersigilli, Rodrigo A. Fraga-Silva, Jessica Sordet-
Dessimoz, Pablo Villanueva-Perez, Marco F.M. Stampanoni, Nikolaos Stergiopulos, and Patrick 
Segers. “Angiotensin II Infusion into ApoE-/- Mice: A Model for Aortic Dissection Rather than 
Abdominal Aortic Aneurysm?” Cardiovascular Research 31, no. 10 (June 2017): 270–U102. 
https://doi.org/10.1093/cvr/cvx128. 
Trapnell, Cole, Davide Cacchiarelli, Jonna Grimsby, Prapti Pokharel, Shuqiang Li, Michael Morse, Niall 
J Lennon, Kenneth J Livak, Tarjei S Mikkelsen, and John L Rinn. “The Dynamics and Regulators of 
Cell Fate Decisions Are Revealed by Pseudotemporal Ordering of Single Cells.” Nature 
Biotechnology 32, no. 4 (March 2014): 381–386. https://doi.org/10.1038/nbt.2859. 
Trigueros-Motos, L., J. M. Gonzalez-Granado, C. Cheung, P. Fernandez, F. Sanchez-Cabo, A. Dopazo, 
S. Sinha, and V. Andres. “Embryological-Origin-Dependent Differences in Homeobox Expression 
in Adult Aorta: Role in Regional Phenotypic Variability and Regulation of NF- B Activity.” 
Arteriosclerosis, Thrombosis, and Vascular Biology 33, no. 6 (June 2013): 1248–1256. 
https://doi.org/10.1161/ATVBAHA.112.300539. 
Tromp, Gerard, Helena Kuivaniemi, Irene Hinterseher, and David J. Carey. “Novel Genetic 
Mechanisms for Aortic Aneurysms.” Current Atherosclerosis Reports 12, no. 4 (July 2010): 259–
266. https://doi.org/10.1007/s11883-010-0111-x. 
165 
 
Tung, Po-Yuan, John D Blischak, Chiaowen Joyce Hsiao, David A Knowles, Jonathan E Burnett, 
Jonathan K Pritchard, and Yoav Gilad. “Batch Effects and the Effective Design of Single-Cell 
Gene Expression Studies.” Scientific Reports 7 (January 2017): 39921. 
https://doi.org/10.1038/srep39921. 
Vallabhaneni, Srinivasa R., Geoffrey L. Gilling-Smith, Thien V. How, Stuart D. Carter, John A. Brennan, 
and Peter L. Harris. “\textlessb\textgreaterHeterogeneity of Tensile Strength and Matrix 
Metalloproteinase Activity in the Wall of Abdominal Aortic Aneurysms\textless/B\textgreater.” 
Journal of Endovascular Therapy 11, no. 4 (August 2004): 494–502. https://doi.org/10.1583/04-
1239.1. 
VanderLaan, Paul a., Catherine a. Reardon, and Godfrey S. Getz. “Site Specificity of Atherosclerosis: 
Site-Selective Responses to Atherosclerotic Modulators.” Arteriosclerosis, Thrombosis, and 
Vascular Biology 24, no. 1 (2004): 12–22. 
https://doi.org/10.1161/01.ATV.0000105054.43931.f0. 
Virmani, R, M Robinowitz, J C Geer, P P Breslin, J C Beyer, and H a McAllister. “Coronary Artery 
Atherosclerosis Revisited in Korean War Combat Casualties.” Archives of Pathology & 
Laboratory Medicine 111, no. 10 (1987): 972–6. 
Wang, Gang, Laureen Jacquet, Eirini Karamariti, and Qingbo Xu. “Origin and Differentiation of 
Vascular Smooth Muscle Cells.” The Journal of Physiology 593, no. 14 (July 2015): 3013–30. 
https://doi.org/10.1113/JP270033. 
Wang, Haidong, Mohsen Naghavi, Christine Allen, Ryan M Barber, Zulfiqar A Bhutta, Austin Carter, 
Daniel C Casey, et al. “Global, Regional, and National Life Expectancy, All-Cause Mortality, and 
Cause-Specific Mortality for 249 Causes of Death, 1980–2015: A Systematic Analysis for the 
Global Burden of Disease Study 2015.” The Lancet 388, no. 10053 (October 2016): 1459–1544. 
https://doi.org/10.1016/S0140-6736(16)31012-1. 
Wang, Yu, Hafid Ait-Oufella, Olivier Herbin, Philippe Bonnin, Bhama Ramkhelawon, Soraya Taleb, Jin 
Huang, et al. “TGF-β Activity Protects against Inflammatory Aortic Aneurysm Progression and 
Complications in Angiotensin II–infused Mice.” Journal of Clinical Investigation 120, no. 2 
(February 2010): 422–432. https://doi.org/10.1172/JCI38136. 
Wang, Zhigao, Da-Zhi Wang, Dirk Hockemeyer, John McAnally, Alfred Nordheim, and Eric N. Olson. 
“Myocardin and Ternary Complex Factors Compete for SRF to Control Smooth Muscle Gene 
Expression.” Nature 428, no. 6979 (March 2004): 185–189. 
https://doi.org/10.1038/nature02382. 
Wasteson, Per, Bengt R Johansson, Tomi Jukkola, Silke Breuer, Levent M Akyürek, Juha Partanen, 
and Per Lindahl. “Developmental Origin of Smooth Muscle Cells in the Descending Aorta in 
Mice.” Development (Cambridge, England) 135, no. 10 (2008): 1823–1832. 
https://doi.org/10.1242/dev.020958. 
Weakley, Sarah M, Jun Jiang, Panagiotis Kougias, Peter H Lin, Qizhi Yao, F Charles Brunicardi, Richard 
A Gibbs, and Changyi Chen. “Role of Somatic Mutations in Vascular Disease Formation.” Expert 
Review of Molecular Diagnostics 10, no. 2 (March 2010): 173–85. 
https://doi.org/10.1586/erm.10.1. 
Wills, Quin F, Kenneth J Livak, Alex J Tipping, Tariq Enver, Andrew J Goldson, Darren W Sexton, and 
Chris Holmes. “Single-Cell Gene Expression Analysis Reveals Genetic Associations Masked in 
Whole-Tissue Experiments.” Nature Biotechnology 31, no. 8 (July 2013): 748–752. 
https://doi.org/10.1038/nbt.2642. 
Wirth, Angela, Zoltán Benyó, Martina Lukasova, Barbara Leutgeb, Nina Wettschureck, Stefan Gorbey, 
Petra Orsy, et al. “G12-G13-LARG-Mediated Signaling in Vascular Smooth Muscle Is Required 
for Salt-Induced Hypertension.” Nature Medicine 14, no. 1 (2008): 64–68. 
https://doi.org/10.1038/nm1666. 
Wolinsky, H., and S. Glagov. “A Lamellar Unit of Aortic Medial Structure and Function in Mammals.” 
Circulation Research 20, no. 1 (1967): 99–111. https://doi.org/10.1161/01.RES.20.1.99. 
166 
 
Wu, Ying-chen, Lei Cui, Gang Li, Shuo Yin, Yong-juan Gao, and Yi-lin Cao. “[PDGF-BB Initiates Vascular 
Smooth Muscle-like Phenotype Differentiation of Human Bone Marrow Mesenchymal Stem 
Cells in Vitro].” Zhonghua Zheng Xing Wai Ke Za Zhi = Zhonghua Zhengxing Waike Zazhi = 
Chinese Journal of Plastic Surgery 23, no. 4 (July 2007): 335–9. 
Xin, M., E. M. Small, L. B. Sutherland, X. Qi, J. McAnally, C. F. Plato, J. A. Richardson, R. Bassel-Duby, 
and E. N. Olson. “MicroRNAs MiR-143 and MiR-145 Modulate Cytoskeletal Dynamics and 
Responsiveness of Smooth Muscle Cells to Injury.” Genes & Development 23, no. 18 
(September 2009): 2166–2178. https://doi.org/10.1101/gad.1842409. 
Xu, Qingbo. “Mouse Models of Arteriosclerosis: From Arterial Injuries to Vascular Grafts.” The 
American Journal of Pathology 165, no. 1 (July 2004): 1–10. https://doi.org/10.1016/S0002-
9440(10)63270-1. 
Yan, Kelley S., Claudia Y. Janda, Junlei Chang, Grace X. Y. Zheng, Kathryn A. Larkin, Vincent C. Luca, 
Luis A. Chia, et al. “Non-Equivalence of Wnt and R-Spondin Ligands during Lgr5+ Intestinal 
Stem-Cell Self-Renewal.” Nature 545, no. 7653 (May 2017): 238–242. 
https://doi.org/10.1038/nature22313. 
Yang, P, MS Hong, C Fu, BM Schmit, Y Su, SA Berceli, and Z Jiang. “Preexisting Smooth Muscle Cells 
Contribute to Neointimal Cell Repopulation at an Incidence Varying Widely among Individual 
Lesions.” Surgery, 2015. 
Yao, Q., M.-A. Renault, C. Chapouly, S. Vandierdonck, I. Belloc, B. Jaspard-Vinassa, J.-M. Daniel-
Lamaziere, et al. “Sonic Hedgehog Mediates a Novel Pathway of PDGF-BB-Dependent Vessel 
Maturation.” Blood 123, no. 15 (April 2014): 2429–2437. https://doi.org/10.1182/blood-2013-
06-508689. 
Yoshida, T., Q. Gan, Y. Shang, and G. K. Owens. “Platelet-Derived Growth Factor-BB Represses 
Smooth Muscle Cell Marker Genes via Changes in Binding of MKL Factors and Histone 
Deacetylases to Their Promoters.” AJP: Cell Physiology 292, no. 2 (August 2006): C886–C895. 
https://doi.org/10.1152/ajpcell.00449.2006. 
Yoshida, T., Mark H Hoofnagle, and Gary K Owens. “Myocardin and Prx1 Contribute to Angiotensin II-
Induced Expression of Smooth Muscle -Actin.” Circulation Research 94, no. 8 (April 2004): 
1075–1082. https://doi.org/10.1161/01.RES.0000125622.46280.95. 
Yoshida, T., Sanjay Sinha, Frédéric Dandré, Brian R Wamhoff, Mark H Hoofnagle, Brandon E Kremer, 
Da-Zhi Wang, Eric N Olson, and Gary K Owens. “Myocardin Is a Key Regulator of CArG-
Dependent Transcription of Multiple Smooth Muscle Marker Genes.” Circulation Research 92, 
no. 8 (May 2003): 856–864. https://doi.org/10.1161/01.RES.0000068405.49081.09. 
Yoshida, Tadashi, Maho Yamashita, Chihiro Horimai, and Matsuhiko Hayashi. “Smooth Muscle-
Selective Inhibition of Nuclear Factor-ΚB Attenuates Smooth Muscle Phenotypic Switching and 
Neointima Formation Following Vascular Injury.” Journal of the American Heart Association 2, 
no. 3 (May 2013): e000230. https://doi.org/10.1161/JAHA.113.000230. 
Yu, Baoqi, Mei Mei Wong, Claire M. F. Potter, Russell M. L. Simpson, Eirini Karamariti, Zhongyi Zhang, 
Lingfang Zeng, et al. “Vascular Stem/Progenitor Cell Migration Induced by Smooth Muscle Cell-
Derived Chemokine (C-C Motif) Ligand 2 and Chemokine (C-X-C Motif) Ligand 1 Contributes to 
Neointima Formation.” STEM CELLS 34, no. 9 (September 2016): 2368–2380. 
https://doi.org/10.1002/stem.2410. 
Yu, Haixiang, Murray C.H. Clarke, Nichola Figg, Trevor D. Littlewood, and Martin R. Bennett. “Smooth 
Muscle Cell Apoptosis Promotes Vessel Remodeling and Repair via Activation of Cell Migration, 
Proliferation, and Collagen Synthesis.” Arteriosclerosis, Thrombosis, and Vascular Biology 31, 
no. 11 (2011). http://atvb.ahajournals.org/content/31/11/2402.long. 
Yuan, Falei, Dong Wang, Kang Xu, Jixian Wang, Zhijun Zhang, Li Yang, Guo-Yuan Yang, and Song Li. 
“Contribution of Vascular Cells to Neointimal Formation.” PloS One 12, no. 1 (2017): e0168914. 
https://doi.org/10.1371/journal.pone.0168914. 
Zahradka, Peter, Greg Harding, Brenda Litchie, Shawn Thomas, Jeffrey P Werner, David P Wilson, and 
Natalia Yurkova. “Activation of MMP-2 in Response to Vascular Injury Is Mediated by 
167 
 
Phosphatidylinositol 3-Kinase-Dependent Expression of MT1-MMP.” American Journal of 
Physiology. Heart and Circulatory Physiology 287, no. 6 (2004): H2861–70. 
https://doi.org/10.1152/ajpheart.00230.2004. 
Zaman, A.G, G Helft, S.G Worthley, and J.J Badimon. “The Role of Plaque Rupture and Thrombosis in 
Coronary Artery Disease.” Atherosclerosis 149, no. 2 (2000): 251–266. 
https://doi.org/10.1016/S0021-9150(99)00479-7. 
Zengin, E., Fariba Chalajour, Ursula M Gehling, Wulf D Ito, Hendrik Treede, Heidrun Lauke, Joachim 
Weil, Hermann Reichenspurner, Nerbil Kilic, and Süleyman Ergün. “Vascular Wall Resident 
Progenitor Cells: A Source for Postnatal Vasculogenesis.” Development 133, no. 8 (April 2006): 
1543–1551. https://doi.org/10.1242/dev.02315. 
Zhang, H., S. Gu, B. Al-Sabeq, S. Wang, J. He, A. Tam, C. Cifelli, et al. “Origin-Specific Epigenetic 
Program Correlates with Vascular Bed-Specific Differences in Rgs5 Expression.” The FASEB 
Journal 26, no. 1 (January 2012): 181–191. https://doi.org/10.1096/fj.11-185454. 
Zhang, Jifeng, Wei Zhong, Taixing Cui, Maozhou Yang, Xing Hu, Kefeng Xu, Changqing Xie, et al. 
“Generation of an Adult Smooth Muscle Cell-Targeted Cre Recombinase Mouse Model.” 
Arteriosclerosis, Thrombosis, and Vascular Biology 26, no. 3 (March 2006): e23–4. 
https://doi.org/10.1161/01.ATV.0000202661.61837.93. 
Zhang, Ming-Jie, Yi Zhou, Lei Chen, Yan-Qin Wang, Xu Wang, Yan Pi, Chang-Yue Gao, Jing-Cheng Li, 
and Li-Li Zhang. “An Overview of Potential Molecular Mechanisms Involved in VSMC 
Phenotypic Modulation.” Histochemistry and Cell Biology 145, no. 2 (February 2016): 119–130. 
https://doi.org/10.1007/s00418-015-1386-3. 
Zhang, Z., M. Wang, X.-H. Fan, J.-H. Chen, Y.-Y. Guan, and Y.-B. Tang. “Upregulation of TRPM7 
Channels by Angiotensin II Triggers Phenotypic Switching of Vascular Smooth Muscle Cells of 
Ascending Aorta.” Circulation Research 111, no. 9 (October 2012): 1137–1146. 
https://doi.org/10.1161/CIRCRESAHA.112.273755. 
Zheng, Grace X. Y., Jessica M. Terry, Phillip Belgrader, Paul Ryvkin, Zachary W. Bent, Ryan Wilson, 
Solongo B. Ziraldo, et al. “Massively Parallel Digital Transcriptional Profiling of Single Cells.” 
Nature Communications 8 (January 2017): 14049. https://doi.org/10.1038/ncomms14049. 
Zheng, Jian-Pu, Donghong Ju, Jianbin Shen, Maozhou Yang, and Li Li. “Disruption of Actin 
Cytoskeleton Mediates Loss of Tensile Stress Induced Early Phenotypic Modulation of Vascular 
Smooth Muscle Cells in Organ Culture.” Experimental and Molecular Pathology 88, no. 1 
(February 2010): 52–57. https://doi.org/10.1016/j.yexmp.2009.10.006. 
Zhu, Shui-Bo, Jian Zhu, Zi-Zi Zhou, Er-Ping Xi, Rong-Ping Wang, and Yu Zhang. “TGF-Β1 Induces 
Human Aortic Vascular Smooth Muscle Cell Phenotype Switch through PI3K/AKT/ID2 
Signaling.” American Journal of Translational Research 7, no. 12 (2015): 2764–74. 
Ziegenhain, Christoph, Beate Vieth, Swati Parekh, Björn Reinius, Amy Guillaumet-Adkins, Martha 
Smets, Heinrich Leonhardt, Holger Heyn, Ines Hellmann, and Wolfgang Enard. “Comparative 
Analysis of Single-Cell RNA Sequencing Methods.” Molecular Cell 65, no. 4 (February 2017): 
631–643.e4. https://doi.org/10.1016/j.molcel.2017.01.023. 
Zong, Chenghang, Sijia Lu, Alec R Chapman, and X Sunney Xie. “Genome-Wide Detection of Single-
Nucleotide and Copy-Number Variations of a Single Human Cell.” Science (New York, N.Y.) 338, 
no. 6114 (December 2012): 1622–6. https://doi.org/10.1126/science.1229164. 
